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SUMMARY
Alzheimer's disease, the most common type of senile dementia, is characterised by p- 
amyloid plaques, neurofibrillary tangles and neuronal loss. Amyloid plaques are 
associated with the increased inflammation and oxidative stress.
Rodent models overexpressing APP are a useful tool to investigate both the processes and 
the consequences of amyloid generation, and are crucial for developing and testing 
hypotheses about treatments and risk factors. Tg2576 transgenic mice overexpress human 
“Swedish” mutated APP and show memory impairment followed by amyloid plaques 
pathology. GP56 rats also overexpress human “Swedish” mutated APP, but show no signs 
of AD-like pathology. In this thesis, I explored the influence of dietary and 
pharmacological modifications on pathogenesis of AD as tested in rodent models.
As epidemiological data implicated the role o f non-steroidal anti-inflammatory drugs 
(NSAIDs) in reducing the risk of AD, I investigated the role of ibuprofen as either 
prevention or treatment in transgenic mice. The results indicated that ibuprofen delayed 
the onset of behavioural impairment but only when it was administered early during the 
evolution of their pathology. Levels of Ap and plaque pathology were not affected. Also 
consumption of n-3 fatty acids seemed to reduce the risk of AD, possibly by acting as an 
anti-oxidant. Thus I investigated the effect of DHA on learning ability and pathology in 
AD mice. Administration of DHA to young mice reduced the impairment in learning but 
did not alter Ap levels or plaque pathology. Finally the role of high cholesterol diet was 
investigated in GP56 rats. Feeding rats for 8 weeks did not induce any amyloid-connected 
pathology.
The results indicate that modulation of inflammatory processes, or lipids can have modest 
ameliorating effects on behavioural impairments in rodent AD models, provided 
intervention is undertaken early, but suggest these may not be the most efficacious targets 
for therapeutic intervention.
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Chapter 1 
General Introduction
1.1. Introduction to the thesis
Alzheimer’s disease (AD) is a fatal neurodegenerative disorder associated with the 
elderly. It is characterised by deterioration o f cognitive functions accompanied by gradual 
loss of all memories, leaving suffering individuals to live in their own solitary world. The 
disease is prolonged, often lasting 8 to 12 years following diagnosis, which severely 
affects not only the afflicted people, but also their families and friends. As the percentage 
and the age of the elderly population in the world is constantly increasing, age-related 
disorders represent a progressively greater burden on western civilisations at the 
economic, social and medical levels. Current treatments are limited, and at best give only 
temporary alleviation of symptoms, with eventual incapacitation and death being 
inevitable. These considerations make the research for the cause of AD and the 
development of effective treatment of great importance.
AD, being a progressive neurodegenerative disorder, is characterised by large numbers of 
Ap (p-amyloid) deposits, neurofibrillary tangles, neuronal cell loss, which is 
accompanied by glial cell proliferation, inflammation and oxidative stress. The presence 
of inflammation and oxidative stress is considered to be either a cause of AD pathology or 
an effect of Ap deposition. Many therapeutic strategies emerged from the idea that 
inhibiting either neuroinflammation or oxidative stress will be beneficial.
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There are two major forms of AD: early-onset familial and late-onset sporadic. Familial 
AD, which generally occurs in persons <60 years of age, is caused by mutation in three 
known genes; presenilins 1 and 2 (PS1 and PS2) and amyloid precursor protein (APP). 
Slower, but promising, progress has been made in studying the complex picture of late- 
onset AD, which is probably associated with susceptibility factors increasing risk but not 
guaranteeing onset of AD. There is currently only one fully established genetic factor -  
polymorphism in Apolipoprotein E (ApoE) gene. Research in this field suggests a crucial 
role of polymorphisms in many other genes (e.g. Interleukin-1 (IL-1) or Urokinase- 
plasminogen activator) as well as numerous environmental factors including diet 
(cholesterol or polyunsaturated fatty acids).
The aim of this thesis is to use transgenic models to evaluate possible treatment strategies 
(Non-Steroidal Anti-Inflammatory Drugs) and to assess the importance of susceptibility 
risk factors (high cholesterol diet or polyunsaturated fatty acids intake).
To study the correlation between AD and inflammation in more detail, I assessed the 
effects of chronic, oral administration of the widely used anti-inflammatory drug 
Ibuprofen, given to transgenic mice over-expressing APP and showing AD-like 
pathology.
I also explored the role o f lipid metabolism and oxidative stress in AD pathology in more 
details in the same transgenic mice by administering chronic, oral supplementation of the 
major brain n-3 fatty acid -  docosahexaenoic acid (DHA), which has anti-oxidant 
properties.
Considering the pivotal role of environmental factors for developing late-onset sporadic 
AD, I also wanted to determine whether chronic, oral administration of a recognised risk 
factor would exacerbate the phenotype of rats over-expressing mutated amyloid precursor 
protein but showing limited amount of AD-like pathology. To this end, I fed transgenic 
rats on a high-cholesterol diet and assessed behavioural, physiological and biochemical 
consequences.
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1.2. Introduction to Alzheimer’s disease
1.2.1. Epidemiology
Alzheimer's disease (AD) is one of the fastest growing neurological conditions in 
developed countries and is the leading cause of dementia. AD alone accounts for 65-70% 
of diagnosed dementia cases (Brookmeyer et al., 1998) and in 2000, there were 4.5 
million persons with AD in the US population. By 2050, this number is predicted to 
increase by almost 3-fold, to 13.2 million (Hebert et al., 2003). Although estimates are 
subject to significant variation, the numbers are alarming and the importance of 
considering a wide range of therapeutic interventions aimed at either finding a cure or 
preventing disease progression is manifestly evident.
1.2.2. Diagnostic Criteria
To date, the diagnosis of probable or possible AD is based on neuropsychological 
examination using criteria such as insidious onset and progressive impairment of memory 
as well as loss of other cognitive functions (McKhann et al., 1984). Standardised sets of 
criteria for dementia (ICD-10 and DSM-IV) help to distinguish AD from other types of 
dementia or delirium, depression and normal aging.
As a support, a number of non-invasive imaging methods have been used to study patients 
with AD. These methods can measure brain functional activity (e.g., positron emission 
tomography [PET], single photon emission tomography, and functional magnetic 
resonance imaging [fMRI]), anatomy (e.g., computer-assisted tomography, and MRI), or 
chemical composition (magnetic resonance spectroscopy [MRS]). When combined with 
clinical, cognitive, and genetic evaluation, they can help to distinguish AD from other 
causes of dementia and to make a positive diagnosis (reviewed in Norfray & Provenzale, 
2004).
Other ways of supporting the diagnosis come from biochemical analysis. The 
cerebrospinal fluid of AD subjects shows significant elevation of tau and reduction in the 
A042, which are characterised in more detail in section 1.3 (Sunderland et al., 2003).
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Definite diagnosis of AD can only be made after post-mortem examination of brain tissue 
for the presence of plaques and tangles. However, it has to be stated that the mere 
presence of plaques and tangles in the brain is not sufficient evidence for a conclusive 
diagnosis of AD as these have also been reported in cognitive healthy elderly (Davis et 
al., 1999). A confirmed diagnosis at early stages is crucial with the advent of new drugs to 
treat AD, as treatment may be most effective if initiated early in the disease course.
1.2.3. Clinical Symptoms
Dr Alois Alzheimer described for the first time symptoms of AD in 1907. He reported the 
case of a middle-aged woman who developed memory deficits and progressive loss o f 
cognitive abilities accompanied by morbid jealousy. The post mortem analysis of her 
brain revealed amyloid plaques and neurofibrillary tangles (Yankner et al., 1996; Price et 
al., 1998).
The typical early symptoms of AD are mild memory loss (like episodic forgetfulness of 
day-to-day events) and subtle behavioural changes. As disease develops, people suffering 
from AD also lose other types of memory, e.g. memory for verbal and visual meaning, 
spatial and delayed memory, and finally short term and working memory is also affected. 
Most suffering people, even at early stages, show abnormalities in problem solving, 
communication skills, language, calculation and visual and spatial perception (reviewed 
in Forstl & Kurz, 1999).
Sufferers may also display a wide range of behavioural disturbances, which are often 
more distressing for carers than the cognitive problems. These include verbal and physical 
aggression, paranoid delusions, hallucinations, sleep disturbances, depression, apathy, 
social withdrawal, wandering and pacing, repetitive actions, inappropriate social 
behaviour (reviewed in Forstl& Kurz, 1999). In late stages of the disease, patients are 
often mute, incontinent and bedridden. They usually die of other medical conditions (e.g. 
pneumonia) 5-10 years after clinical onset (Price et al., 1998).
1.2.4. The role of genetic risk factors
There are two groups of AD patients that differ in age of onset, but have indistinguishable 
clinical and pathological features. The majority o f AD cases are sporadic type of AD
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(SAD), which is characterised by onset after 65 years of age (Katzman et al., 1998). Early 
onset autosomal dominant form of AD (familial AD) is connected to certain gene 
mutations and represents approximately 1% of diagnosed cases (Campion et al., 1999).
Studies of the familial AD (FAD) revealed mutations in genes encoding either APP, 
located on chromosome 21, or PS1 and PS2 located on chromosome 1 and 14, 
respectively (Goate et al., 1991; Mullan et al., 1992; Citron et al., 1992; Campion et al., 
1999; Sherrington et al., 1996; Citron et al., 1997).
Significantly, the majority of the mutations in APP that are linked to FAD have been 
reported to alter the generation of AP (for relationship between APP and Ap see section 
1.3). For example, the "Swedish” APP mutation results in enhanced production of Ap40 
and Ap42 (Citron et al., 1997). Furthermore, plasma Ap42 levels from FAD patients with 
PS1 gene mutations are elevated, suggesting increased generation of what is thought to be 
the more amyloidogenic form of the Ap peptide (Borchelt et al., 1996).
Most cases of AD are sporadic and they cannot be explained by identified genetic 
mutations. The ApoE e4 allele has been genetically linked to SAD and has a gene dose 
effect on the risk and age of onset of the disease (Corder et al., 1993; Saunders et al.,
1993). Individuals with two copies of the e4 allele have a 50-90% chance of developing 
AD by the age of 85 years, and those with one copy have an around 45% chance (Corder 
et al., 1993). The mechanisms by which the e4 allele conveys the development of AD are 
largely unclear but many studies have revealed isoform specific effects on 
neurodegeneration, Ap deposition, fibrillisation, and neuritic plaque formation (reviewed 
in Bales et al., 2002).
1.2.5. Environmental risk factors
Most cases of AD are sporadic late-onset, and although there are no known definite 
causes of late-onset SAD, there are several known, non- genetic risk factors.
Risk factors of a medical nature include traumatic head/brain injury (Rasmusson et al., 
1995), low cerebral perfusion (de la Torre et al., 1999), cerebral infarcts (Heyman et al.,
1998), strokes and cardiovascular disease (Brayne et al., 1998), hypertension (Kokmen et
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al., 1991), thyroid disease (Genovesi et al., 1996), viral infections (Grant et al., 2002) and 
depression (Palsson et al., 1999).
Dietary risk factors include a high cholesterol diet and high dietary fat intake (Luchsinger 
et al., 2002; Grant et al., 2002), low intake of n-3 fatty acids (Morris et al., 2003) and 
aluminium in drinking water (Flaten et al., 2001).
13. Neuro pathologies I Hallmarks of AD
There are four major anatomical changes that occur in the AD diseased brain: cortical 
atrophy, degeneration of neurons, accumulation of extracellular amyloid plaques and 
accumulation of intracellular neurofibrillary tangles. The latter two, plaques and tangles, 
are the hallmarks of AD and their main histological components are two proteins, 
amyloid (J-peptide (A0) and tau, respectively (reviewed in Selkoe, 2001).
13.1. Senile Amyloid Plaques
There are two major types of amyloid plaques in AD brain, neuritic plaques and diffuse 
plaques. Neuritic plaques contain dense bundles of amyloid fibrils and are surrounded by 
dystrophic neurites, astrocytes, and microglia. Diffuse plaques contain non-structural 
amyloid and are not surrounded by dystrophic neurites. Neuritic plaques may develop 
from diffuse plaques (reviewed in Selkoe, 2001).
The number of neuritic plaques has not shown a clear correlation with the severity of 
dementia in AD (Terry et al., 1991). Some cognitively preserved aged individuals have 
such a high density of neuritic plaques in brain that the diagnosis of AD would be made if 
the individual exhibited any clinical signs of dementia (Katzman et al., 1988; Price et al.,
1999). However, these cases may represent preclinical AD.
13.2. p-amyloid peptides
P-amyloid peptides are the main constituent o f senile plaques. They are formed by the 
proteolytical processing of amyloid precursor protein (APP). In healthy brain, the major 
cleavage product is 40 amino acids long P-amyloid (Ap40), but some longer P-amyloid 
42 is also produced (Selkoe, 2001). P-Amyloid 42 (AP42) seems to be the important
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isoform in plaque formation, since it is less soluble due to its additional N-terminal (3- 
pleated sheet structure, which increases its tendency for fibril formation and aggregation 
(Selkoe, 2001). The initial extracellular Ap deposits are composed mainly of Ap42, 
although the senile plaques contain both aggregated Ap40 and Ap42 (Iwatsubo et al.,
1994). Many studies indicate that the aggregation of Ap42 may be the critical event in the 
pathogenesis o f AD (Younkin, 1995), particularly in the formation of plaques, but 
possibly also in cell death after intracellular Ap accumulation.
. Studies of Ap neurotoxicity have traditionally focused on the effects of insoluble amyloid 
fibrils (reviewed in Selkoe, 2001), but recent work suggests that soluble, pre-fibrillar 
aggregates of Ap may also confer toxicity to cultured neurons (Lambert et al., 1998; 
Klein et al., 2001; Lashuel et al., 2002; Walsh et al., 1997, 2002). Behavioural and 
morphological alterations found in several strains of APP transgenic mice prior to the 
apparently fibrillar amyloid plaques suggest that soluble monomeric or oligomeric Ap 
species can mediate neuronal injury in these animals (Mucke et al., 2000). Moreover, 
microinjected intracerebroventricularly soluble oligomers were found to inhibit the late 
phase of long term potentiation (LTP) in the rat hippocampus in vivo (Walsh et al., 2002).
The research interest was not only shifted from insoluble Ap to more soluble forms, but 
also from extracellular to intraneuronal. Increasing evidence indicates the role of Ap 
accumulation inside the cells, in particular, neurons. Intraneuronal Ap may trigger 
intracellular and/or extracellular Ap fibrillogenesis (La Ferla et al., 1995; Walsh et al.,
2000) and intraneuronal toxicity (Kienlen-Campard et al., 2002). Neurons in AD- 
vulnerable brain regions specifically accumulate amyloidogenic Ap42 and this 
intraneuronal Ap42 immunoreactivity appears to precede both neurofibrillary tangles and 
Ap plaque depositions (Gouras et al., 2000). Ap42 aggregates into oligomers within 
endosomal vesicles and along microtubules o f neuronal processes. It occurs both in 
neurons in culture from APP transgenic mice (Tg2576, for details see section 1.7.2) and 
in Tg2576 and human AD brain (Takahashi et al., 2004), which is associated with 
pathological alterations within processes and synaptic compartments in Tg2576 mouse 
and human AD brains
Therefore, prevention or disruption of intracellular Ap deposition could be one of the 
important therapeutic goals for AD. The discovery that the APP transgenic mice (Tg2576,
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for details see section 1.7.2) demonstrate an initial intraneuronal Ap deposition in the 
somata o f the hippocampal CAl/subiculum neurons as early as 4 months of age, prior to 
the first presence of extracellular Ap plaques at 9 months of age is an important finding 
(Shie et al., 2003). This presence of Ap in the neuronal bodies may be one of the initial 
steps in a cascade of events leading to neuronal death and extracellular amyloid 
deposition or be responsible for dementia. Also the intraneuronal hippocampal Ap might 
have disturbed the integrity of the hippocampal circuit, explaining the behavioural 
changes observed in young Tg2576 mice prior to any formation of amyloid plaques.
U 3 .  Amyloid Precursor Protein metabolism
Amyloid Precursor Protein (APP) is a type-I transmembrane protein (Selkoe, 2001). The 
major isoforms consisting of 695, 751, and 770 amino acid residues are expressed widely, 
with brain neurons expressing primarily the 695 isoform (Selkoe, 2001). Despite years of 
intense investigation, the normal functions of APP and its catabolites remain unclear. The 
APP holoprotein may be involved in cell-cell interaction, cell adhesion, protease 
inhibition (for the longer APP isoforms), and neurite outgrowth (King, 2004) and the 
secreted fragment APPs may have neuroprotective and neurotrophic properties (King & 
Scott, 2004).
The proteases involved in the proteolytical processing of APP into Ap, are the a-, P- and 
y-secretases (reviewed in Selkoe, 2001, see Figure 1.1). Studies shown that a-secretase is 
a zinc metalloproteinase and several candidates fulfil the criteria required of a-secretase 
(reviewed in Allinson et al., 2003).
The formation of p-amyloid peptides involves the cleavage of APP by p- and y-secretases 
(Haass et al., 1992, Shoji at al, 1992). P-secretase cleaves APP just before the p-amyloid 
region, which releases a large amino-terminal part of APP and creates a 12 kDa carboxy 
terminal fragment (Citron et al., 2002). p-secretase was identified by five groups as a 
novel membrane-bound aspartyl protease and is also called as the p-site-APP-cleaving- 
enzyme 1 (BACE1) or membrane aspartyl protease (Memapsin2) (Lin et al., 2000; Vassar 
et al., 1999; Sinha et al., 1999; Yan et al., 1999; Hussain et al., 1999).
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Figure 1.1 Processing o f  amyloid precursor protein
(a) Normal processing o f APP involves cleavage predominantly by the a-secretase, which cuts APP in the 
middle o f  the 3-amyloid sequence, thus precluding the formation o f  A3 In the brains o f  FAD patients, 
processing by the 3_and y-secretases dominates, producing an excess o f 3-amyloid. Mutations to the APP 
gene cluster around the 3_ and y-secretase sites, suggesting one mechanism by which APP processing can be 
misdirected towards producing the more toxic A3 peptide.
(b) Presenilin has multiple membrane-spanning domains (green), two o f which contain conserved aspartate 
residues that suggest aspartyl protease activity In vitro and in vivo evidence that presenilins bind APP 
suggest a model like that shown in (b), in which presenilin cleaves APP into A3 within the membrane 
Mutations directed towards and around the putative aspartyl protease site lead specifically to overproduction 
of the highly amyloidogenic A342 (adapted from Chapman et a l , 2001).
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The cleavage o f the 12 kDa fragment by the y-secretase generates the 4 kDa P-amyloid 
peptide. The y-secretase can generate p-amyloid peptides ending at different residues, 
valine-40 or alanine-42 (Ap40 and AP42) (Selkoe, 2001). y-secretase catalyses 
intramembrane proteolysis o f various type I membrane proteins, including the APP and 
the Notch receptor. Four membrane proteins are now known to be members of the 
protease complex: presenilin-1 or -2-nicastrin-aphl-pen2 (Esler et al., 2002; Li et al., 
2000; Steiner et al., 2002 and Wolfe et al., 1999). Recent findings suggest that these four 
proteins are sufficient to reconstitute the active y-secretase complex and that together they 
mediate the cell surface signalling o f a variety of receptors via intramembrane proteolysis 
(reviewed in Kimberly et al., 2003). The p- and y -secretases are obvious targets for drug 
development for the prevention and treatment of AD, but these proteases have a 
widespread tissue distribution and multiple substrates including Notch for presenilin y - 
secretase, which creates difficulties (Citron et al., 2002; Selkoe & Kopan, 2003).
13.4. Neurofibrillary tangles and tau protein
Neurofibrillary tangles (NFTs) are comprised primarily o f paired helical filaments formed 
from tau protein (Wood et al., 1986) and are found primarily in the pyramidal regions of 
the amygdala, hippocampus and neocortex. In non-AD patients, tau protein provides 
support to the cell's framework o f microtubules. In AD patients, tau protein is hyper- 
phosphorylated. The extra phosphate is thought to cause microfilaments to become 
abnormally paired into helical filaments, which in turn form tangles. The cell then 
collapses and dies. A variety o f kinases are capable of phosphorylating tau in vitro and 
these may represent a target for AD pharmacotherapy (reviewed in Hamdane et al., 2003)
Tangles predominantly affect those areas o f hippocampus that are involved in processing 
learning and memory, which correlates with clinical deficits observed at early stage AD 
(Guillozet et al., 2003). It has been suggested that NFTs are related to the progression of 
AD (Braak et al., 1995; Guillozet et al., 2003), and a correlation between the number of 
NFTs and cognitive decline in AD has also been reported (Samuel et al., 1994; Nagy et 
al., 1995; Guillozet et al., 2003).
Unlike APP and the presenilins, no genetic links have been found between tau and AD 
(Buee et al., 2000). More than ten mutations have been described in the tau gene among
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families with cases diagnosed as frontotemporal dementia with parkinsonism linked to 
chromosome 17 (Buee et al., 2000). Neuropathologically, these patients exhibit frontal 
and temporal lobe atrophy, filamentous tau pathology in neurons, gliosis, and neuronal 
loss (Buee et al., 2000).
1.3.5. Neuronal and synaptic loss
AD is characterised by degenerative changes in selected brain regions, including the 
temporal and parietal lobes and restricted regions within the frontal cortex and cingulate 
gyrus (reviewed in Wenk, 2003). The earliest neuronal cell loss is detected in the 
entorhinal cortex (Gomez-Isla et al., 1996), hippocampus (West et al., 1994) and in the 
basal nucleus o f Meynert (Vogels et al., 1990). The exact mechanism of cell death in AD 
is unknown, but it may be linked to the neurotoxicity of Ap, the development o f NFTs, 
synaptic degeneration or apoptosis as evidenced by the expression of proteins related 
apoptotic pathways (Anderson et al., 1996; Su et al., 1997).
Along with (and possibly because of) the neuronal loss, AD is associated with 
degenerative changes in a variety of neurotransmitter systems. These include alterations 
in the function o f the cortical cholinergic, serotoninergic, adrenergic and glutamergic 
systems in the hippocampal perforant pathway (reviewed in Wenk, 2003).
The degeneration of these systems may underlie specific aspects of the dementia 
associated with Alzheimer's disease.
1.4 Current theories underlying pathology of AD
Current theoretical characterisation o f the pathological mechanisms underlying AD can 
be grouped into four main categories.
1.4.1. Amyloid Cascade Hypothesis
The amyloid hypothesis is the most powerful o f the four hypotheses. It proposes that 
deposition of AP, the main component o f senile plaques, is the causative agent of amyloid 
pathology and that the neurofibrillary tangles, cell loss, vascular damage, and dementia 
follow as direct results o f this deposition (Hardy & Higgins, 1992). This amyloid cascade
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is schematically illustrated in Figure 1.2. Key observations supporting p-amyloid as the 
initiating factor in AD include:
•  Mutations causing AD increase the production of Ap, or disturb the normal 
proteolytical processing o f APP (reviewed in Selkoe, 1997). APP mutations at codons 
716 and 717 lead to increased production o f Ap42 (Suzuki et al., 1994, Eckman et al., 
1997), mutations at codons 670/671 (Swedish mutation) increase Ap42 and Ap40 
production (Citron et al., 1992; Scheuner et al., 1996), and PS 1 and 2 mutations increase 
the production o f Ap42 (Borchelt et al., 1996; Duff et al., 1996; Scheuner et al., 1996).
• ApoE4, a major risk factor for SAD, increases Ap deposition (Holtzman et al., 2000).
• In Down syndrome (trisomy 21), the overexpression o f chromosome 21-linked genes, 
including the APP gene, is related to the development of the neuropathological changes 
similar to AD around the age of 40 years (Iwatsubo et al., 1995).
• Transgenic mice exclusively overexpressing a FAD-linked mutant APPs develop first 
diffuse and then fibrillar Ap plaques, associated with dystrophic neurites, astrocytes, and 
microglia. These plaques reproduce the major features of AD pathology, and cause in 
mice impairments in cognitive tasks. (Games et al., 1995; Masliah et al., 1996; Hsiao et 
al., 1996).
• Ap can self-aggregate in vitro, and these aggregates can directly and indirectly 
mediate neurotoxicity (reviewed in Yanker, 1996).
Initially, investigators proposed that Ap accumulation triggered a pathological cascade 
that ultimately produced the complete pathological and clinical symptoms of AD (Hardy 
& Higgins, 1992). Today, this hypothesis remains valid, except that it is less clear whether 
Ap deposited as amyloid, or some other less well-characterized Ap aggregate, initiates the 
cascade leading to neuronal death and dysfunction.
Small AP oligomers (Lambert et al., 1998), also referred to as AP-derived diffusible 
ligands (ADDLs), and protofibrils (Walsh et al., 1997, Lashuel et al., 2002) have emerged 
as alternative aggregated forms of Ap that may mediate toxicity. Moreover, there is some 
evidence that intracellular accumulations o f Ap may also be neurotoxic (LaFerla et al., 
1995, Gouras et al., 2000). Taken together these data support the hypothesis that AD 
results from the overproduction of the Ap peptide(s).
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Figure 1.2. Amyloid-based versus tau-based hypothesis for AD pathology According to the amyloid 
hypothesis, pathological processing o f APP leads to increased brain concentration o f AP, which in turn leads 
to amyloid plaque deposition. The plaques and/or more soluble AP can lead to neuronal death and tau 
pathology Cognitive loss, culminating in dementia, can occur as a result o f amyloid plaque formation, 
neuronal loss, direct effects o f non-deposited AP, or some combination o f these
The tau hypothesis emphasises the role o f tau and the consequent neurofibrillary tangles in producing cell 
loss and dementia While amyloid pathway is more accepted, tau pathology is better correlated with dementia 
in humans (adapted from Chapman, 2001).
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1.4.2. The Tau Hypothesis
The tau hypothesis argues that in AD, the normal role o f tau in stabilising microtubules is 
impaired leading to tangle formation and neurodegeneration (reviewed in Mudher & 
Lovestone, 2002). The tau and tangle hypothesis is supported by the fact that tangles 
occur in the neuron, accumulate to occupy much o f the neuron and apparently result in 
neuronal death, as extracellular tangles in the shape of neurons are abundant in late stages 
of AD (Mudher & Lovestone, 2002).
Support for this hypothesis arose from studies showing that tangles develop in neurons 
and that their abundance correlated with dementia severity (Samuel et al., 1994; Nagy et 
al., 1995; Guillozet et al., 2003). One of the assumptions of this hypothesis is that tau 
mutations alter tau phosphorylation, reducing the binding of tau to microtubules and 
leading to tangle formation (Mudher & Lovestone, 2002). However, tau mutations that 
lead to hyperphosphorylation and aggregation o f tau do exist, but they do not cause AD 
(Hutton et al., 1998). Recent evidence from two transgenic studies (Gotz et al., 2001; 
Lewis et al, 2001) has demonstrated that NFTs and senile plaques formation are 
pathogenically related, illustrating that in some incidences amyloid influences the 
formation o f NFTs. This in turn, provided some support for the amyloid cascade 
hypothesis.
1.43. The role of inflammation
The concept of inflammation as a major factor in AD has been based on post-mortem 
findings o f immunological changes associated with the plaques, coupled with 
epidemiological evidence o f a protective effect of anti-inflammatory agents (reviewed in 
McGeer & McGeer, 1995; Akiyama et al., 2000; Fassbender, 2000).
Microglial cells and astrocytes orchestrate the immunological reactions in AD. Highly 
activated microglial cells (the brain-resident cells o f the mononuclear phagocyte system) 
cluster around plaques, express complement receptors and produce pro-inflammatory 
proteins (Akiyama et al., 2000). Microglia are normally the first cells in the brain to react 
to injury or infection and they recruit astrocytes by secreting proteins o f the complement 
system, and through the release of cytokines, such as Interleukin-ip (IL-ip) and tumour
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necrosis factor-a (TNF-a) (Eikelenboom et al., 1998). Astrocytes respond by releasing 
other complement proteins and acute-phase proteins, such as al-anti-chymotrypsin and 
a2-macroglobulin, as well as neuronal growth factors and various cytokines -  such as 
Interleukin-6 (IL-6) (Eddleston et al., 1993). Murine models of AD that overexpress APP 
and develop Ap plaques also exhibit pro-inflammatory activation o f microglia and 
astrocytes (Frautschy et al., 1998; Benzing et al., 1999; Stalder et al., 1999; Mehlhom et 
al., 2000; Bomemann et al., 2001). Also IL-6 mRNA levels in the hippocampus and 
cortex are shown to be increased in both young and old APP transgenic mice as compared 
to non-transgenic mice (Tehranian et al., 2001). This increase in IL-6 mRNA levels is an 
early event in an Ap-induced immune response cascade occurring before amyloid plaques 
can be detected and thus can represent a potential marker.
Microglia have been suggested to be responsible for either Ap deposition (Frackowiak et 
al., 1992) or Ap clearance (Bacskai et al., 2000; Chung et al., 1999; Jantzen et al., 2001). 
Microglia's role in neurodegeneration is not clear, although it has generally been assumed 
to be more negative. Studies o f transgenic mice that overexpress mutant human APP and 
develop plaques have shown that crossing such mice with mice overexpressing a natural 
inhibitor o f complement C3 results in a worsening of AP plaques load and more neuronal 
loss (Wyss-Coray et al., 2002). This result suggests that the inflammatory changes found 
in AD and mouse models, including activation o f the classical complement cascade, may 
represent a beneficial response, at least in part.
There is evidence that the risk o f AD is substantially influenced by polymorphisms in the 
inflammatory agents - IL -la , IL-ip, IL-6, TNFa, a-(2) macroglobulin and 
antichymotrypsin (McGeer, 2001). It appears that AD is associated with alleles that 
promote increased transcription (McGeer & McGeer, 2001). This risk is increased when 
individuals carry AD-associated polymorphisms in two or more genes, as single 
nucleotide polymorphisms in the IL -la  and the IL-ip genes can give an almost four-fold 
elevated risk o f contracting AD (Hedley et al., 2002).
AP peptide itself can induce a local inflammatory response, as fibrillar Ap was shown to 
bind the complement and activate the classical complement pathway (Rogers et al., 1992). 
The activated complement products are suggested to play a key role in the recruitment 
and activation o f microglia at the sites o f fibrillar Ap deposits (Eikelenboom et al., 1996).
15
In turn, these activated microglia produce multiple pro-inflammatory cytokines, which 
can start in turn a positive feedback loop that may trigger further dysregulation of the 
APP metabolism and local production of complement proteins and acute-phase proteins 
(Eikelenboom et al., 1996).
In summary, the idea that inflammatory processes are involved in AD pathogenesis is 
supported by genetic, pathological and epidemiological findings. But the problem is still 
to determine whether neuroinflammation is a cause or a consequence of the disorder.
1.4.4. The role of oxidative stress
The hypothesis that oxidative stress might be involved in AD pathogenesis was originally 
based on the free radical hypothesis o f aging, which stated that age-related accumulation 
of reactive oxygen species (ROS) results in damage to major components of cells. The 
fact that age is a key risk factor in AD provides support for the free radical hypothesis, 
because the effects o f the attacks by free radicals can accumulate over the years.
Oxidative stress is caused by an imbalance between the increased production of free 
radicals and the anti-oxidative defences (Halliwell, 1992). Free radicals are powerful 
harmful agents causing cell death or other forms o f irreversible damage to major 
components o f cells: nucleus, mitochondrial DNA, membranes, and cytoplasmic proteins 
(Christen, 2000). Neurons appear to be particularly vulnerable to attack by free radicals, 
because their content o f glutathione, an important natural antioxidant, is low, their 
membranes contain a high proportion o f polyunsaturated fatty acids and brain metabolism 
requires substantial quantities o f oxygen (Christen, 2000).
Oxidative stress can occur for a variety o f reasons, some as common as the action of 
toxins from smoking or pollution (reviewed in Halliwell, 1997). This has been associated 
with numerous diseases including cancer, atherosclerosis, diabetes, and 
neurodegenerative disorders such as brain ischemia, Parkinson’s disease, familial 
amyotrophic lateral sclerosis and AD (Halliwell, 1997)
Multiple lines of evidence have implicated oxidative stress and free radical damage to the 
pathogenesis and possible aetiology o f AD (reviewed in Markesbery, 1997; Christen, 
2000; Smith et al., 2000; Veurink et al., 2003).
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The oxidation o f mitochondrial DNA and, to a lesser extent, o f nuclear DNA has been 
observed in the parietal cortex of AD patients (Mecocci et al., 1994). Protein oxidation 
has been observed in elderly individuals with and without AD, but appears to be more 
marked in AD patients in the regions presenting the most severe histopathological 
alterations (Hensley et al., 1995). Many studies have shown increased lipid peroxidation 
in the brains o f AD patients, particularly in the temporal lobe, where histopathological 
alterations are very noticeable (Palmer et al., 1994; Lovell et al., 1995; Marcus et al., 
1998). Montine (1998) and co-workers found that cerebrospinal fluid F2 -isoprostane 
concentrations are elevated in AD patients. These compounds are produced by free 
radical-catalysed peroxidation o f arachidonic acid, independent of the cyclooxygenase 
enzyme. This discovery is important because it confirms that lipid peroxidation is elevated 
in AD, but also because it suggests the possible use of the quantification of cerebrospinal 
fluid F2 -isoprostane concentrations as a biomarker o f this disease.
There is a dual relation between Ap and the production of free radicals. Not only can the 
oxidative processes transform non-aggregated Ap into aggregated Ap in vitro (Dyrks et 
al., 1992), but also p-amyloid itself is a source o f free radicals (reviewed in Veurink et al., 
2003). It has been demonstrated that Ap causes ROS accumulation in cultured 
hippocampal neurons (Mattson et al., 1995). It also induces lipid peroxidation (Butterfield 
et al., 1994). Ap can cause excess production o f superoxide radicals by interaction with 
vascular endothelial cells (Thomas et al., 1996). More recently, it has been shown that Ap 
can elevate levels o f hydrogen peroxide via its superoxide dismutase-like activity (Chan 
et al., 1999).
Collectively, this evidence suggests that assessing and reducing oxidative damage may be 
a beneficial clinical strategy to help prevent or delay the development and progression of 
AD. If, as appears more likely, oxidative damage is a downstream consequence of cell 
death caused by other specific mechanisms (hyperphosphorylation of tau), it is likely to 
be a key component in the cascade o f pathology and pathogenesis and as such a potential 
target for neuroprotective therapy.
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1.5. Treatment strategies
There is no cure for Alzheimer’s disease. However, there are several drug treatments that 
may provide some symptomatic relief. Clinical treatments aim to provide support for 
surviving neurons and also seek to compensate for the partial loss of specific populations 
o f cells, e.g. the cholinergic neurones by enhancing the function of remaining ones. This 
is the action o f cholinesterase inhibitors, which can only produce a mild delay in the 
development of symptoms. Recent therapeutic approaches are directed to decreasing Ap 
production or aggregation, or increasing its removal. Furthermore, more distal pathways 
are also targeted. Researchers are looking into modulating downstream events due to the 
presence o f Ap oligomers, such as free radical toxicity, inflammation, cell membrane 
damage, calcium dishomeostasis and excitotoxicity, or blocking the cellular response to 
injury through inhibition o f neuronal apoptosis.
1.5.1. Cholinesterase inhibitors
Chol inesterase inhibitors enhance neuronal transmission by increasing the availability of 
acetylcholine at the receptors. They have been approved by the US Food and Drug 
Administration (FDA) and the European Medicines Evaluation Agency (EMEA) as 
treatment for AD for a long time, although they only provide symptomatic relief, not a 
recovery. Four inhibitors are currently available: tacrine, donepezil, rivastigmine, and 
galantamine (Cummings et al., 2002). These agents have been shown to produce 
improvements in global function and cognition. As such, they provide “cognitive 
enhancer’ function and improve the individuals capacity to compensate for disability, 
rather than alleviating a specific component o f the disease process per se. Secondary 
benefits include reduction in behavioural disturbances, temporary stabilisation o f 
activities o f daily living, delay o f nursing home placement, and reduced demands on 
caregiver time (reviewed in Wynn & Cummings, 2004).
1.5.2. Vaccination
Despite very positive findings from APP mice models that immunization with synthetic 
Ap or passive transfer o f Ap antibodies can markedly decrease the number and density of 
Ap deposits in the brain (Schenk et al., 1999; Bard et al., 2000) and reverse impaired 
learning and memory (Dodart et al., 2002), the clinical trials in which Ap42 synthetic
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peptide was administered parenterally to individuals with mild to moderate AD had to be 
discontinued (Weiner et al., 2002; Hock et al., 2003). A phase II trial was discontinued 
when about 5% of the treated participants developed inflammatory reaction in the brain, 
although the preliminary evidence indicated an improvement in cognition scores over 
controls, including immunised patients that didn’t produce any antibody (Weiner et al., 
2002; Hock et al., 2003). Although initial clinical trials met problems, multiple studies are 
still investigating this treatment strategy further.
1.5.3. Memantine
Memantine, a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, was 
shown to have clinical benefit and good tolerability in AD. Due to its mechanism of 
action, memantine is considered a neuroprotective drug, whose value has been 
demonstrated in preclinical studies (Miguel-Hidalgo et al., 2002). Memantine exhibited 
efficacy and safety in trials in patients with moderate to severe AD (Reisberg et al., 2003). 
In October 2003, the FDA approved memantine for the treatment of moderate to severe 
AD.
1.5.4. Non- Steroidal Anti-Inflammatory Drugs (NSAIDs)
The pharmacological activity o f NSAIDs is generally attributed to the inhibition of 
cyclooxygenases (COXs), enzymes necessary for the production of prostaglandins and 
leukotrienes from arachidonic acid. There are two kinds of COXs - COX-1 and COX-2, 
the constitutive and inducible forms of COX, respectively. They are known to be involved 
in inflammatory responses and normal neuronal functions.
The first indication that anti-inflammatory drugs might lessen the risk of Alzheimer’s 
disease came from an observation that people with rheumatoid arthritis had an 
unexpectedly low prevalence of dementia (McGeer et al., 1990). It was an inventive idea, 
and more data have now accumulated, but the matter still remains unsettled. Up to now, 
there is compelling epidemiological evidence that long-term NSAID therapy has a 
dramatic effect on the risk of developing AD (Breitner et al., 1995; McGeer et al., 1996; 
Stewart et al., 1997; in t ’ Veld et al., 2001). Moreover, NSAID treatment delays disease 
onset, acts to ameliorate symptomatic severity, and slows disease progression (Rogers et 
al., 1993; Breitner et al., 1995, Rich et al., 1995, Stewart et al., 1997). Recently published
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systematic review corroborated that NSAIDs do offer some protection against AD, 
particularly when taken long term (Etminan et al., 2003). Additionally, in humans, 
NSAIDs therapy results in a substantial reduction in the number of microglia associated 
with senile plaques, supporting the view that these cells are the targets of drug action 
(Mackenzie et al., 1998).
Although the NSAIDs data are encouraging, recommendations for chronic NSAID 
therapy in healthy elderly individuals are tempered by the documented risk o f 
gastrointestinal bleeding and ulceration (James et al., 1999). To reduce the risk o f 
gastrointestinal injury, new classes o f NSAIDs have been developed, including selective 
inhibitors o f cyclooxygenase-2 (COX2) and nitric oxide (NO)-donating NSAIDs.
These epidemiological findings have stimulated substantial interest in clinical trials of 
various anti-inflammatory agents to improve symptoms or delay progression in patients 
diagnosed with AD. The first study used indomethacin treatment for 6 months and 
provided slight but statistically significant improvement on a battery of cognitive tests, 
whereas placebo-treated patients declined (Rogers et al., 1993). However, this finding 
could not be reproduced in other studies using diclofenac/misoprostol (Scharf et al., 1999) 
prednisone (Aisen et al., 2000) or hydroxychloroquine (van Gool et al., 2001).
Although a lot o f interest was placed in the newest group of NSAIDs - selective COX-2 
inhibitors, studies have failed to support the hypothesis that they can slow the rate of 
decline in AD (Sainati et al., 2000; Aisen et al., 2003; Reines et al., 2004). The failure o f 
selective COX-2 inhibition to slow the progression of AD may indicate either that the 
disease process is too advanced to modify in patients with established dementia or that 
COX-2 does not play a significant role in the pathogenesis of the disorder.
Epidemiological findings have stimulated substantial interest in the biological basis of the 
effect of this class of drugs, but the way that NSAIDs act to reduce the risk of AD is 
presently unclear. There are a variety o f hypotheses, some of them conflicting with each 
other.
• The well-established function o f NSAIDs is inhibiting COXs, both 1 and 2, and 
therefore, interleukin and prostaglandin formation. The prostaglandin (PG) H2 was shown 
to markedly accelerate the formation o f dimers and higher oligomers of amyloid Ap42
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(Boutaud et al., 2002). Moreover, in studies in vitro, neurones treated with NSAIDs were 
protected against the toxic effects of A(142 and COX-1 selective inhibitors provided 
greater protection than did COX-2 selective inhibitors, suggesting that activation of COX- 
1 is required for A|34 -induced neurotoxicity (Bate et al., 2003). Another study suggested 
that expression of COXs may influence Ap peptide generation through mechanisms that 
involve PG-E2-mediated potentiation of y-secretase activity, further supporting a role for 
COX-2 and COX-1 in Alzheimer's disease neuropathology (Qin et al., 2003)
• Another target of NSAIDs action is the nuclear receptor and transcription factor 
peroxisome proliferator-activated receptor-y (PPARy) (Lehmann et al., 1997; Landreth et 
al., 2001). The binding of NSAIDs to PPARy results in the inhibition of proinflammatory 
gene expression (Delerive et al., 2001). PPARy activation leads to inhibition of 
microglial-mediated neurotoxicity and cytokine expression elicited by Ap fibrils both in 
vitro (Combs et al., 2000) and in vivo (Heneka et al., 2000).
• The potential neuroprotective properties of the NSAIDs were investigated by 
examining whether ibuprofen could reduce lipid peroxidation and superoxide radical 
generation. Lipid peroxidation and superoxide anion formation were induced in rat brain 
homogenate and ibuprofen significantly reduced this induction, suggesting possible 
neuroprotective features of this agent (Lambat et al., 2000).
• NSAIDs show direct nitric oxide radical scavenging activities in neuronal cells. 
Aspirin, mefenamic acid, indomethacin and ketoprofen directly scavenge generated nitric 
oxide radicals, while ibuprofen, naproxen or steroidal drugs have less marked or no 
scavenging effects. These results suggest that the protective effects of the former four 
NSAIDs against apoptosis might be mainly due to their direct nitric oxide radical 
scavenging activities in neuronal cells indicating neuroprotective activities against 
neurodegeneration (Asunama et al., 2001).
• NSAIDs protect neurons against glutamate toxicity. Ibuprofen significantly attenuated 
the decrease in dopamine uptake caused by glutamate, indicating preservation of neuronal 
integrity (Casper et al., 2000). Glutamate excitotoxicity has been implicated in 
Alzheimer's disease thus NSAIDs deserve further consideration as neuroprotective agents.
• NSAIDs have been shown to target directly y-secretase. Eriksen (2003) and 
colleagues studied a whole range of NSAIDs in a human cell line and in APP transgenic 
mice. They showed that NSAIDs lower Ap42 in vitro and in vivo and there is a significant
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correlation between Ap42 lowering and levels of ibuprofen. Moreover, flurbiprofen and 
its enantiomers selectively lower Ap42 levels in broken cell y-secretase assays, indicating 
that these compounds directly target the y-secretase complex that generates Ap from APP. 
Weggen (2001) and colleagues reported that a subset of NSAIDs, including ibuprofen, 
selectively suppressed the production of the amyloidogenic Ap42 species both in vitro 
and in an acute treatment paradigm in vivo. In vitro, the decrease in Ap42 secretion was 
accompanied by an increase in the Ap (1-38) isoform, indicating that NSAIDs subtly alter 
y-secretase activity. This group suggested that NSAIDs directly affect amyloid pathology 
in the brain by reducing Ap42 peptide levels independently of COX activity.
•  NSAIDs can lower amyloidogenic AP42 by inhibiting Rho, a small GTP-binding 
protein (G protein) that is involved in numerous cellular processes, including cell 
migration and survival, transcriptional regulation and vesicle transport (Zhou et al., 2003). 
They showed that increasing the activity of small G proteins in cultured cells selectively 
increased the concentration of Ap42 while inhibition of the Rho effector Rho-associated 
kinase (Rock) reduced Ap42 levels. Furthermore, treating a transgenic mouse model of 
Alzheimer’s disease with Rock inhibitor reduced brain levels of Ap42. Only the NSAIDs 
that were effective as Rho inhibitors lowered as well Ap42 (Zhou et al., 2003).
•  Gasparini (2004) and co-workers investigated the effects of compounds from every 
chemical class of NSAIDs on AP40 and Ap42 secretion using in vitro studies and found 
that flurbiprofen and sulindac sulfide reduced the secretion not only of Ap42 but also of 
AP40. Surprisingly, both COX-2 and COX-1 selective compounds significantly increased 
Ap42 secretion. The levels o f pAPP C-terminal fragments and Notch cleavage were not 
altered by any of the NSAIDs, indicating that y-secretase activity was not overall changed 
by these drugs (Gasparini et al., 2004)
• Finally, NSAIDs have poorly defined effects on intracellular signalling pathways 
(Tegeder et al., 2001), including those used by cytokines (Baek et al., 2002).
The mechanisms through which NSAIDs act are likely to be complex and diverse. 
Although they have been examined extensively, no consistent conclusions can be drawn 
and further examination is clearly required.
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1.5.5. Vitamin £  and C
Antioxidants may protect the aging brain against oxidative damage associated with 
pathological changes of AD. As shown in recent cross-sectional and prospective study of 
dementia, the use of vitamin E and C supplements in combination is associated with 
reduced prevalence and incidence of AD (Zandi et al., 2004)
1.5.6. Oestrogen
Oestrogen replacement therapy for menopausal women has been shown to have potential 
both as a preventive and as a treatment for AD (reviewed in Cutter et al., 2003). Evidence 
from basic science demonstrates that oestrogen has multiple protective effects on neurons 
and neurotransmitter systems. However, the evidence for oestrogen’s clinical role in the 
treatment and prevention of neuropsychiatric disorders is not well established (Cutter et 
al., 2003). Furthermore Henderson (2000) and colleagues failed to show that oestrogen 
given in standard doses can improve cognition in postmenopausal women with AD.
1.5.7. Statins
Statins are used to treat hypercholesterolemia and reduce de novo cholesterol synthesis by 
inhibition of the HMG-CoA reductase. Recently, two retrospective epidemiological 
studies indicated that there is up to a 70% lower prevalence and incidence of AD in 
subjects taking statins (Jick et al., 2000; Wolozin et al., 2000). The role of cholesterol in 
AD pathology is reviewed in section 1.6.3 and chapter 5.
1.5.8. y-secretase inhibitors
Inhibition of production of amyloid peptides by inhibitors of y-secretases has been 
suggested as the rational and most specific therapeutic approach. Unfortunately, y- 
secretase complex is responsible for cleavage of various proteins, including Notch 
receptor. Recently, a y-secretase inhibitor was developed that is able to reduce Ap 
production without affecting Notch signalling, which raises the possibility that targeted y- 
secretase inhibitor therapy might enter into clinical trials (Petit et al., 2001) Moreover, y- 
secretase inhibitors were shown to reduce amyloid burden in animal models (Dovey et al.,
2001).
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1.5.9. Reversal or Prevention
When formed, amyloid plaques cause serious destruction to the surrounding brain tissue. 
This leaves the production of Ap as the major target for consideration as therapeutic 
intervention. Usually the symptoms of AD do not appear until Ap deposition in brain is 
extensive. Currently no pre-mortem diagnostic tool exists and substantial quantities of Ap 
have already formed by the time AD is suspected or a diagnosis is made. By this time, the 
amount of AP already deposited may be sufficient to lead to an inevitable decline in 
neuronal viability and ultimate demise. In such situations the reduction, or even complete 
elimination, o f Ap production would not yield a 'cure', or possibly even much therapeutic 
benefit.
The scenario for the prevention, or early intervention, of Ap deposition in persons who 
are pre-disposed to AD or suspected of having early signs of the disease is quite different 
from that presented above for reversal or cure. If the concept of giving any drugs as 
preventative proves to be a viable strategy, then questions arise regarding the appropriate 
time that administration of such drugs should be initiated. For example, should all persons 
over some pre-specifled age be given the prophylaxis? Or should they be withheld until 
some suspicion of AD arises? Further what about members of families with the 'familial' 
form of the disease and the persons with Down syndrome?
Before these particular issues can be considered, we need to develop a better 
understanding o f the pathology of AD.
1.6. Lipid metabolism in Alzheimer’s disease
1.6.1. Overview
Lipids are major components of the mammalian diet. They consist of three main groups -  
neutral glycerides, phosphoglycerides and steroids. Neutral glycerides are primarily used 
to supply energy for cellular activities and are made up of a glycerol molecule esterifled 
with one to three fatty acids. Triacylyglycerol is the major neutral glyceride. Fatty acids 
usually contain an even number of carbon atoms (16-20 are most common) bonded in a 
chain with a carboxyl group (COOH) at the end. If all the carbon atoms are joined by 
single carbon-carbon bonds, these fatty acids are called saturated. If they have one or
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more double bonds between carbon atoms, they are called monounsaturated or 
polyunsaturated fatty acids respectively. The double bonds are counted from the methyl 
group determining the metabolic family, noted by n-x (n being the total number of 
carbon, x the position of the last double bond). Thus, for example, linoleic acid is named 
in the shorthand nomenclature 18:2, n-6. This compound has 18 carbon atoms, 2 double 
bonds and 6 carbon atoms from the last double bond to the terminal methyl group. A 
phosphoglycende molecule consists o f a glycerol bound to two fatty acids with a 
phosphate group at the third carbon atom. Phosphoglycerides are structural components 
of all cell membranes and differ from each other in the nature of the group attached to the 
phosphate. Steroids are lipids that include in their structure four rings of interconnected 
carbon atoms. The main steroid in mammals, cholesterol, is a major structural component 
of cell membranes and is used to synthesize other steroids, like the sex hormones 
(Lehninger, 2000).
1.6.2. Fatty Acids
Synthesis and structure
Although diet is a major source of fatty acids, most tissues synthesise fatty acids de novo. 
In addition, organs like the liver can also convert fatty acids from one form to another. 
However, humans cannot synthesise certain fatty acids de novo, such as linoleic acid (LA; 
18:2, n-6), a-linolenic acid (ALA; 18:3, n-3) and their metabolites: ylinolenic acid 
(GLA; 18:3, n-6), dihomo-GLA (DGLA; 20:3, n-6), arachidonic acid (AA; 20:4, n-6), 
eicosapentaenoic acid (EPA; 20:5, n-3), and docosahexaenoic acid (DHA, 22:6, n-3) 
(Yehuda et al., 2002). Because both n-3 and n-6 polyunsaturated fatty acids are required 
for good health, they are called Essential Fatty Acids and must be obtained from diet. LA 
is found in vegetable and nut oils such as sunflower, safflower, com, soy and peanut oils. 
ALA is present in seed oils, such as linseed oil, rapeseed oil, soy oil and some nuts, 
particularly walnuts (Das et al., 2003).
LA is a precursor of the n-6 series of fatty acids, which include GLA and AA; ALA is a 
precursor of n-3 series of fatty acids - EPA and DHA. The main active components in 
both series are the longer chain polyunsaturated fatty acids (PUFA) -  AA, DHA and EPA 
(Hansen et al., 1994). They are produced by desaturation and elongation using
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microsomal enzymes from LA and ALA, respectively, or obtained directly from diet (AA 
- meats, eggs and prawns; EPA and DHA - deep-sea fish). The metabolic pathway for the 
synthesis of AA and DHA is shown on Figure 1.3 (Haag et al., 2003). During synthesis 
the n-3 and n-6 acids compete for the same enzyme systems (Sprecher et al., 1995).
Fatty acids in human brain
Lipids make up 50 to 60 percent o f the dry weight of the brain, which represents the 
highest lipid content in human tissues after adipose tissue. Most of lipids are in the form 
of myelin surrounding neuronal axons. 35% of the total fatty acids of the brain are long 
chain PUFA, particularly DHA and AA (Sastry et al., 1985; Yehuda et al., 1999). 
Arachidonic acid is distributed in membrane phosphoglycerides throughout the body and 
is critically involved in second messenger pathways, cell signalling and eicosanoid 
pathways, whereas DHA is selectively enriched in synaptic plasma and retinal membranes 
(Sastry et al., 1985). The normal ageing process involves decreases in PUFA levels and 
changes in metabolism caused by decreased delta-6-desaturase activity (Horrobin et al., 
1981), increased inflammatory responses (McGeer et al., 1995) and oxidative damage to 
the cell membrane (Markesby et al., 1997).
PUFA in human diet
A typical adult in Western society ingests l-2g/day of ALA and the n-6/n-3 ratio o f the 
diet is typically in the area o f 8-16:1 (Lauritzen et al., 2001). The balance between the 
intakes of n-6 and n-3 fatty acids has been recognised by dieticians to be at least as 
important as the intake levels of individual fatty acids. This is because the metabolism of 
LA and ALA requires the same enzymes (they compete for them) and therefore if more n- 
6 is consumed, less long chain n-3 PUFA will be produced (Horrocks et al., 1999). 
Various health organisations now recommend a ratio of between 3:1 and 4:1 for dietary n- 
6/n-3 fatty acids (reviewed by Horrocks et al., 1999), though this does depend on the 
nature of the n-3 and n-6 fatty acids in the diet (Cunnane et al., 2003).
A typical daily supply of total very long chain n-3 PUFA in Western diets is estimated to 
be around 600 mg/day, with half of this amount coming from the diet (mainly fish) and 
the other half arising from endogenous production from ALA (Lauritzen et al., 2001).
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PUFA synthesis from Essential Fatty Acids
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Figure 1.3. PUFA synthesis from parent Essential Fatty Acids.LA and ALA are desaturated and 
lengthened progressively by microsomal enzyme systems, to form important, very long chain PUFA 
-  AA and DHA. Members o f  these two groups are inconvertible and they compete for the same 
enzyme systems in the cells (adapted from Haag et al., 2003).
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Biological functions of PUFA in the brain
To date, a multitude of functions for DHA and other PUFA have been explored and there 
is a considerable evidence for their many roles in the brain. These include both 
physiological and patho-physiological functions:
• AA, DHL A and EPA are precursors of eicosanoids (e.g. prostaglandins, 
thromboxanes and leukotriens), which are local hormones that participate in a number of 
physiological effects (e.g. parturition initiation, platelet aggregation, renal electrolyte 
regulation, blastocyte implantation and activation of immune cells) as well as patho­
physiological conditions (inflammation). Eicosanoids derived from n-6 PUFA generally 
have pro-inflammatory properties and activate immunological responses, while the ones 
derived from n-3 (mainly EPA) usually have anti-inflammatory features (Haag et al.,
2003). Thus, high intake of n-6 PUFA can lead to aggravated inflammatory conditions. 
The n-3 PUFAs may also have anti-inflammatory effects by suppressing synthesis of 
inflammatory cytokines such as IL-lp, IL -la  and TNF in humans (Endres et al., 1989).
• Modification of the PUFA content in a membrane may be associated with changes 
in its physical properties such as fluidity, flexibility and permeability, which in turn 
influence the activities o f membrane-associated molecules (Suzuki et al., 1998). PUFAs 
sustain cell membrane fluidity, i.e., the degree of freedom for molecules to move in the 
membrane. The ageing process is associated with a decrease in membrane fluidity and a 
decrease in the level of PUFA, particularly in hippocampus and cortex (Yehuda et al.,
2002). Changes in membrane fluidity have been shown to affect various membrane 
functions, including neurotransmitter release (e.g. glutamate). McGahon et al. (1999), in 
three published studies, postulated that age-related impairment in LTP is linked closely to 
a decrease in membrane fluidity affecting glutamate release. Eight week dietary 
supplementation of DHA, ALA, LA or AA reversed the age-related decrease in glutamate 
release and the impairment in LTP in vitro in the rat dentate gyrus. By increasing the 
fluidity of membranes, PUFAs also affect the activity of many major membrane-bound 
enzymes, like the Na/K-ATPase, which functions in maintaining neuronal membrane 
potential. The activity o f this enzyme in rat brain nerve endings was depressed by 40% in 
n-3 deficient rats, compared with the n-3 adequate group (Bourre et al., 1989).
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•  The n-3 PUFAs are essential for regulating neuronal excitability. Vreugdenhil et 
al. (1996) reported that extracellular application of either DHA or EPA caused a shift of 
the inactivation state towards a more hyperpolarising direction for both sodium and 
calcium currents in freshly-isolated rat hippocampal neurons from CA1 region of the 
hippocampus. Furthermore Xiao et al. (1999) reported that both DHA and EPA applied 
extracellulary to mouse brain slices reduced the frequency of electrically evoked action 
potentials in hippocampus regions and also hyperpolarised the resting membrane and 
raised the stimulatory threshold of action potentials. This stabilising membrane 
excitability function for n-3 PUFAs could be useful in the treatment of epileptic seizures.
• The PUFAs can influence various neurotransmitters levels in the brain. Delion and 
colleagues (1996, 1997) reported lower dopamine levels in the cerebral cortex in the n-3 
deprived rats, coupled with increased serotonin levels, accompanied by a low ratio of n-3 
to n-6 PUFA in the membrane. Furthermore, when Chalon (1998) and co-workers 
increased the ratio of n-3 to n-6 PUFA in rat diet, this resulted in increased dopamine 
levels in the cerebral cortex.
•  DHA appears to be crucial in brain development. Martin (1998) and co-workers 
showed selective accumulation of DHA in synaptic growth cones during neuronal 
development. The outgrowth of neurites induced by nerve growth factor was promoted 
by DHA and suppressed by AA (Ikemoto et al., 1997) and dietary n-3 PUFA deficiency 
decreased nerve growth factor content in rat hippocampus (Ikemoto et al., 2000). DHA 
deficiency caused a reduction in the size of neurons in the CA1 region of the 
hippocampus, hypothalamus and cortex, which could be linked to a loss in the optimal 
function of neurons (Ahmad et al., 2002).
•  The presence of PUFAs in the brain seems to be beneficial for preventing 
neuronal death. Lauritzen et al. (2000) showed that LA prevented neuronal death in 
animal models of global ischemia, even when administered acutely after the insult. Okada 
et al. (1996) showed that chronic administration of DHA to rats protected hippocampal 
neurons from damage caused by either hypoxia or ischemia and significantly improved 
the spatial learning deficit following hypoxic conditions. DHA also protected neural cells 
from induced apoptotic death (Akbar et al., 2002).
• PUFAs increase the number of receptors expressed on the cell membrane, 
including the insulin receptor, possibly by increasing membrane fluidity. Insulin receptors 
are on neurons and are believed to have a role in cognitive function, including learning
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and memory (Zhao et al., 1999). These insulin receptors are affected by deficiency of n-3 
fatty acids (reviewed by Das, 2002). Also, AA has been shown to stimulate glucose 
uptake when applied directly to cultured cerebral cortical astrocytes (Yu et al., 1993).
PUFA in cognitive function and AD
Adequate supplies of both AA and DHA are critical for optimal growth and functional 
development of the brain in infants (reviewed by Horrocks et al., 1999; Haag et al., 2003). 
First the placenta and then breast-feeding are the main sources of long chain PUFA for 
growing children, but these fatty acids are absent in most commercial infant formulas 
(Jensen et al., 2000). A meta-analysis of 20 published studies confirmed the association of 
breast-feeding with significantly higher scores for cognitive development compared with 
the infants who received formula feeding (Anderson et al., 1999).
In recent years, numerous studies have examined the influence of nutrition on ageing 
processes, particularly cognitive decline. For example, a study performed among aged 
men has shown that a high n-3 PUFA intake (via fish consumption) was inversely 
associated with cognitive impairment (Kalmijn et al., 1997).
The role o f DHA and other PUFAs has also been widely investigated in AD patients. 
Concentrations o f essential fatty acids were found to be abnormal in plasma and red blood 
cell phospholipids from AD patients compared to age-matched controls (Corrigan et al., 
1991). A particularly marked decrease in DHA content of phosphatidylethanolamines (a 
major class of brain phosphoglycerides) has been observed in frontal grey matter and 
hippocampus of AD patients (Soderberg et al., 1991). Yehuda et al. (1996) reported that 
an essential fatty acid mixture SR-3 (ALA and LA, in a ratio of 1:4) improved the quality 
of life (mood, appetite, sleep) of AD patients. Further clinical studies suggested that low 
serum DHA might be a significant risk factor in the development of AD in elderly 
patients (Kyle et al., 1999). Plasma levels of DHA, total n-3 fatty acids, and the ratio n- 
3/n-6 were lower in AD patients, patients suffering from other types of dementia and 
people with cognitive impairment when compared to normal patients. This study implied 
that a decreased level of plasma DHA was common in all types of cognitive impairment 
and not unique to AD (Conquer et al., 2000). Finally, two major epidemiological studies 
performed by Morris (2003) and co-workers revealed that intake of saturated or trans­
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unsaturated (hydrogenated) fats may increase the risk of developing AD and that 
consumption of fish or DHA reduces the risk of incidence of AD to 60% compared to a 
people on low n-3 diets.
Although the numerous studies reviewed above show that levels of DHA and other PUFA 
in the central nervous system during development and in adulthood could alter cognitive 
functions in humans, the precise mechanism of action of these fatty acids is still largely 
unknown.
1.63. Cholesterol
Cholesterol is the most prevalent steroid in humans and is an essential structural 
component o f cell membranes (Lehninger, 2000). Elevated levels of cholesterol are 
known to increase the risk of cardiovascular diseases such as heart attack and stroke, but 
accumulating evidence suggests that cholesterol may contribute to Alzheimer’s disease as 
well.
Cholesterol in the brain
The brain accounts for only 2% of the whole body mass but it contains almost a quarter of 
the total cholesterol. Relatively little is known about cholesterol homeostasis in the brain, 
as most of the studies on cholesterol metabolism have been performed in peripheral cells 
(reviewed in Dietschy & Turley, 2001, see Figure 1.4.). Lipoproteins circulating in 
plasma are the main source of cholesterol for peripheral cells, but they cannot cross the 
blood-brain-barrier (BBB) (Dietschy & Turley, 2001). Although some researchers 
suggest that a small fraction of lipoproteins could cross the BBB (Koudinov et al., 1996), 
it still means that the brain is almost entirely dependent on cholesterol synthesized de 
novo (reviewed in Dietschy & Turley, 2001). In fact, it has been established that 
cholesterol used by oligodendrocytes to produce myelin is made locally in the brain and is 
not transported from the periphery (Jurevics et al., 1995). It is also known that neurons 
form functioning synapses only in the presence of astrocyte derived cholesterol (Mauch et 
al., 2001).
31
Cholesterol metabolism in the brain
Cholesterol transfer within the 
brain (ApoE) P-amyloid
aggregation
Cholesterol 
influx into the 
brain from 
plasma
Action of a-, P- 
and y-secretasesNEURONAL CHOLESTEROL 
POOL
APP processing
Cholesterol 
Synthesis 
de novo
A
Statins
HMG CoA
Figure 1.4. Schematic view  o f  cholesterol homeostasis in neurons. Neurons maintain cholesterol 
homeostasis mainly through de novo biosynthesis (indicated by a thick arrow) but also to a lesser 
extent through internalisation o f  lipoproteins, obtained from either plasma or other parts o f  the brain 
(indicated by dotted arrows). Statins reduce de novo synthesis o f  cholesterol by inhibition o f  HMG- 
CoA reductase. The intracellular pool o f  cholesterol affects APP processing, A3 aggregation and the 
action o f  all secretases cleaving APP.
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Cholesterol is the product o f a multienzyme pathway that begins with the action of (3- 
hydroxy-p-methylglutaryl coenzyme A (HMG-CoA) synthase and reductase (Lehninger, 
2000). The latter enzyme is the target of statins, which are widely used to treat 
hypercholesterolemia. Cholesterol homeostasis is maintained by the interplay between 
synthesis, uptake and catabolism. Excess cholesterol is eliminated by acetylation or 
oxidation. In the brain, cholesterol when converted to 24-hydroxycholesterol can cross the 
BBB (Bjorkhem et al., 1998), and this is a putative way for it to be removed from the 
brain.
Brain cholesterol turnover is much lower than that of the periphery (Andersson et al.,
1990). As it is generally assumed that lipoproteins cannot cross the BBB, Edmond et al. 
(1991) has suggested that an increase in cholesterol in liver and plasma does not change 
the concentration of cholesterol in brain. However, animal studies brought contradictory 
results (reviewed in chapter 5). To support animal results, some studies show that a 
fraction of lipoproteins could cross the BBB (Koudinov et al., 1996),
Cholesterol in the periphery is transported by lipoproteins. The brain contains its own 
fraction of lipoproteins in cerebrospinal fluid, which could be responsible for local re­
distribution of cholesterol (Dietschy & Turley, 2001). Apolipoprotein E (ApoE) is the 
main transport protein in the brain for cholesterol. Intracellular cholesterol is absorbed 
onto ApoE leading to the formation of ApoE lipid complexes, which transport this sterol 
from regions high in cholesterol to regions low in cholesterol (Zhang et al., 1996; Mahley 
et al., 1988).
As an integral component of all membranes, cholesterol affects markedly their ordering, 
rigidity and fluidity. In general, higher cholesterol levels enhance the rigidity of the 
membrane and make it less permeable to small water-soluble molecules (Yeagle et al.,
1991).
The cell membrane is not considered a homogenous mixture of lipids and proteins any 
more, but also contains particular areas, called lipid domains (reviewed by Simons & 
Ehehalt, 2002; Lai, 2003). Lipid domains contain particularly high concentrations of 
sphingolipids and cholesterol. Lipid rafts (which are presumed to be too small and 
transient to be observed in situ) and caveolae are the main types of lipid domains. The
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latter are morphologically identifiable and have been recognised as stable flask-like 
invaginations of the plasma membrane (Lai, 2003). Lipid domains play a central role in 
many cellular processes, including membrane sorting and trafficking, cell polarisation and 
signal transduction (Simons & Ikonen, 1997). Lipid domains have been identified in most 
mammalian cells, including neurons and glia and have been implicated in pathogenesis of 
many diseases such as viral infections, AD and prion diseases (Simons & Ehehalt, 2002). 
Cholesterol plays a crucial role in composition, function and generation of lipid domains 
and, when present in either markedly low or high amounts, changes functioning of these 
structures (reviewed Simons & Ehehalt, 2002; Lai, 2003).
Cholesterol and AD Epidemiology
There have been a number of epidemiological studies that have pointed to a relationship 
between cholesterol and the development o f AD. Sparks (1990) and co-workers were one 
of the first groups to suggest a possible link between cholesterol and AD. They found that 
patients with critical coronary artery disease also showed deposition of Ap similar to that 
seen in AD patients. The link between cholesterol and AD became stronger when a 
genetic linkage study by Strittmatter et al. (1993) identified a variant of the gene that 
encodes the cholesterol-carrying ApoE as a late-onset AD risk factor. Approximately 
40% of AD patients have at least one ApoE s4 allele, and being homozygous for ApoE e4 
allele increases the risk of AD 4-fold. The leading hypothesis for the mechanism by 
which ApoE e4 increases the risk of AD is that ApoE binds Ap. This in turn, will either 
promote the aggregation of Ap or reduce clearance of aggregated Ap (reviewed Wolozin,
2004).
Further, cross-sectional analysis has described an association of atherosclerosis (for which 
hypercholesterolemia is a recognised risk factor) with AD in the Rotterdam Study 
(Hofman et al., 1997). Many other longitudinal studies in various populations have 
supported this discovery, suggesting inter-relationships between elevated cholesterol 
levels, ApoE genotype and late-life cognitive impairment or AD risk (Jarvik et al., 1995; 
Notkola et al., 1998; Evans et al., 2000; Kivipelto et al., 2001; Launer et al., 2001).
Recendy, two retrospective epidemiological studies indicated that there is up to a 70% 
lower prevalence and incidence of AD in subjects taking statins (Jick et al., 2000;
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Wolozin et al., 2000). Statins are used to treat hypercholesterolemia and reduce de novo 
cholesterol synthesis by inhibition of the HMG-CoA reductase. Whether statins reduce 
cerebral Ap by lowering cholesterol in the brain or by another mechanism remains an 
open question.
The role of serum cholesterol in cognitive performance in an aging population has also 
been studied. Teunissen et al. (2003) reported that relatively high ratios of the cholesterol 
precursors - lanosterol and lathosterol, indicative of a high rate of endogenous cholesterol 
synthesis, are associated with relatively low memory performance. No research has been 
done on the role of these precursors in the neurodegenerative processes.
Although these are interesting results, epidemiological studies cannot reveal the cause of 
disease. They can only suggest that cholesterol and AD pathogenesis are in some way 
linked.
Cholesterol and the processing of APP
There is growing biochemical evidence from studies in vitro that excess cholesterol may 
promote amyloid plaque formation. Although many studies have been performed, the 
results indicate various mechanisms and no unifying conclusion can be drawn. Here is a 
short overview o f interactions between cholesterol, APP and p -amyloid.
• APP and Ap are both associated with lipid domains (Bouillot et al., 1996; Lee et 
al., 1998; Refolo et al., 1991). Lipid domains have been proposed to regulate APP 
processing by favouring the clustering of APP and both y- and p-secretases (Ehehalt et al., 
2003; Ikezu et al., 1998; Lee et al., 1998). Also the physical association of Ap to 
ganglioside (GM1), another component of lipid domains, facilitates the aggregation of 
soluble AP in the form of amyloid fibrils (Yanagisawa et al., 1995). Another study 
suggested that Ap associated with lipid domains adopts a different conformation, acting as 
a ’’seed” for amyloid plaque formation (Mizuno et al., 1999). Various studies confirmed 
that caveolae-like lipid domains contain several proteins important in the pathophysiology 
of AD including APP, Ap, ApoE, PS1 and possibly both a- and P-secretases (Anderson et 
al., 1998; Cole et al., 1999; Ikezu et al., 1998; Lee et al., 1998; Nishiyama et al., 1999;
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Sambamurti et al., 1999). This clustering may help in promoting the specific interactions 
between all o f them.
•  The cell cholesterol levels can actively regulate APP processing and Ap 
generation. An increase in cell cholesterol content up-regulates, whereas a decrease 
down-regulates, Ap generation (Fassbender et al., 2001; Frears et al., 1999; Simons et al., 
1998). Cholesterol depletion in rat hippocampal neurons leads to a reduction of the C- 
terminal fragment, suggesting that P-secretase cleavage could depend on cholesterol 
(Simons et al., 1998). Furthermore, secretion of the APP ectodomain generated by a- 
secretase pathway was shown to increase in response to cholesterol depletion (Bodovitz et 
al., 1996; Kojro et al., 2001). Thus, the presence of cholesterol seems to promote the 
amyloidogenic (p- and y-secretase) pathway while inhibiting the non-amyloidogenic (a- 
secretase) pathway of APP processing (Bodovitz et al., 1996; Kojro et al., 2001; Wahre et 
al., 2002).
•  Intracellular cholesterol distribution regulates APP processing and Ap generation 
(Puglieli et al., 2001). This group suggested that the dynamic equilibrium between free 
cholesterol bound to the membrane and cholesteryl-esters regulates the generation of Ap. 
A selective increase in cholesteryl-esters is sufficient to up-regulate the generation of Ap. 
This group also established that blockade of the enzyme acyl-coenzyme A cholesterol 
acyltransferase (ACAT), which catalyses the formation of cholesteryl-esters from 
cholesterol, reduced both cholesteryl-esters and Ap synthesis in a dose-dependent manner 
(reviewed in Puglieli et al., 2003).
• Cholesterol affects membrane physical properties such as ordering, rigidity, and 
fluidity (Yeagle et al., 1991). APP is a transmembrane glycoprotein and the secretase 
cleavage sites lies within, or near, its intramembranous domain. Thus, it is possible that a 
change in membrane cholesterol levels would affect the way APP resides or function in 
the membrane.
• Cholesterol has indirect effects via the ApoE s4 allele, a susceptibility gene of 
SAD (Strittmatter et al., 1993). ApoE e4 allele, compared with ApoE e2 allele and ApoE 
c3 allele is less effective in neuronal repair, increases Ap fibrillogenesis and decreases Ap 
clearance (reviewed by Weisgraber & Mahley, 1996). The ApoE e4 allele is associated 
with higher cholesterol levels (Sing et al., 1985) and a recent study has shown that ApoE 
e4 promotes the efflux of cholesterol from neurons less efficiently than ApoE s2 and
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ApoE e3 (Michikawa et al., 2000). However, it is also possible that ApoE contributes to 
the pathology of AD by effects on general lipid metabolism (Roher et al., 1999; Wood et 
al., 1999).
Taken together these results suggest that cellular cholesterol levels, as well as the 
distribution of cholesterol throughout the cell, could mediate APP-A0 processing. These 
interactions suggest also that there must be a link between cholesterol and AD.
Cholesterol in AD patients
Although there is a confirmed association between cholesterol and AD, the role of this 
steroid in the pathogenesis of this disease is not clearly understood. Individuals with 
elevated levels of plasma cholesterol have an increased susceptibility to AD, apparently 
influenced by the ApoE e 4 genotype (Jarvik et al., 1995, Kuo et al., 1998). Moreover, AD 
patients have increased levels of total serum and low-density lipoprotein (LDL) 
cholesterol (Jarvik et al., 1995, Kuo et al., 1998) along with a reduced level of high- 
density lipoprotein (HDL) in their plasma (Kuo et al., 1998, Fernandes et al., 1999), as 
compared to age-matched controls. This metabolic profile (high plasma cholesterol with 
high LDL, and low HDL) is commonly found in patients with atherosclerosis. 
Atherosclerosis has also been shown to correlate with an increased risk of AD, with 
higher risk being associated with more advanced arteriosclerosis (Hofman et al., 1997).
AD patients in early stages of dementia have increased levels of 24S-hydroxycholesterol 
in the cerebro-spinal fluid (Papassotiropoulos et al., 2002) and in plasma 
(Papassotiropoulos et al., 2000). 24S-hydroxycholesterol can cross the BBB into the 
circulation and reflects cholesterol homeostasis in the brain (Papassotiropoulos et al., 
2000). As 24S-hydroxycholesterol is elevated in AD and vascular dementia patients, it 
could suggest that brain cholesterol turnover is increased during neurodegeneration.
Although higher amounts of cholesterol accumulate in the dense cores of amyloid plaques 
in the brain of AD patients (Mori et al., 2001), data on the cholesterol content of the brain 
tissue of Alzheimer's patients have been ambivalent. Mason et al. (1992) found that the 
cholesterol content was lower in the temporal gyrus of autopsied brains of AD patients in 
contrast to control subjects. However, Sparks et al. (1997) showed a small but significant
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increase in frontal cortex grey matter of AD patients with the ApoE e4 genotype 
compared with ApoE e4 control subjects. Technical differences (e.g. different tissue 
preparation and different brain region analysed) in the studies could account for the lack 
of consistent results. Additionally, mRNA levels of HMG-CoA reductase in brain were 
found to be indistinguishable between AD samples and control samples (Yasojima et al., 
2001).
Clearly an understanding of cholesterol biosynthesis in the brain and its role in AD 
requires further investigation. It is possible that cholesterol on its own could trigger AD 
pathology but also that cholesterol homeostasis failure may be a result of developing AD 
pathology.
1.7. Animal Models of Alzheimer’s disease
Historically, models of AD were focused on drug or CNS lesion-induced behavioural 
deficits based on specific neuroanatomical lesion or neurotransmitter deficit associated 
with the disease. The beginning of transgenic technology and identification of AD- 
associated genes has revolutionised animal models o f AD allowing a better understanding 
of pathology and treatment of this disease. Gene-targeted and transgenic mice have 
proven to be invaluable for studying the pathogenesis of AD. Transgenic animals display 
neuropathological and behavioural features o f AD including amyloid Ap and amyloid 
deposits, neuritic plaques, gliosis, synaptic alterations and signs of neurodegeneration as 
well as memory impairment.
1.7.1. Rational for animal studies
The key purpose for attempting to replicate AD neuropathology in animals is to gain:
• A better understanding of the impact of certain types of AD pathology on specific 
brain systems (e.g. temporal lobe versus frontal lobe systems);
• A better understanding of the physiological processes which are responsible for 
the formation of AD neuropathologies;
• An increased understanding of how specific pathologies, or the development of 
pathologies, affect physiological functions and cognition;
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• An opportunity to evaluate potential therapies on specific aspects/features of AD 
and cognition.
1.7.2. Mouse Models
Transgenic mice show some of the characteristic AD pathology, such as an age-dependent 
formation of Ap plaques. However, they usually (until recent multiple transgenic 
development, see below) lack both the tau pathology (neurofibrillary tangles) and the 
neurodegeneration. Importantly, many of these transgenic lines develop age-dependent 
deficits in some relevant behavioural tests and thus provide an animal model not only for 
amyloidosis but also for the cognitive deficits o f AD patients. The best-characterised AD 
mouse transgenic models are:
PDAPP mouse
Games (1995) and colleagues created the first successful transgenic mouse model of AD 
using a transgene construct of the human APP gene containing the V717F mutation under 
a PDGF-P promoter. It developed many of the pathological hallmarks of AD, including 
neuritic plaques surrounded by dystrophic neurites, astro- and microgliosis, and synapse 
loss, but no neurofibrillary tangles. Behavioural studies with the PDAPP mouse have 
been reported independently by two groups (Dodart et al., 1999; Chen et al., 2000) and 
describe similar early cognitive deficits at a time point before amyloid plaques could 
reliably be detected. Redwine et al. (2003) recently described a magnetic resonance 
imaging (MRI) and stereological analysis of PDAPP mice. Hippocampal volume (mainly 
dentate gyrus) was reduced in PDAPP mice before Ap plaques could be histologically 
identified.
APP Tg2S76 mice
First reported by Hsiao and colleagues (Hsiao et al., 1995), to date this has probably been 
the most widely reported AD transgenic mouse model. This mouse over-expresses a 
human APP with the K670N/M671L (“Swedish mutation” - a lysine at residue 670 is 
exchanged for asparagine and methionine at residue 671 is exchanged for leucine) 
mutation (APP695) under control of the prion protein promoter to ensure high CNS 
expression. Initially this transgene was engineered into FVB/N mice, resulting in an early
39
lethality before any amyloid pathology was manifested (Hsiao et al., 1995). Creating a 
new line in a different genetic background (C57BL/6JxSJL cross) resulted in better 
survival and the emergence of thioflavin-S-positive amyloid plaques with age (onset 
approximately 9-12 months) (Hsiao et al., 1996). Extensive neuropathological studies 
provided evidence of an age-related increase in amyloid deposits, neuritic dystrophy, 
astrogliosis, reactive microglia and abnormal tau phosphorylation (Hsiao et al., 1996, 
Irizarry et al., 1997, Frautschy et al., 1998, Kawarabayashi et al., 2001). Since genetic 
background is known to influence susceptibility to excitotoxic cell death, attempts to 
backcross these mice onto a ‘pure’ C57BL/6J line were undertaken but resulted in early 
lethality (Carlson et al., 1997).
Several laboratories have reported deficits in learning and memory in aged, but not young 
Tg2576 mice, including spatial reference memory deficits in the water maze (Hsiao et al., 
1996; King et al., 1999; Westerman et al., 2002) and spatial working memory deficits in 
the radial-arm water maze (Morgan et al., 2000) and T-maze (Chapman et al., 1999, King 
et al., 1999). Westerman (2002) and colleagues reported that cognitive changes in Tg2576 
mice might be more related to soluble forms o f Ap rather than plaque. By examining 
mice at several ages, they reported an inverse correlation between overall water-maze 
performance (mean probe score) and insoluble Ap.
In electrophysiological studies o f the hippocampus, these mice showed normal synaptic 
transmission but exhibited reduced hippocampal LTP in CA1 and the dentate gyrus 
(Chapman et al., 1999). It was proposed that these alterations in synaptic plasticity 
underlie some of the cognitive deficits in AD. In similar studies Fitzjohn (2001) and co- 
workers found impaired synaptic transmission but normal levels of LTP. This data 
favours excitotoxicity rather than a direct deficit in the LTP process as the major correlate 
of the cognitive dysfunction in this mouse strain relevant to AD. A variety of 
inflammatory and oxidative stress markers have also been studied in the Tg2576 mice to 
examine the involvement of these processes in AD-like pathology. Tg2576 mice show the 
same type of oxidative damage that is found in AD, and this damage directly correlates 
with the presence of Ap deposits (Smith et al., 1998) and increased lipid peroxidation 
precedes AP plaque formation (Pratico et al., 2001). IL-lp and TNF-a immunopositive 
microglia and IL-6 immunoreactive astrocytes surround fibrillar Ap deposits (Benzing et
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al., 1999) and a number of cytokines is induced in a surrounding of plaques (Mehlhom et 
al., 2000).
APP23 mouse
Developed at Novartis and first reported by Sturchler-Pierrat et al. (1997), the APP23 
mouse uses a human APP751 construct containing the K670N/M671L mutation, under 
the control of a Thyl promoter for high neuronal expression. These mice have been 
characterized extensively in terms of pathology, and recapitulate many of the features 
reported in the PDAPP and Tg2576 mice, namely neuritic plaques accompanied by local 
astro- and microgliosis, with a regional expression largely confined to neocortical and 
hippocampal areas (Sturchler-Pierrat et al., 1997). Interestingly, neurodegeneration has 
been reported in the hippocampal CA1 region of 14-18-month-old mice with an apparent 
correlation with plaque load (Calhoun et al., 1998). The APP23 mouse is also a good 
model of cerebral amyloid angiopathy (Winkler et al., 2001). Behavioural 
characterization studies showed similarities to other APP transgenic lines (PDAPP, 
Tg2576 lines) with age-dependent and amyloid-related cognitive changes (Lalonde et al., 
2002; Kelly et al., 2003; Van Dam et al., 2003).
PSAPP mouse
Shortly after the identification of mutations to the PS1 gene as a genetic cause of some 
cases o f familial AD (1995), Duff and colleagues reported on a mouse line 
overexpressing the PS1 gene containing the M146L mutation (Duff et al., 1996). 
Although these mice do not appear to develop plaques, they show an increase in 
extracellular Ap42 levels. Subsequently, the crossing of the Tg2576 with the PS1 
transgenic mice resulted in a novel mouse line (PSAPP) that showed greatly accelerated 
plaque pathology and associated gliosis (Holcomb et al., 1998). In contrast to the 9-12 
month onset of plaque deposition seen in the Tg2576 line, by 3 months of age thioflavin- 
S-positive plaques can be detected in the cingulate cortex of PSAPP mice and by 6-8 
months of age, amyloid deposition and plaque size increased and extended to most 
cortical regions (McGowan et al., 1999). Despite the extensive amyloid pathology by 12 
months o f age, no clear evidence for neurodegeneration or neurofibrillary tangles was 
evident. The clearest age-related impairment in spatial learning and radial arm maze
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working memory (both tests performed in a water maze) emerge at 15-17 months of age, 
a time point where there is intense amyloid deposition and signs of local oxidative stress 
and neuroinflammation (Arendash et al., 2001). This age of onset seems later than that 
described for the PDAPP and Tg2576 lines, which display lesser amyloid pathology. 
Initially, Holcomb et al. (1998) described reduced Y-maze alternation in 12-14 week 
PSAPP and Tg2576 mice compared to wild-type controls, a finding that clearly suggests 
no relationship to AP pathology, but these results could not be replicated (Arendash et al., 
2001).
CRND8 mouse
The CRND8 mouse encodes a double-mutated form of hAPP695 under the control of the 
prion protein promoter. The combination of V717F and K670N/M671L APP mutations 
results in extremely high levels of Ap42, such that thioflavin-S-positive amyloid deposits 
became evident in all mice by 3 months of age (Chishti et al., 2001). These plaques are 
associated with dystrophic neurites and gliosis, although it is unknown at the present time 
whether neurodegeneration occurs in this mouse model. In terms of cognitive status, at 11 
weeks of age, the CRND8 mice show impaired acquisition of spatial learning in a Morris 
water maze, although cued learning and swim speeds were similar between groups 
(Chishti et al., 2001). CRND8 mouse seems like a particularly valuable model, but the 
early lethality is a problem in this line.
JNPL3 (tau) mouse
Although tau mutations do not cause AD, an attempt to create a tau-overexpressing 
mouse has been made (Lewis et al., 2000). The transgene contains the most common tau 
mutation, associated with frontotemporal dementia and Parkinsonism (FTDP-17 mutation 
P301L) under the control o f the mouse prion promoter. Hemizygous JNPL3 mice express 
the transgenic tau at equivalent levels to endogenous tau, while homozygous mice express 
double this amount. From 6-7 months, a neurological phenotype becomes manifest in 
hemizygous JNPL3 mice, consisting of delayed righting reflex, hypolocomotion and 
muscular weakness (Lewis et al., 2000). Within 4 weeks of symptom onset, the mice 
become moribund. In terms of pathology, in contrast to the APP transgenic mice, the 
JNPL3 mice develop neurofibrillary tangle (NFT) pathology, confirmed by tau
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immunostaining, silver staining and electron microscopy. No amyloid plaques have been 
identified.
An attempt to cross the JNPL3 mouse with the Tg2576 mouse was described by Lewis et 
al. (2001). The resulting double transgenic mouse (tau/APP) developed Ap deposits at the 
age similar to Tg2576; however, relative to JNPL3 mice, the double mutants exhibited 
neurofibrillary tangle pathology that was substantially enhanced in the limbic system and 
olfactory cortex. These results indicate that APP/Ap influences the formation of 
neurofibrillary tangles and this mouse is the first mouse model to exhibit these two 
cardinal signs of AD pathology.
JxTg-AD
In a search for manifestation of all of the hallmarks of AD in murine models, a triple 
transgenic model of AD was generated (Oddo et al., 2003). The triple transgenic mice 
(3xTg-AD) harbour three mutant transgenes: PS1M146V, APPSwe, and tauP301L. The 
3xTg-AD mice develop an age-dependent and progressive neuropathology that includes 
plaque and tangle pathology. Further analysis of these mice has shown that, despite 
equivalent overexpression of human APP and tau, Ap pathology precedes conformational 
or hyperphosphorylation changes in the tau protein (Oddo et al., 2003). These results 
support the amyloid cascade hypothesis, which predicts that Ap deposition is the earliest 
pathological trigger of AD. However, pathology in these transgenic mice is due to three 
independent transgenes, and it cannot be used directly to infer what might be the primary 
causation in human AD in the absence of mutations.
1.73 Rat Modeb
All known rodent models are generated in mice strains, as the transgenic techniques for 
creating mice are far more advanced than for rats. An advantage of using a rat strain to 
investigate APP overexpression is that this species has been well characterised in terms of 
basic learning and memory processes and a rat APP overexpressor may, therefore, offer a 
broader practical base to evaluate the effects of the APP mutation on different cognitive 
systems.
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GP56 Rats
A transgenic rat (GP56 line) was created by Vanessa Marshall in Paul Chapman’s lab as a 
part of her thesis (Marshall, 2002). Transgenic rats were created in Sprague-Dawley 
background and overexpressed a human APP with the “Swedish mutation” (APP695, the 
same as Tg2576 mice) under control o f the prion protein promoter to ensure high CNS 
expression. They had an estimated 12 copies of the transgene (Tg2576 have 90 copies) 
and APP was expressed at levels approximately 55-61% of that displayed by the Tg2576 
mouse. As measured by ELISA the amount of SDS-soluble AP40 and Ap42 was higher 
than in controls, and it did not appear to increase as a function of age. There was very 
little evidence that deposited Ap was present in the GP56 rat brains at any age tested.
These levels of soluble amyloid were insufficient to induce performance differences 
between transgenic and control rats on a range of behavioural tasks sensitive to the same 
mutation in mice, from 8  to 24 months of age. Hemizygous GP56 rats were tested on a 
battery of tasks, including a forced-choice alternation task in the T-maze, spatial matching 
to position task in the water-maze and finally at the age of 24 months, on a standard 
reference memory water-maze task.
All studies were performed in hemizygous rats. As the pathology was limited, crossing 
two transgenic hemizygous rats generated homozygous transgenic rats. Homozygous rats 
were not characterised behaviourally but there was some indication that their Ap levels 
are higher then in hemizygous rats and might increase with age.
1.7.4. Electrophysiological studies of hippocampus
Memory loss is a major symptom of AD. Long Term Potentiation (LTP) of synaptic 
transmission in the hippocampus is the primary experimental model for investigating the 
synaptic basis of learning and memory (Kandel & Abel, 1995). It was first reported by 
Bliss and Lomo (1973) and it is a prolonged increase in the efficiency of synaptic 
transmission following brief, high frequency stimulation, i.e. a stimulus evoked at a 
constant amplitude and low frequency results in a larger synaptic response after a short 
period of high frequency stimulation. This effect occurs within milliseconds and can last 
for hours in vitro and days in the awake animals (Bliss & Collingridge, 1993). LTP is
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mainly induced by the activation of the A-methy 1 -d-aspartate (NMDA) receptor complex. 
It is a subtype of glutamate receptor that allows electrical events at the postsynaptic 
membrane to be transduced into chemical signals, which are thought to activate both pre- 
and postsynaptic mechanisms to generate a persistent increase in synaptic strength (Bliss 
& Collingridge, 1993). There is strong evidence suggesting that NMDA receptors are 
involved in spatial learning in the hippocampus (Collingridge & Singer, 1990). Chronic 
intraventricular infusion of an NMDA receptor antagonist dose dependency caused a 
parallel impairment of spatial learning in water maze and in perforant path LTP in vivo 
(Davis et al, 1992). Furthermore, studies on Tg2576 mouse have demonstrated a 
correlation between behavioural deficits and impairment of both CA1 and dentate gyrus 
LTP (Chapman et al., 1999). Thus for my PhD I decided to try to show correlation of 
behaviour and its impairment with electrophysiology LTP measurements in vivo.
1.8. Overview of structure of the PhD
Well-characterised transgenic animal models of AD were used to evaluate potential 
treatment strategies using NSAIDs and to determine the importance of susceptibility risk 
factors (high cholesterol or polyunsaturated fatty acids intake) on behavioural, 
electrophysiological and biochemical measurements.
Each chapter raises a different question about AD-like pathology assessed in animal 
models, while reporting on the use of similar techniques. NSAID treatment questioned 
whether it is possible to prevent/treat cognitive deficit and synaptic physiology in 
transgenic mice. High cholesterol diet was tested for the potential of inducing amyloid 
pathology in the transgenic rat model. DHA supplementations tested the potential of n-3 
fatty acids to prevent development of AD-like pathology in transgenic mice models.
The methods I concentrated on were: 1) behavioural assessment of cognitive function by 
using tasks like forced choice alternation task in the T-maze and standard reference 
Morris water maze; 2) electrophysiological analysis of hippocampal plasticity in vivo and 
3) biochemical and histological assessment which included ELISA measurements and 
immunostaining.
Two animal models were used for experiments. APP Tg2576 mice demonstrate well- 
established and well-documented deficits in cognitive tests, and GP56 rats which fail to
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show any impairment in a battery of tests (reviewed in chapter 1.7). Therefore, for testing 
agents that were supposed to prevent/treat AD-like impairment in rodent models, Tg2576 
mice were used. Whereas for testing agents that were supposed to induce AD-like 
pathology, GP56 transgenic rats were chosen. For the studies with cholesterol, 
homozygous rats were chosen. Although not well characterised, they had a greater 
potential for developing pathology (higher and increasing with age Ap levels).
Behavioural tests were chosen to be the most descriptive for the respective transgenic 
models e.g. for Tg2576 mice Forced choice alternation task in the T-maze was chosen as 
it was validated by Paul Chapman’s laboratory (Chapman et al., 1999) and it shows 
constant significant difference between transgenic and non-transgenic littermates. For 
GP56 rats, the standard reference memory version of the Morris water maze was chosen. 
Marshall (2002) had previously demonstrated that Sprague-Dawley rats failed to move in 
the Forced Choice Alternation task in the T-maze and that spatial matching to position 
task in the water-maze was too difficult even for non-transgenic rats.
1.9. Aims of this PhD
This thesis reports a comprehensive study of the role of an APP transgenic mouse and an 
APP transgenic rat model of AD as tools for testing new treatment strategies (NSAIDs) 
and validating susceptibility factors (cholesterol and DHA).
To summarise, the aims of this thesis are:
1. To determine the effect of Ibuprofen treatment on behaviour, synaptic plasticity
and basic neuropathology of Tg2576 mice in two paradigms -  prevention versus
treatment.
2. To inspect the role of high-cholesterol in behaviour and synaptic plasticity
impairment and basic amyloid neuropathology in GP56 rats.
3. To study effects of early DHA supplementation on behaviour and basic
neuropathology of Tg2576 mice (prevention study).
4. To rationalise the importance of a multidisciplinary approach to investigating
neurodegeneration.
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Chapter 2 
General methods
2.1. Behavioural testing
Measuring learning and memory in behavioural tasks in rodent models of Alzheimer 
disease can provide insight into both the mechanisms of the disease and the basic 
processes of learning and memory. It also allows testing effects of various treatments and 
susceptibility risk factors.
2.1.1. Forced Choice Alternation Task in the T-maze 
Theoretical background
The Forced-Choice Alternation (FCA) task performed in the T-maze is a well-established 
behavioural test that measures a spatial working memory, sometimes referred to as an 
“episodic-like memory”. Most of the earlier work, which established both the memory 
requirements for FCA and the relevance of the hippocampus and the prefrontal cortex, 
was conducted in rats (Rawlins et al., 1982; Aggleton et al., 1990). As Tg2576 transgenic 
mice show pathological changes both in the prefrontal cortex and the hippocampus, the 
FCA task was successfully adapted to be used in mice and detect memory deficits 
(Chapman et al., 1999).
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Subjects
Tg2576 transgenic mice and non-transgenic littermate controls (on a C57B6/SJL 
background) at ages ranging from 8  to 14 months were tested. Details about Tg2576 mice 
are provided in section 1.7.2. Mice were taken from a colony bred at Cardiff University. 
They were housed either individually (males) or in cages of no more than three mice 
(females). Males required separation due to a high level of aggression towards each other. 
While progressing through behavioural testing, it turned out that females show higher 
degree of variability in testing and higher numbers are necessary for statistical analysis 
(however statistical comparison did not reveal any significant differences between 
females and males). Thus further testing (Exp C in ibuprofen and DHA study) was 
performed only in males. When not undergoing behavioural testing, animals received a 
constant supply of water and food pellets containing either control or treatment (e.g. 
ibuprofen or DHA; see chapters 3 and 4 for details). Mice were checked regularly for 
symptoms of illness and weighed every two weeks during the treatment period. The 
lighting was set to 14 hours of light and 10 hours of darkness. During testing, animals 
were water deprived for 20 hours prior to running in the T-maze. After finishing testing 
each day (around 2 hours), mice were given 2 hours of free access to water. The 
experimenter was blinded to the genotype of the mice throughout the study. All 
procedures were carried out in strict accordance with the UK Animals (Scientific 
Procedures) Act, 1986.
Testing apparatus
The dimensions of the T-maze are shown in Figure 2.1. The walls of the T-maze were 
constructed of clear Perspex and the floor was made of laminate. The maze was mounted 
on a table, raised 75 cm from the floor, and situated in the middle of a room at roughly 
equal distance from each wall. There were external cues (posters, cupboards and door) in 
the room to help mice to navigate. The T-maze consisted of one long (start) arm and two 
slightly shorter (reward) arms of equal length, put together in a shape of letter T. A 
removable opaque Perspex door, located 10 cm from the beginning of the longer arm, 
separated the Start Box from the rest of the maze. The left and the right reward arm of the 
T-maze were also separated from the longer start arm by removable opaque Perspex 
doors. Black Perspex drinking wells were placed at the end of both reward arms.
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Figure 2.1 Dimensions of the T maze. All the walls are 25cm high.
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Testing procedure
Adaptation
Adaptation consisted of 4 days of pre-training during which animals learned to run down 
the start arm, drink 25% sucrose solution in tap water from the wells at the end of the 
reward arms and associate the reward with the maze. On each of the adaptation days, 
mice were allowed to drink sucrose and explore the T-maze for 5  min. One day prior to 
the first T-maze exposure, mice were handled for approximately 5-10 min. On the first 
day following handling, mice were allowed to explore the T-maze with all of the doors 
open and drops of sucrose were placed all around the maze. On the second day, sucrose 
was placed in the shorter reward arms. On the third and the fourth day, the sucrose was 
placed only in the drinking wells in both arms, so the mice came to associate the wells 
with the reward. On day 2, 3 and 4 o f adaptation, animals were closed in one of the 
reward arms (chosen at random) after 4 min and 30 sec of free exploration. Special care 
was taken when opening and closing the Perspex door to avoid frightening the mice and 
stress induced behavioural changes. Similarly the handling was as gentle as possible, and 
the mice were treated equally and in the same way every day. On day 4, the Start Box was 
introduced. The animal was placed in the Start Box for approximately 10 sec, and then the 
opaque Perspex door was removed and the mouse was given 5 min to explore the maze 
and drink sucrose. If a mouse did not drink or move from the Start Box during the 4 
adaptation days, it was excluded from testing.
Testing protocol
The testing consisted of sessions o f six trials per day for 10 days. Each trial consisted of 
two runs in the maze: a Sample (information) run and a Choice (test) run. Each mouse 
received three left and three right Sample runs a day. The order of trials for each day was 
determined by a pseudo-random schedule with no more than two consecutive left or right 
trials. The mice were tested in groups of six to eight, resulting in an interval ranging from 
10 to 15 min between each trial-pair. Reward consisted of an approximately 50 pi drop 
(as measured by pipette) of 25% sucrose solution in tap water. On the Sample run, a 
Perspex door was placed at the entrance of the opposite reward arm forcing the mouse to 
enter the assigned arm where it found a drop of 25% sucrose in the well. The animal was
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given time (approximately 15 sec) to drink the reward and then was placed in the Start 
Box again. The Test Run started immediately (no delay between Sample Run and Test 
Run). On the Test run, the Perspex door was removed and the animal was presented with 
the choice of both goal arms of the maze. To receive a reward the animal had to enter the 
arm previously un-visited (non-match to place). A choice was considered to be made 
when the mouse placed both of its back feet across an entrance to a reward arm. After the 
animal made its choice, the entrance to the chosen arm was blocked off to prevent the 
mouse from leaving. If the mouse entered the incorrect arm, it was enclosed in the goal 
arm, without reward, for approximately 30 sec. The testing protocol is illustrated in 
Figure 2.2. If after 5 min the mouse failed to enter an arm on either run, the trial was not 
included in the data. If the mouse did not complete more than 50% of the trials for the 
first 3 days, it was excluded from the study.
Data analysis
Percentage of correct choices was counted for each mouse for each day. The results were 
averaged over blocks of 2 days and over testing groups. A learning curve was created and 
differences between groups were calculated using repeated measures ANOVA (with 
genotype, diet and sessions as factors). The learning criterion was gained if the mouse 
reached >80% correct choices for three consecutive days. The percent of mice from each 
group reaching a learning criterion was counted and the difference between groups was 
calculated using chi-square test (Fisher’s test). Further analysis included measuring the 
tendency to respond persistently by turning in the same direction within a single test 
session. This analysis was carried out to determine whether animals that were performing 
poorly were doing so because they persevered with one response, or because they 
responded randomly. The perseveration count was calculated for each mouse as the 
number of consecutive free choices made in the same direction every day (regardless of 
the direction (left or right) the higher score was chosen). Finally to evaluate if the 
conditions throughout the testing time were biased, the preference towards either side 
(Right or Left) was calculated for each mouse by counting the number of trials on which 
an animal made a right and a left choice, regardless of whether this was the correct 
response. The statistical significance of differences in the value of Perseveration Count 
and Right/Left Preference was determined by the two-factor ANOVA, with genotype and
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Sample Phase
Mouse is placed in the Start Box. It is forced to go to the right arm and 
receives the reward
i
Test Phase
Animal is placed in the Start Box again. The reward is in the opposite arm -  on the left. 
After Start Door is removed, the mouse has a free choice of both arms of the maze
Correct Choice
Animal chooses the left arm and 
receives a reward
Incorrect Choice
Animal chooses the right arm and 
does not receive a reward
Figure 2.2. Forced Choice Alternation Task protocol. Example with the sample 
choice to the right arm. § represents a reward - drop of sucrose.
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the diets as factors and Tukey's pair-wise comparisons post hoc tests to assess differences 
between groups.
2.1.2. Morris Water Maze, Rat Reference Memory 
Theoretical background
The Morris water maze was first described 20 years ago as a device to investigate spatial 
learning and memory in laboratory rats (Morris et al., 1984). Since then it has become one 
of the most frequently used laboratory tools in behavioural neuroscience. Many 
methodological variations of the Morris water maze task have been and are being used by 
research groups, for many different applications. Lesions in distinct brain regions like 
hippocampus, striatum, basal forebrain, cerebellum and cerebral cortex were shown to 
impair water maze performance (reviewed in D’Hooge & De Deyn, 2001). Finally, the 
Morris water maze task has often been used in the validation of rodent models for 
neurocognitive disorders and the evaluation of possible treatments (D’Hooge & De Deyn, 
2001). Transgenic heterozygous GP56 rats were tested in two kinds of Morris water maze 
task showing no significant impairment comparing to non-transgenic littermates 
(reviewed in Marshall, 2002).
Subjects
The animals tested were homozygous transgenic GP56 rats and non-transgenic littermate 
controls (on a Sprague- Dawley background) at the age of 18 months. Details about GP56 
rats are provided in chapter 1.7.3. Rats were taken from a local colony created and bred at 
Cardiff University. They were housed in cages of no more than three rats. Animals 
received a constant free supply of water and food pellets, either control or containing 
high-cholesterol. Rats were checked regularly for symptoms of illness and weighed every 
week. The room temperature was monitored daily and kept at a constant level and the 
lighting was set to 14 hours of light and 10 hours of darkness. During testing the 
experimenter was blinded to the genotype of the rats. All procedures were carried out in 
strict accordance with the UK Animals (Scientific Procedures) Act, 1986.
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Testing apparatus
Water maze experiments were performed in a circular pool (diameter: 200 cm, height: 60 
cm) made of fibreglass with the inner surface painted white. The pool was filled to a 
depth of 35 cm of water (maintained at 26.0±1.0°C), under which a 10 cm square 
platform was submerged to a level approximately 1.5-2 cm below the surface of the 
water. The water was made opaque by addition of 500 ml of non-toxic white paint 
(Opacifier E308, Rohm Haas). The pool was located in the centre of a small room 
illuminated by four 50W halogen lamps. Extra-maze visual cues such as posters on the 
wall, a screen (behind which the experimenter stood) and a curtain were present in the 
room.
Swimming activity of each rat was monitored via a video camera mounted in the ceiling 
directly above the pool. This was connected to a video recorder with an attached tracking 
device and software (HVS Image analysis, LTD). The head of each rat was painted black 
with a marker pen in order to provide adequate contrast for the software to track the path 
of the rat. A PC computer recorded latency to find the platform, swim speeds and path 
lengths The software automatically ended a trial after 120 sec. The experimenter was 
able to follow the rat’s progress during the course of the experiment on a monitor, 
connected to the video camera.
Testing protocol
The animals were divided into four groups that were counterbalanced for genotype, diet 
and gender. These groups were assigned a particular platform location (NE, NW, SE or 
SW) to avoid being biased to any position of the platform. Each rat was given four trials 
per day for nine consecutive days to locate the hidden platform. For each trial, the rat was 
placed in the pool facing the wall at one of eight pseudorandomly assigned start positions 
representing compass points (see Figure 2.3). For each trial, the rat was allowed to swim a 
maximum of 120 sec in order to find the platform. When successful the rat was allowed 
20 sec rest on the platform. If unsuccessful, within the allotted time period, the rat was 
guided to the platform by the experimenter. It was given a score of 120 sec and then also 
allowed the 20 sec rest period. In either case the rat was immediately given the next trial
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Figure 2.3. W ater m a z e  - p la tform  p o s itio n s , quadrant a llo c a tio n s  and start lo c a t io n s  
P latform  p o s it io n s  and  start lo ca tio n s . S m a ll c ir c le s  rep resen t fo u r  p la tform  p o s it io n s  fo r  
fou r  rat grou p s. T h e  letter  o u ts id e  th e  m a z e  rep resen t 8  d ifferen t start p o in ts . T h e  m a z e  is  
d iv id e d  in to  fou r  eq u a l quadrants. N -  N orth ; S -S o u th ; E -E ast; W -W est; N E -N o rth -E a st;  
N W -N o r th -W e st;S E - S o u th -E a st or S W -S o u th -W e st.
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after the rest period. Once all the trials had been completed, the rat was dried with a hand 
towel and returned to its holding box.
On day 4, 7 and 1 0 , approximately 20 hours after the last training session, the animals 
received a 120 sec probe trial. During the probe trial the platform was removed from the 
pool to measure spatial bias for the platform location. The animal was released from the 
quadrant opposite to the platform location. The computer recorded the swim path and the 
time travelled in each of the four quadrants. The proportion of time spent in the target 
quadrant searching for a platform served as a measure of retention.
Data analysis
The mean escape latency of four trials was counted for each rat for each day. The results 
were averaged over testing groups. A learning curve was created and differences between 
groups were calculated using repeated measures ANOVA (with genotype, diet and 
sessions as factors). Tukey's pair-wise comparisons post hoc tests were carried out to 
determine the source of any significant interaction. Further analysis included measuring 
the swim speed and path length, which were also analysed using repeated measures 
ANOVA with genotype, diet and sessions as factors and Tukey's pair-wise comparisons 
as post hoc tests to calculate differences between groups. During the probe trials (no 
escape platform present), time spent in each quadrant was measured and preference 
towards the target quadrant (platform during training) was calculated. Differences were 
determined by the two-way ANOVA, with group and a diet as factors and Tukey's pair 
wise comparisons post hoc tests to calculate differences between groups.
2.2. Electrophysiological studies of hippocampus in vivo
Theoretical background
The hippocampus is one of the first structures in the brain affected in AD and it also 
appears to play a crucial role in spatial learning and memory (Kandel & Abel, 1995). The 
hippocampus is also the structure in which electrophysiological recordings first revealed 
the phenomenon of long-term potentiation (LTP) (Bliss & Lomo, 1973). LTP is a 
prolonged increase in the efficiency of synaptic transmission following brief, high 
frequency stimulation and it is widely considered to represent a molecular correlate of
56
learning and memory. Hippocampal synaptic transmission and plasticity are disrupted in 
transgenic mice overexpressing human APP (reviewed in Rowan et al., 2003 and chapter 
1.7.2), and in rats after exogenous application of synthetic Ap in vivo (Walsh et al., 
2002).
Subjects
Tg2576 mice from the Ibuprofen study and GP56 rats from the cholesterol study were 
tested for hippocampal synaptic transmission and plasticity impairments in a paradigm in 
vivo. Tg2576 mice overexpressing human mutated APP and littermate controls weighing 
20-30g were obtained from the local colony at Cardiff University. Animals were 
anaesthetised with urethane (15% saline solution 1 . 2  - 1 .8 g/kg body weight i.p. for non- 
recovery surgery). GP56 rats overexpressing human mutated APP and littermate controls 
weighing from 300 (females) to 900g (males) were also obtained from the local colony at 
Cardiff University. Animals were anaesthetised with urethane (30% saline solution 
1 .2 g/kg body weight i.p. for non-recovery surgery).
Anaesthetised animals were placed in a stereotaxic device (ASI Instruments, Bilaney 
Consultants, Sevenoaks, Kent, UK), the skull was exposed and the animal's body 
temperature was monitored and regulated at the range of 36-37°C with a heating pad. 
Animals were chosen blindly to genotype and drug treatment throughout the experiments.
Testing equipment
Extracellular recordings were made with electrodes placed in the dentate gyrus of 
hippocampus. Inputs to this layer come from the medial perforant path, which arises from 
the medial entorhinal cortex and terminates mainly on granule cells of dentate gyrus. 
Field excitatory postsynaptic potentials (fEPSPs) were evoked from the dentate granule 
cell population in response to electrical stimulation of the medial perforant path.
A concentric bipolar stimulating electrode (250 pm diameter wire insulated with Teflon 
except for the cut tips) was placed in the medial perforant path. Coordinates with the skull 
surface flat were for rats - 7.5 mm posterior from bregma, 4.1 mm lateral from the 
midline, 2.8 mm ventral below dura, and for mice - 4.2 mm posterior from bregma (the 
level of lambda), 2 . 8  mm lateral to the midline, 1 .8 -2 . 2  mm ventral.
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Evoked potentials were recorded extracellularly from the cell body layer of the dentate 
gyrus using either a stainless steel electrode or carbon-fibre electrode (made in the 
laboratory). Coordinates with the skull surface flat were, for rats - 3.8 mm posterior from 
bregma, 2 . 2  mm lateral to the midline, 2 . 8  mm ventral, and for mice - 2 . 0  mm posterior to 
bregma, 1.8 mm lateral to the midline, 1.7-2.2 mm ventral, below dura. The recording 
electrode was lowered into the dentate gyrus until the maximal response was observed.
Electrical stimulation was provided by a Digitimer stimulator, amplified and filtered 
using a Warner DP-301 Differential Amplifier. Stimuli were given every 15-30 sec and 
the intensity of the test stimuli was chosen to be between 10 and 1000 pA. Evoked 
fEPSPs were recorded using the LTP analysis program (http://www.ltp-program.com; 
Anderson & Collingridge, 2001).
Testing protocol
When a satisfactory response from dentate gyrus was found, the experiment started. First 
the Input/Output curves (I/O) were generated by increasing the stimulus intensity in 100 
pA steps from 0 to 1000 pA. Three fEPSPs were recorded at each intensity, and the slope 
and maximum amplitude of the fEPSP as well as the amplitude of the population spike 
were measured and averaged. Calculating I/O curves helps to evaluate synaptic potency 
and also allows selection of the optimal intensity for synaptic plasticity experiments. The 
chosen intensity was intended to evoke 30-40% maximal slope and/or 1 mV population 
spike (although this was not always possible; see results chapter 3). The intensity was 
typically 300-400 pA and was used for paired pulse studies, tetanisation and LTP 
recording.
To evaluate short-term synaptic interactions, paired-pulse stimuli were delivered to the 
perforant pathway with inter-stimulus intervals ranging from 30 to 300 ms (performed 
only for rats). Three consecutive impulses delivered at each interval were averaged. The 
relative amplitude of the second population spike (P2) to the first one (PI) was calculated 
and expressed as percent (%P2/P1).
Following collection of input/output data and paired-pulse study, baseline stimulation was 
performed for at least 20 min by stimulating every 30 sec. LTP was induced by tetanising 
the perforant pathway with theta-burst parameters consisting of 6  trains of 6  bursts, and
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each burst consisted of 6  pulses at 400 Hz, which were delivered every 20 sec over 2 min. 
Immediately after the end of tetanus, recordings of the evoked potential continued for 
further 60 min.
Data analysis
The characteristic response of the dentate granule cells to perforant path stimulation 
consists of a positive-going excitatory postsynaptic potential (fEPSP) with a 
superimposed negative-going field Population Spike (PS). The fEPSP slope was 
measured as the maximum slope of the fast rising phase. The PS amplitude was measured 
by averaging the distance from the negative peak to the midpoint of the preceding and 
following positive peak. All values were expressed as percentage change relative to the 
mean control response during the 2 0  min baseline prior to tetanic stimulation.
Statistical analyses included the repeated measures ANOVA for I/O curves, Paired-Pulse 
Study and LTP experiments with diet, genotype and either intensity, or interval or time as 
repeated measures. ANOVA was followed by Tukey's pair-wise comparisons as post hoc 
tests to assess differences between groups.
23 . ELISA -  Enzyme Linked-Immuno-Sorbent Assay
Theoretical background
The Biosource Signal Select human p-Amyloid 40 and 42 ELISA kits are used for the in 
vitro quantitative determination of human AP40/42 in samples. A04O and Ap42 kits are 
based on a solid phase sandwich Enzyme Linked-Immuno-Sorbent Assay (ELISA). A 
monoclonal capture antibody specific for the NH2 terminus of human Ap has been coated 
onto the wells of the microtiter strips. Samples, including standards of known human Ap 
content and unknowns are pipetted into these wells, followed by the addition of a rabbit 
polyclonal antibody specific for the 1-40 or 1-42 sequence of human Ap. The sandwich 
antibody was then detected using a horseradish peroxidase conjugated mouse anti-rabbit 
IgG. After removal of excess anti-rabbit antibody, a substrate solution is added, which 
works with the bound enzyme to produce colour. The intensity of this coloured product is 
directly proportional to the concentration of Ap40 or Ap42 present in the original 
specimen.
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The brains of Tg2576 mice show increasing concentrations of both detergent-soluble 
(SDS) and detergent-insoluble (FA) Ap 40 and 42 with age (Kawarabayashi et al., 2001). 
GP56 rats have significant, but lower concentrations of both Ap species, and these 
concentrations do not increase with age (Marshall, 2002). The insoluble Ap (FA) was not 
present in the GP56 rat brains at any age tested.
Brain sample preparation
For the determination of Ap levels by ELISA, frozen samples of mouse and rat brains 
were used. The brains for ELISA and immunohistochemistry (see chapter 2.4) were 
collected after electrophysiological experiments (for DHA and the last Ibuprofen group 
after the end of behavioural testing). In order to remove the brain, the cranial bone was 
cut away and the brain was lifted and freed from the vessels and cranial nerves connecting 
it to the base of the skull. The cerebrum, cerebellum and some of the hindbrain were 
removed in one piece. The brain was either quick-frozen in isopentane on dry ice for 
ELISA or immersed in fixative for immunohistochemical staining. For the Ibuprofen 
study the whole Tg2576 mouse brain was used. For the DHA study, one hemisphere 
separated along the midline of Tg2576 mouse brain was used. For the cholesterol study 
with GP56 rats, half of the brain cut along the midline was used.
For the Tg2576 mice, two-step extraction with sodium dodecyl sulfate (SDS) and formic 
acid (FA) was performed, while for rats only the FA fraction was measured. The SDS 
fraction represents soluble Ap, while FA represents insoluble Ap, possibly from plaques 
(Kawarabayashi et al., 2001). For rats, only FA extraction was used as it allows 
determination of total Ap content, as they do not have insoluble Ap (Marshall, 2002).
The brain samples were weighed and the volume of 2% SDS or 70% FA (containing 
Complete protease pellet, Roche), was calculated (75 or 150 mg of brain per 1 ml). The 
frozen brain samples were then put in 5 ml round-bottom tubes with the appropriate 
volume of SDS or FA and sonicated. The tube was placed on ice and sonicated in 10 
seconds bursts two or three times, until brain structure was dissolved. Care was taken to 
avoid foaming by keeping the sonicator probe in the solution.
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After sonication, 1.4 ml was taken from each brain extract and spun at 100,000 g for 1 
hour at 4°C. After centrifugation, the supernatant was transferred to a new tube. For the 
two-step extraction, it was labelled as SDS extracts and for the one-step extraction with 
FA, it was labelled as the final extract.
For the two-step extraction further 1.4ml of 70% formic acid in water was added to the 
pellet from the SDS extraction and sonicated and spun as above. The supernatant was 
carefully removed from under the lipid layer and put in tubes as FA extract.
All the extracts (SDS and FA) were aliquoted into small tubes (60-80pl) and kept frozen 
at -80°C.
ELISA protocol summary
ELISA was performed using commercially available human p-Amyloid 40 and 42 kits 
from Biosource.
Standard peptide (Ap40 or Ap42) provided in the kit was resuspended following 
manufacturer’s instructions and serial dilutions (1000, 500, 250, 125, 62.5, 31.25, 15.63, 
0 pg/ml) were prepared. Standards for FA extracts were diluted with Standard Diluent and 
for SDS extracts, with Standard Diluent with the amount of SDS equal to the amount 
contained in the samples, e.g. for dilution 1:80 for SDS AP40, the concentration of SDS 
was 0.025%.
Once samples were defrosted, the 2% SDS extracts were first diluted 1:40 in EC buffer 
(0.02 M phosphate buffer, pH 7, 0.4 M NaCl, 2 mM EDTA, 0.4% Block Ace 
[Dainipponseiyaku, Suita, Osaka, Japan], 0.2% bovine serum albumin, 0.05% CHAPS 
and 0.05% sodium azide) and further dilutions were performed in Sample Diluent from 
the kit. The Ap capture took place in buffer containing 0.025% or 0.02% SDS. FA 
extracts were neutralized initially by 1:20 dilution into 1 M Tris phosphate buffer, pH 11, 
and then diluted as necessary with the Sample Diluent buffer from the kit. The dilution 
factors for samples for both 40 and 42 P-Amyloid in SDS and FA fractions are provided 
in the table in the table in Figure 2.4.
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Table A
Ab40-SDS Ab42-SDS Ab40-FA Ab42-FA
Tg2576 mice 1:40 with EC 
buffer, then 1:2 or 
1:2.5 with Sample 
Diluent 
1:80/100 final
1:40 with EC 
buffer, then 1:2 or 
1:2.5 with Sample 
Diluent 
1:80/100 final
1:20 with TPB, 
then 1:5 or 1:7 
with Sample 
Diluent
1:100/140 final
1 20 with TPB, 
then 1:5 with 
Sample Diluent 
1:100 final
GP56 rats X X 1:20 with TPB, 
then 1:2 with 
Sample Diluent 
1:40 final
1:20 with TPB, 
then 1:2 with 
Sample Diluent 
1:40 final
Table B
Primary Antibody Specificity Dilution Source
Rabbit Polyclonal Antibody to 
Glial Fibrillary Acidic Protein 
(GFAP)
Astrocytes in 
the brain
1/3000 (1%BSA in PBS) DAKO
Monoclonal Mouse Antibody 
Anti- Alzheimer Precursor 
Protein A4
full-length APP 1/200 (1%BSA in PBS) Chemicon
Rabbit Polyclonal Antibody 
anti-amyloid-beta, 37-42
Human
Amyloid-beta,
37-42
1/200 (1%BSA in PBS) Chemicon
Isolectin Activated
Microglia
1/100 (solution containing ImM 
Ca)
Sigma
Secondary Antibody Specificity Dilution Source
Goat Anti-Rabbit (GAR)-HRP 
Conjugate
Rabbit IgG 1/200 (1%BSA in PBS) Biorad
Goat Anti-Mouse (GAM)-HRP 
Conjugate
Mouse IgG 1/200 (1%BSA in PBS) Biorad
Figure 2.4. Table A encloses all the dilutions for FA and SDS extracts for measuring 13- 
amyloid 40 and 42 in the brain. Table B contains the antibodies, both primary and 
secondary, used for immunohistochemical staining of paraffin-embedded brain sections.
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Initially, the plate was washed 4 times with the Wash Buffer provided in the kit. 100 pi of 
standards dilutions and samples were then pipetted into appropriate wells of the pre­
coated microtiter plate. All standards and samples were run in duplicate. The plate was 
incubated with brain extracts for 2  hours at room temperature while shaking on an orbital 
plate shaker or overnight at 4°C without shaking.
Unbound amyloid peptide was removed from standards and samples by washing the plate 
4 times with the Wash Buffer. 100 pi of diluted detection antibody (rabbit polyclonal 
anti-Ap40 or Ap42) was pipetted into the wells. The plate was incubated for further 2 
hours at room temperature while shaking. After this time, excess antibody was removed 
using Wash Buffer as above. 100 pi of the horseradish peroxidase-conjugated anti-rabbit 
antibody was then pipetted into the wells and the plate was incubated for additional 2  
hours at room temperature with shaking.
After final wash with Wash Buffer (5 times), 100 pi of the chromogen solution was added 
to each well and the liquid in the wells began to turn blue (due to its reaction with 
peroxidase). The plate was incubated for 20-25 min at room temperature and protected 
from light. Horseradish peroxidase reaction was terminated by adding 100 pi of the Stop 
Solution into each well. The absorbance was measured at 450 nm. The blank well was 
created for the plate reader by adding 100 pi of both Stabilised Chromogen and Stop 
Solution. The plate was read within 2 hours after adding the Stop Solution.
Data analysis
After reading absorbance, standard curves were plotted. The curve was drawn from the 
absorbance of the standards (optical density) against the known standard concentrations. 
Analysis was performed using Microsoft Excel and the best curve linear fit was used. The 
Ap40 or AP42 concentrations for unknown samples were read from the standard curve 
and multiplied by the dilution factor (details in the table A in Figure 2.4). Differences 
were calculated using two-way ANOVA with genotype and treatment as factors.
As these Biosource kits had not been tested on SDS and FA brain extracts before, I 
encountered an unexpected problem. For the SDS extracts, the readings of optical density 
for low concentrations were not linear, but were bending logarithmically towards axis Y.
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As a result, some of the low readings for the SDS brain extracts (especially non- 
transgenic) were below the detectable level. The probable explanation would be that 
either the presence of SDS in the standards or reaction between SDS and brain in samples 
were shifting the optical density. To optimise it, standards should have been spiked with a 
small amount of non-transgenic brain tissue, to keep the conditions more similar. It is also 
possible that the problem involved antibody reacting to endogenous APP. In that case the 
proper control would be an APP knockout brain, but it was not available.
2.4. Immunohlstochemlstry -  paraffin wax sections
Theoretical background
Immunohistochemistry techniques are used for staining various tissues with antibody 
stains. The tissue is fixed, embedded in a wax medium, then sectioned, stained and 
examined under a microscope. The antibodies recognising epitopes of specific proteins 
present in the tissue are labelled with tagged secondary antibodies, which are conjugated 
with coloured markers. For this project, the immunohistochemistry was used to analyse 
the effect o f different modulators (ibuprofen, DHA and cholesterol) on the derivatives of 
APP and cerebral inflammation, particularly astrocytes and microglia, in the brain of 
Tg2576 transgenic mice and transgenic GP56 rats. Tg2576 mice start showing P-amyloid 
plaques and activated astrocytes and microglia after the age of 9 months (Hsiao et al., 
1996). There was no data on histopathology of GP56 rats.
Tissue preparation
Brains from 20 mice from the DHA experiment, 20 mice from the last Ibuprofen 
experiment and 1 0  rat brains from the cholesterol experiment were processed for 
immunohistochemistry for APP, P-amyloid, astrocytes and activated microglia. Some of 
the sections were double-stained to visualise both amyloid plaques and the astrocytes that 
surround them. Brains were removed as described in section 2.3, and immediately 
immersed in a fixative (4% paraformaldehyde in water) for at least 24 hours to avoid 
tissue autolysis and enhance subsequent staining of the tissue. After the fixation period 
the brain was cut coronally and processed for paraffin wax embedding using automatic 
tissue processors. The automated processor takes the cassettes through a series of graded
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Ethanol baths to dehydrate the tissues (70% Methanol 1 hour, 90% Methanol 1 hour, 95% 
Methanol 1 hour, 100% Methanol 1 hour, 100% Ethanol 1 hour) and then into xylene (1 
hour x 2) Hot paraffin (65°C) can then permeate the tissues. Processed tissue blocks can 
be stored in the cassettes at room temperature for years.
For sectioning, paraffin blocks were cooled on ice for at least 2 hours and the excess wax 
was trimmed away. 6  pm sections were cut from the tissue block by means of a Surgipath 
microtome. At the cutting edge of the knife, the wax shavings accumulated in the form of 
a continuous ribbon, which was picked up with forceps and floated on the surface of the 
water bath warmed to 45°C. Individual sections were separated with forceps and placed 
onto the surface of clean superffost pre-coated microscope glass slides. The slides with 
paraffin sections were placed to dry in a 65°C oven for 30 minutes and afterwards in a 
37°C oven overnight to bond the tissue to the glass. Slides were stored at room 
temperature.
Before the staining could be performed, the paraffin had to be removed from the tissue. 
The sections were first washed with xylene (3 changes of 5 min) and then re-hydrated in 
100% ethanol baths (3 changes of 5 min). After de-paraffinisation and re-hydratation, 
epitopes were exposed by treating the sections with 10 mM citrate buffer, pH 6.0 (2g of 
citric acid in 1 litre of distilled water, pH adjusted to 6.0 with 5M NaOH) in a microwave 
for 30 min. As soon as the boiling finished, slides were removed from the microwave and 
left at room temperature for about 45 min to cool down. Special care was taken not to 
allow the slides to dry during the procedure.
Staining - peroxidase anti-peroxidase (PAP) technique
Dry slides were washed with phosphate buffered saline (PBS; 10 mM sodium phosphate, 
150 mM NaCl, pH 7.5) for 5 min. To reduce background, the endogenous peroxidase 
activity was blocked by incubating slides in 0.3% hydrogen peroxidase solution (4ml of 
30% H20 2 in 400ml of PBS) for 30 min at room temperature.
Afterwards, slides were washed with PBS three times for 5 min. Excess buffer was 
drained off from slides and brain sections were marked around with Pan Pen (to keep the 
antibody solution on the section). Non-specific binding was blocked by incubation in 150-
65
200 pi of 1% Bovine Serum Albumin (BSA) solution in PBS for 30 min at room 
temperature. Then, sections were incubated with the primary antibody diluted in 1% BSA 
in PBS overnight in a humidifying chamber at 4°C (150-200 pi per section). Primary 
negative controls were also included by incubating sections in 1% BSA in PBS alone to 
control non-specific staining of secondary antibodies. The primary antibodies and 
dilutions are summarised in the Table B on Figure 2.4.
The next day, sections were removed from the humidifying chamber, adjusted to room 
temperature and washed for 15 min with PBS (3 changes). The secondary antibody was 
prepared in 1% BSA in PBS, applied to the sections (150-200 pi per section) and left for 
2 hours at room temperature. The secondary antibodies and dilutions are summarised in 
Table B on Figure 2.4. For isolectin, secondary antibody was not added. Excess antibody 
was removed by washing in three changes of PBS for 15 minutes.
The next step was 3,3-diaminobenzidine (DAB) development. The sections were 
incubated in 0.05% DAB, 0.003% H2O2 in PBS until the optimal colour intensity had 
been achieved (up to 5 min). Once the desired signal was achieved, the reaction was 
stopped by washing the slides in the PBS for 5 min.
If the sections were double stained with another primary antibody, the procedure was 
repeated by first blocking the peroxidase activity. Then the sections were washed in PBS, 
incubated with the second primary antibody overnight, washed with PBS and incubated 
with the appropriate secondary antibody. After that the sections were developed with 
Vector SG. 5ml of PBS, 3 drops of Chromogen from the kit and 3 drops of Hydrogen 
Peroxide Solution were mixed and sections were incubated at room temperature until 
optimal staining developed, usually 5-10 min. Once the desired signal was achieved, the 
reaction was stopped by washing the slides in the PBS for 5 min.
Finally the sections were washed in running water and counterstained in haematoxylin 
solution for 30 to 45 sec. After counter-staining, sections were again washed in tap water 
to blue the nuclei.
After these procedures, the sections were dehydrated in 100% ethanol for 5 min, and 
dried at room temperature. Finally, the sections were mounted in a drop of mounting
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medium DPX. A protective glass cover slip was placed over the section. After drying, the 
sections were examined under the light microscope.
Data analysis
Sections were examined under a light microscope and pictures were taken with a digital 
camera (Nikon) attached to the microscope. Analysis was limited to basic plaque and 
surrounding astrocytes count.
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Chapter 3 
Can ibuprofen treatment prevent, 
treat or delay AD-like impairment in 
transgenic Tg2576 mice?
3.1. Introduction
Overview
Ibuprofen, one of the NSAIDs, has been implicated in many epidemiological studies in 
reducing the risk of developing Alzheimer’s disease. Transgenic mice modelling this 
disease show reduced learning ability and Ap pathology, which develops with aging. This 
project investigated the effect of dietary administration of ibuprofen on learning ability, 
synaptic physiology and pathology in Tg2576 Alzheimer's disease model mice at different 
stages of development of pathology.
Ibuprofen
Boots-affiliated Company first introduced ibuprofen in the UK in 1969 under the trade 
name Brufen. It belongs to a family of non-steroidal anti-inflammatory drugs described in 
section 1.5.4. The chemical name of ibuprofen is 2-(4-Isobutyl-phenyl)-propionic acid
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and its chemical formula is C 13H18O2. Ibuprofen is a white powder and exists in two 
enantiomers but only the S-ibuprofen is active in humans (reviewed in Rainsford, 1999).
Ibuprofen is used to relieve the symptoms of a wide range of illnesses such as headaches, 
backache, period pain, dental pain, neuralgia, rheumatic pain, muscular pain, migraine, 
cold and flu symptoms and arthritis. Ibuprofen has a low incidence of serious side effects, 
like gastrointestinal or kidney damage. It is rapidly metabolised in humans, usually 
leaving the body within 24 hours (reviewed in Rainsford, 1999). Ibuprofen crosses the 
BBB and acts on the central nervous system. Its concentration in the cerebrospinal fluid 
peaks in 3 hours after the oral dose (Bannwarth et al., 1995).
Neuroinflammation and animal models
Murine models of AD that overexpress APP and develop Ap plaques also exhibit 
proinflammatory activation of microglial cells and astrocytes (Frautschy et al., 1998; 
Benzing et al., 1999; Stalder et al., 1999; Mehlhom et al., 2000; Bomemann et al., 2001). 
Microglial activation around plaques in Tg2576 transgenic mice (Frautschy et al., 1998) 
is accompanied by the release of a wide range of pro-inflammatory molecules (IL-lp, 
TNF-a and IL-6 ) that mediate the auto-activation of these cells and a concomitant 
astrocytosis (Benzing et al., 1999). These findings provide evidence that Tg2576 mice 
exhibit features of the inflammatory pathology seen in AD and suggest that this mouse is 
a useful animal model for studying the role inflammation may play in this disease.
The influence of neuroinflammation on learning ability and synaptic plasticity was also 
investigated outside of explicit AD models (Hauss-Wegrzyniak et al., 1998; 2000; 2002). 
Chronic neuroinflammation produced by infusion of lipopolysaccharide (LPS) into the 
fourth ventricle for 4 weeks resulted in impaired performance of rats in spatial memory 
spontaneous alternation test in a T-maze (Hauss-Wegrzyniak et al., 1998). The effects of 
longer infusion of LPS and assessment whether these effects could recover over time 
were also investigated (Hauss-Wegrzyniak et al., 2000). The results showed that 
prolonged LPS infusion did not increase the inflammatory reaction and did not produce a 
significantly greater behavioural impairment. Furthermore waiting for 37 days after the 
cessation of the LPS infusion did not decrease the density of activated microglia and did 
not improve performances in the Morris water maze task. The results suggest that 
inflammation may contribute to the pathogenic mechanisms that underlie the clinical
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expression of AD (Hauss-Wegrzyniak et al., 2000). Further studies showed that numerous 
highly activated microglia were distributed throughout the cingulate gyrus, entorhinal 
cortex, hippocampus and dentate gyrus (Hauss-Wegrzyniak et al., 2002). In addition, 
chronic neuroinflammation resulted in the loss of pyramidal cells within the entorhinal 
cortex and a significant attenuation of LTP within the dentate gyrus (Hauss-Wegrzyniak 
et al., 2002). All these changes reproduce some features of AD supporting the hypothesis 
that inflammatory processes play a role in the pathogenesis of AD.
Testing further the LPS model, this same group showed that Flurbiprofen attenuated the 
neuroinflammatory reaction and reduced the inflammation-induced memory deficit as 
tested in spatial learning in the Morris water maze (Hauss-Wegrzyniak et al., 1999). 
Flurbiprofen improved the performance of young rats, but had no effect on older animals 
(Hauss-Wegrzyniak et al., 1999). The results suggest that NSAID therapies may work 
better before the onset of AD. Therefore the potential treatments should be initiated in 
adults before age-associated inflammatory processes within the brain have a chance to 
develop.
NSAIDs studies in animal models
Epidemiological results showing that long-term treatment with NSAIDs reduces the risk 
of developing AD (reviewed in chapter 1.5.4) have lead to extensive studies in AD animal 
models. The aim is to gain further understanding of the mechanism of preventive action 
of NSAIDs and other anti-inflammatory agents.
Lim and colleagues (2000) first reported that treatment of Tg2576 mice for 6  months 
(from 1 0  to 16 months of age) with ibuprofen resulted in a significant reduction of 
amyloid plaque burden and in total Ap measured by ELISA. These studies also 
demonstrated that ibuprofen treatment led to a reduction of plaque-associated microglia 
and a corresponding reduction in proinflammatory cytokine levels in the brain.
As excessive use of NSAIDs targeting COX-1 can cause gastrointestinal, liver and renal 
toxicity, Lim and colleagues (2001) also tested curcumin, as an alternative to NSAIDs, in 
a similar paradigm. Curcumin derives from the curry spice turmeric and has potent 
antioxidant properties. Treatment with curcumin resulted in reduction of the astrocytic
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marker GFAP, insoluble Ap, soluble Ap and plaque burden. Microgliosis was also 
suppressed in neuronal layers but not adjacent to plaques.
To further investigate the effect reported in 2000, Lim and co-workers (2001) attempted 
to assess the influence of chronically administrated ibuprofen over 3 to 6 months on 
mouse behaviour in an open field task, that is sensitive to hippocampal and basal ganglia 
damage, as well as to hind limb dysfunction. Ibuprofen treatments in transgenic females 
restored values of the open field behaviour to non-transgenic levels. Also, significant 
reductions of both soluble and insoluble Ap were observed. Although IL-lp and insoluble 
Ap were more effectively reduced with longer treatment, the magnitude of the effect on 
soluble Ap was not dependent on treatment duration. However, the direct relationship 
between the diet-induced changes and learning performance in training tests was not 
established.
Ferulic acid is an antioxidant and anti-inflammatory agent derived from plants and Yan 
and colleagues (2001) assessed its potential protective activity against Ap toxicity in vivo. 
Mice were given water containing ferulic acid or control and after 4 weeks Ap42 was 
administered via intracerebroventricular injection. Injection of control mice with AP42 
impaired performance on the step-through passive avoidance test, the spontaneous 
alternation in the Y-maze and the spatial reference water. However mice treated with 
ferulic acid prior to Ap42 administration were protected from these changes.
Similar results were obtained in the study using NCX-2216, a nitric oxide (NO)-releasing 
derivative of the COX-1-preferring NSAID flurbiprofen (Jantzen et al., 2002). Doubly 
transgenic APP/PS1 mice were treated with NCX-2216, ibuprofen and cyclooxygenase-2- 
selective NSAID celecoxib between 7 and 12 months of age. The NO-releasing derivative 
of flurbiprofen dramatically reduced both Ap loads and Congo red staining. This 
reduction was associated with a dramatic increase in the number of activated microglia 
suggesting their role in clearing Ap deposits. In contrast, ibuprofen caused only modest 
reductions in Ap load and celecoxib had no effects on amyloid deposition at all.
Yan et al. (2003) studied the effect of pioglitazone (PPARy agonist) and ibuprofen 
administered orally for four months in 11-month-old transgenic Tg2576 mice. They 
confirmed that ibuprofen reduced amyloid plaque burden, microglial activation and
71
soluble A(342, but in their study pioglitazone only modestly reduced soluble Ap levels 
and did not affect amyloid plaque burden or microglia activation. Further studies using 
APP-expressing cells showed that ibuprofen directly affected APP processing, 
specifically reducing the production of AP42. This could indicate that PPARy activation 
is not involved in the Ap lowering effect, although other studies gave contradictory 
results (see chapter 1.5.4).
All these studies performed in rodents suggest that ibuprofen and other NSAIDs are 
important agents that can modify amyloid pathology as well as learning and memory 
functions in AD animal models. The diversity of results, however, reflect the fact that the 
mechanism(s) by which NSAIDs may reduce the severity of Alzheimer's disease and 
stage of the illness at which intervention would be most effective are not yet well 
understood. The main hypotheses how NSAIDs act to achieve these effects are described 
in section 1.5.4.
The aim of this study was to test whether ibuprofen can prevent, postpone or treat the 
development of amyloid pathology, memory impairment and synaptic disturbances in the 
brains of APP over-expressing Tg2576 transgenic mice. The project was intended to 
assess the effect of various paradigms of chronic ibuprofen administration on learning and 
memory impairment in the Forced Choice Alternation task, in synaptic physiology and in 
the induction of LTP in vivo, in the levels of AP40 and 42 in the brain and on markers of 
amyloid pathology in the brain.
3.2. Materials and methods
Animals and diets
Male and female transgenic Tg2576 mice, aged from four to fourteen-months, and their 
non-transgenic littermates (20-35 g body weight) were used for experimental procedures. 
The project consisted of three experimental parts, which are described and shown in 
Figure 3.1. The mice for each type of experiment were randomly divided into four 
groups: the transgenic/ibuprofen group, the transgenic/control-diet group, the non- 
transgenic/ibuprofen group and the non-transgenic/control-diet group. Mice were group 
housed with littermates (with transgenic and non-transgenic housed together), and all
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Figure 3.1. Experimental design. Testing was performed in three parts, part A and C were 
performed at Cardiff University while part B was done at the University o f Minnesota in 
collaboration with Prof Karen Hsiao Ashe. Mice were all tested in the T-maze (indicated by |J ). 
In experiment C mice were tested for the second time after 2 months. Group A went through 
electrophysiology in vivo, and the brains were analysed for p-amyloid using ELISA in Prof 
Steven Younkin’s laboratory (indicated by a star (*), results not available). Group B was left in 
Prof Ashe’s laboratory for further analysis.
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testing was conducted during the light phase. Transgenic mice were compared to 
littermate controls to ensure that age and background strains were as equivalent as 
possible.
The ibuprofen group was put on a special chow prepared by Harlan (US) by incorporating 
ibuprofen powder into standard rodent chow. The ibuprofen-enriched special diet 
contained 375ppm of ibuprofen, corresponding to lg of chow-contained 0.375mg of 
ibuprofen. Assuming that a healthy mouse eats around 5g of a chow a day, the ibuprofen 
dose for a mouse was estimated to be 1.875 mg per day. That accounts for a dose of 
around 62.5 mg/kg per day (assuming the average mouse weighs 30g). This value is 
similar to the dose typically administered to humans (15-30mg/kg/day; Rainsford, 1999). 
Also this dose has already been found to be effective at reducing Ap and used by other 
groups in Tg2576 mice studies (Lim et al., 2000; 2001).
For the control chow, nothing was added to the standard Harlan rodent chow. The chows 
were stored at 4°C and fresh supplies were given to the mice every day. The quality of the 
diet and the ibuprofen content was assessed and provided by Harlan (US).
Experimental Procedures
The full experimental procedure consisted of a series of phases, which were conducted on 
all animals. These included:
• Maintaining on the special chows (ibuprofen or control) and drinking water ad libitum 
for a various amount of time depending on the experimental group (Figure 3.1). For 
longitudinal experiments, some mice were kept on ibuprofen while others were 
transferred from control to ibuprofen for an additional 11 weeks.
• Forced Choice Alternation task as described in Chapter 2.1.1. During testing, mice 
were put on water deprivation regime (20 hours of no water, 2 hours experiment with 
25% sucrose reward and 2 hours of free water access after experiment). Mice were kept 
on the special chow diets until the end of testing.
• Electrophysiology in vivo was performed in only one of the experimental groups 
(group A, see Figure 3.1). Basic synaptic transmission and induction of LTP was assessed
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in vivo by recording from dentate gyrus whereas stimulating the perforant pathway 
(described in chapter 2.2).
• Mice were killed after behavioural and electrophysiological experiments. The brains 
were dissected and the hemispheres separated along the midline (excluding cerebellum). 
The half brains were assigned for p-amyloid ELISA, ibuprofen measurements and 
immunohistochemistry.
• ELISA was conducted using commercially available kits (Biosource) in SDS and FA 
brain extracts to assess the amount of p-amyloid 40 and 42 in brain tissue (details in 
Chapter 2.3). ELISA measurements in mice brains from groups A and B were performed 
in Prof Steven Younkin’s laboratory.
• Immunostaining was undertaken using antibodies recognising p-amyloid, APP, 
activated astrocytes and microglia recognising antibodies (as described in Chapter 2.4);
• Ibuprofen levels were measured in plasma and in chopped and mixed whole half of 
the brain (hippocampus was not extracted separately). The measurements were performed 
by Pablo Morentin-Gutierrez in collaboration with Prof Paul Chapman in the Merck 
laboratories.
Statistical analysis
All data were expressed as means ± SEM. The statistical significance of differences in the 
learning parameters in the FCA and the values of electrophysiological analysis were 
measured by repeated-measures 3-factor ANOVA, with genotype and diet as between 
subject factors and time or stimulus intensity as within subject factor. Tukey's pair-wise 
comparisons post hoc tests were carried out to determine the source of a significant main 
effect or interaction. The statistical significance of differences in the value of 
Perseveration Count and the p-amyloid levels between the groups was determined by the 
2-factor ANOVA, with genotype and diet as bewteen subject factors and Tukey's pair 
wise comparisons post hoc tests. The proportion of mice reaching learning criterion was 
compared using pair-wise Fisher’s test.
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33. Results
Body weighty survival assessment and chow quality
There were no significant differences in weight gain over the treatment period between 
the transgenic and non-transgenic groups, whether on control or ibuprofen-enriched diets 
(data shown in Figure 3.2.). The weight data are only available from experimental group 
A and C, as mice in group B were fed and cared for by Research Animal Services at the 
University of Minnesota, under the supervision of Prof K. Hsiao Ashe’s group. Two age 
groups of mice from experiment A were combined into one weight group as all the mice 
were on the special diets for the same period of time and were adult. Although the mice 
on ibuprofen seemed to be fatter, repeated measures 3-factor ANOVA with week as a 
repeated measure and diet and genotype as between-subject factors revealed no 
significant differences (all p>0.05).
During the time of chronic administration of either ibuprofen or control diets some of the 
mice died (data shown in Figure 3.2.). The numbers of lost mice were similar for all 
groups on both types of diet, but show a higher mortality rate for transgenic Tg2576 mice 
compared to non-transgenic littermates. This finding is consistent with other groups 
breeding Tg2576 mice (Karen Hsiao Ashe's or Steven Younkin’s laboratories).
The quality of the diet and the ibuprofen content was assessed and provided by Harlan 
(US). The content o f ibuprofen in a rodent chow during storage time (around 3months at 
4 °C) was not confirmed. Fresh supplies were bought every 3 months from Harlan (US).
Forced Choice Alternation task in the T-maze
The forced-choice alternation (FCA) task assesses spatial episodic-like memory using the 
T-maze. Training lasts for 10 days and each mouse receives 6 trials per day. The percent 
of correct choices for each mouse was calculated daily. The aim of the experiment was to 
compare the influence of ibuprofen supplementation as prevention (before 8 months of 
age) and as a treatment (after 8 months of age). Before the age of 7-8 months, Tg2576 
mice show no impairments in T-maze FCA, while after that age the deficit in FCA task 
and others starts to develop (Chapman et al., 1999).
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Body weight and survival assessment
Final weight
Non-transgenic/Ibuprofen 33.1 ± 0.9g
Non-transgenic/ControI 32.8±1.2g
Died during treatment 
period (4-6 months)
Group A
Transgenic/Ibuprofen 30.9±1.4g ^
Transgenic/Control 29.9 ± 1.5g ^
Group C
Transgenic/Ibuprofen 30.7±0.7g ^
Transgenic/Control 29.9 ±0.5g j
Non-transgenic/Ibuprofen 32.1 ± 0.8g
I t
Non-transgenic/ControI 32.4 ± 0.9g j
Figure 3.2. Final weights for mice from experimental groups A (age 9 months) and C (age 11- 
12 months). Data are expressed as means ± SEM. Repeated measures 3-factor ANOVA with 
week as a repeated measure and diet and genotype as between-subject factors revealed no 
significant differences (all p>0.05). During the time o f chronic administration o f either ibuprofen 
or control diets more transgenic than non-transgenic mice died. The diet did not seem to have 
influence but the results show a higher mortality rate for transgenic Tg2576 mice.
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Experiment A. The aim of the first experiment was to compare the prevention and 
treatment effects of ibuprofen given to mice at the age of 2-3 months and 6-8 months. 
During testing none of the mice was excluded from analysis. Graphs A and B on Figure 
3.3 show the effect of chronic administration of dietary ibuprofen on episodic-like 
memory related learning ability in Tg2576 and their non-transgenic littermates at the age 
of 8 and 12-14 months, respectively.
Figure 3.3A shows learning curves for the prevention group averaged across groups and 
for 2 days. Repeated measures ANOVA (with day as a repeated factor and genotype and 
diet as between subject factors) revealed a significant effect of day of training (F=2.8, 
p=0.018) confirming overall improvement during training for all the groups. The main 
effect of genotype was just significant (F=4.8, p=0.043) indicating that both groups of 
transgenic mice were impaired in the FCA task compared to non-transgenic mice. The 
effect of diet and the interaction between genotype and diet did not reach significance (all 
p> 0.05). Post-hoc Tukey's pair-wise comparisons did not confirm any significant 
differences between groups. Although not significant, there was a visible predisposition 
of transgenic mice on ibuprofen diet to reach a higher percent correct each day. Also the 
numbers of mice were low (4-6) making statistical analysis problematic.
Figure 3.3B illustrates learning curves for the older group, testing the effect of ibuprofen 
as a treatment. Data was averaged across groups and for 2 days. Repeated measures 
ANOVA (with day as a repeated factor and genotype and diet as between subject factors) 
revealed a significant effect of day of training (F=4.4, p<0.001) confirming the overall 
improvement during training of all the groups. The main effect of genotype was highly 
significant (F=57.8, p<0.001) indicating that all the transgenic mice were impaired in the 
FCA task compared to non-transgenic mice. Also the interaction between day and 
genotype reached significance (F=2.2, p=0.046) indicating that transgenic mice reacted in 
a different way to training in the T-maze, meaning that they did not learn as well as non- 
transgenic littermates. The effect of diet and the interaction between genotype and diet 
did not reach significance (all p> 0.05) indicating no influence of ibuprofen on 
performance in the T-maze. Post-hoc Tukey's pair-wise comparisons confirmed that 
transgenic mice on both diets were significantly different from non-transgenic mice 
regardless of which diet they were fed. This result confirms the finding that an effect of 
genotype on performance of Tg2576 mice is very strong.
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Learning in Tg2576 and non-transgenic littermates on Ibuprofen/Control
chow as a prevention and as a treatment -  experiment A
Prevention Group -  8 months
— tg/ibu,n=6 
—■— tg/conUi=6
- 0  - nontg/ibu, n=5
- -a- - nontg/con, n=450
T T V
1/2 3/4 5/6 7/8 9/10
time (days)
B 100 Treatment Group -  12-14 months
90
80
70
60
—■— tg/ibu, n=12 
—■— tg/con, n=12
- -D- - nontg/ibu, n= 10
- -O- - nontg/con, n=9
50
40
1/2 3/4 5/6
time (days)
7/8 9/10
Figure 3.3. C h ro n ic  ad m in istra tion  o f  Ibuprofen  in  T g 2 5 7 6  m ic e  as a  p rev en tio n  (fro m  2  to  8 
m o n th s) and  a s  a  treatm en t (fro m  6 -8  to  1 2 -1 4  m o n th s) o f  age . G raph A  rep resen ts th e  p ercen ta g e  
o f  co rrect r e sp o n s e s  a v era g ed  a cro ss  g ro u p s and fo r  2  d a y s  in p rev en tio n  grou p . A n a ly s is  
rev e a le d  s ig n if ic a n t m ain  e f fe c t  o f  d ay  o f  train ing and g en o ty p e . T h e  e f f e c t  o f  d ie t and in teraction  
b e tw e e n  g e n o ty p e  and  d ie t d id  n ot reach  s ig n ific a n c e . G raph B  sh o w s  lea rn in g  a cq u is it io n  cu rve  
fo r  tra n sg en ic  and  n o n -tra n sg en ic  m ic e  from  a treatm ent group . D ata  w e r e  a v era g ed  a cro ss  grou p s  
and  for ev ery  2 d a y s. A n a ly s is  rev ea led  s ig n ifica n t m a in  e f fe c ts  o f  d ay  o f  train ing, g e n o ty p e  and a  
s ig n if ic a n t in teraction  b e tw e e n  d ay  and  g en o ty p e . T h e  e f fe c t  o f  d ie t and in teraction  b e tw e e n  
g e n o ty p e  and  d ie t d id  n o t reach  s ig n if ic a n c e  in d ica tin g  n o  in f lu e n c e  o f  ib u p ro fen  on  p erform an ce  
in  the T -m a z e  at th is  a g e  o f  m ic e .
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Comparing graphs from the prevention and treatment groups, it seems that 8-month-old 
transgenic mice were protected to some extent against developing impairment in the FCA 
task. To verify this effect, higher numbers of mice were put on ibuprofen diet before the 
onset of impairment in the T-maze.
Experiment B. As the prevention study suggested an effect of ibuprofen, but did not 
reach significance, another, larger, cohort was tested. 40 transgenic mice were split 
randomly into two groups and put on either ibuprofen or control diet at the age of 4-5 
months. Testing took place at the age of 8 months. Only 4 non-transgenic mice were 
trained as controls. During testing, 2 transgenic mice on ibuprofen diet and 3 transgenic 
mice on control were excluded because they failed to move. The criteria for exclusion are 
described in Chapter 2.1.1.
Figure 3.4A shows the effect of chronic administration of ibuprofen on acquisition of an 
episodic-like memory task in Tg2576 mice. The percent correct value for each mouse was 
calculated daily and averaged over the groups. Repeated measures ANOVA (with day as 
a repeated factor and diet and sex as between subject factors) revealed a significant effect 
of diet (F=4.6, p=0.04) and its interaction with a training day (F=4.5, p<0.001) indicating 
that mice on ibuprofen reacted in a different way to the training comparing to mice on 
control diet. The effect of sex and other interactions were not significant (all p>0.05). 
Performance was also significantly different across training sessions (F=3.8, p<0.001) 
confirming an overall improvement during training of all the groups.
The percent of mice reaching Learning Criterion (defined as 80% correct or better on at 
least 3 consecutive days during training) was also affected by ibuprofen pre­
administration as shown on Figure 3.4 (B). The paired comparison between groups was 
performed using Fisher's exact test, two-sided and revealed that a significantly smaller 
percent of transgenic mice on control diet (p=0.0032) reached the Learning Criterion 
comparing to transgenic littermates on ibuprofen diet, indicating a significant effect of 
treatment. Finally, the nature of the response strategies in the transgenic animals and the 
influence of diet were also examined. Figure 3.4C shows the mean Perseveration Count, 
which is measured as a maximum number of consecutive free choices made in the same 
direction for each animal per day, averaged over the training days and the groups. A 2-
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Learning in Tg2576 transgenic mice on Ibuprofen/Control ch ow -
experiment B
A
90, tg/ibu, n=16 
tg/con, n=16
Testing Day
B
■ % Reached
C
Figure 3.4. C h ro n ic  p re -ad m in istra tion  o f  Ibu profen  in  T g 2 5 7 6  m ic e  d e la y s  th e  o n se t  o f  im p a irm en t  
in sp atia l e p is o d ic  - l i k e  m e m o r y  a s s e s se d  u sin g  th e  T -m a ze . G raph  A  rep resen ts th e  p e r c e n ta g e  o f  
correct r e sp o n se s  fo r  ea ch  d ay  during 10 d a y s  o f  tra in in g  for  ea ch  m o u s e  a v era g ed  o v er  th e  grou p s. 
A n a ly s is  co m p a r in g  tra n sg en ic  m ic e  on  con tro l and ib u p ro fen  d ie ts  rev ea led  s ig n ific a n t e f f e c t  o f  d iet, 
tra in in g  d ay  an d  th eir  in teraction . T h e  e f f e c t  o f  s e x  w a s  n o t s ig n ifica n t. G raph B  s h o w s  th e  p ercen ta g e  
o f  m ic e  in  e a ch  g ro u p  that reach ed  learn in g  cr iter ion , d e fin e d  a s 80 %  correct or better  o n  at least 3 
c o n s e c u t iv e  d a y s. T h e  p a ired  c o m p a r iso n s b e tw e e n  g ro u p s rev ea led  s ig n ific a n t d if fe r e n c e  b e tw een  
tra n sg en ic  m ic e  o n  con tro l and ibu p rofen  d ie ts . G raph  C  s h o w s  P ersev era tio n  C ou n t M ean  w h ic h  is  
m ea su red  a s a m a x im u m  n u m b er o f  c o n se c u t iv e  free  c h o ic e s  m a d e  in th e sa m e  d irec tio n  fo r  each  
a n im a l p er  d ay  a v era g ed  o v er  th e  d a y s  and  th e  grou p s. A  2 -fa c to r  A N O V A  d id  n o t sh o w  an y  
s ig n if ic a n t d if feren ces .
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factor ANOVA (with diet and sex as between subject factors) did not show any 
significant differences.
Experiment C. On establishing the preventive effect of ibuprofen on learning deficit, the 
next task was to measure how long this prophylaxis lasts. The influence of previous 
testing at younger age on learning impairment was also addressed, as some of the 
transgenic mice on control diet were put on ibuprofen chow after the first part of testing 
(mimicking treatment paradigm). Experiment A already established that if transgenic 
mice were naive, they could not learn the FCA task in the T-maze.
During testing, 3 transgenic mice on ibuprofen diet, 2 transgenic mice on control, 1 non- 
transgenic mouse on ibuprofen and none non-transgenic mice on control were excluded 
because they failed to move (see criteria for exclusion in Chapter 2.1.1). Repeated 
measures ANOVAs were carried out on the percent correct scores from 10 training 
sessions.
The first part of longitudinal testing in FCA task took part at the age of 8 months. As 
indicated in Figure 3.5, all groups showed improvement in the percent of correct choices 
over the 10 training days, with final performance showing significant improvement from 
the first day of training. Non-transgenic mice on both diets reached above 90% correct by 
the end of testing, transgenics on ibuprofen were just below, reaching above 80% while 
transgenic on control stayed below 60% correct. Repeated measures ANOVA (with day 
as a repeated factor and genotype and diet as between subject factors) revealed a highly 
significant effect of day of training (F=7.3, p<0.001) confirming overall improvement 
during training of all the groups. The main effect of genotype was significant (F=31.1, 
p<0.001) indicating that all the transgenic mice were impaired in the FCA task compared 
to non-transgenic mice. The interaction between genotype and diet (F=4.2, p=0.045) 
reached significance, indicating that ibuprofen influenced performance of Tg2576 mice in 
FCA task. Also, the interaction between day and diet (F=2.1, p=0.04) reached 
significance, pointing to an influence of diet on acquisition of the FCA task. The effect of 
diet and any other interactions were not significant (all p>0.05). As non-transgenic mice 
in this task are approaching a ceiling effect (more than 90% correct choices on the last 
day of testing) it was impossible to distinguish between non-transgenic on control or 
ibuprofen enriched diets. To examine the effect of ibuprofen on non-transgenic animals,
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delays between the sample and test trials in the FCA task in the T-maze could have been 
introduced.
To avoid this confound, transgenic mice were also analysed separately. Repeated 
measures ANOVA (with training day as a repeated factor and diet as the between subject 
factor) revealed a significant main effect of training day (F=4.3, p=0.001), confirming a 
genera] improvement during testing. The analysis also showed a significant main effect of 
diet (F=9.1, p=0.004) indicating a significant influence of ibuprofen on tested animals. 
Also the interaction between day and diet remained significant (F=2.9, p=0.009) pointing 
to an influence of ibuprofen on acquisition of FCA task in transgenic mice.
Post-hoc Tukey's pair-wise comparisons confirmed that transgenic mice on control diet 
were significantly worse than non-transgenic on either diet and transgenic mice on 
ibuprofen diet. However transgenic mice on ibuprofen diet were significantly different 
from transgenic and non-transgenic on control diets but no different from non-transgenic 
on ibuprofen diet. The interaction between day and diet might also be explained as both 
the transgenic and non-transgenic mice on ibuprofen diet started at better percent of 
correct choices than mice on control diet (Figure 3.5). After accomplishing ten training 
days, all mice on control diet were switched to ibuprofen diet while those on ibuprofen 
diet did not change.
The analysis of the first part of testing suggests that transgenic mice on control diet 
showed impairment in the FCA task and ibuprofen diet made this impairment 
significantly smaller. Nonetheless, transgenic mice on ibuprofen were still different from 
non-transgenic, so ibuprofen only minimised deficit in the T-maze.
10 weeks later, the same mice were re-tested (at 11 months of age). During 10 weeks 1 
transgenic mouse on control diet and 2 transgenic mice on ibuprofen diet died and no 
further mice were excluded from testing. As pictured on Figure 3.5, all the non-transgenic 
mice regardless of diet had maintained the same performance levels demonstrated at 8 
months, but all transgenic animals (regardless of diet) showed impaired performance on 
the task. This interpretation was confirmed by repeated measures ANOVA (with day as a 
repeated factor and genotype and diet as between subject factors) and revealed a 
significant main effect of genotype (F= 45.9, p<0.001) and a significant main effect of 
day (F=7.76, p<0.001) indicating that all mice improved during training. A main effect of
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Learning in Tg2576 and Non-Transgenic litterm ates on Ibuprofen/Control
chow -  experim ent C
2 months100-1
90
80
8
60 4
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Figure 3.5. C h ro n ic  p re-a d m in is tra tio n  o f  Ibu profen  in  T g 2 5 7 6  m ic e  d e la y s  th e o n se t  o f  
im p a irm en t in  sp a tia l e p is o d ic  - l i k e  m e m o r y  a sse sse d  u sin g  th e  T -m a ze . D ata  are m ean  ±  S E M  
o f  th e  p er c e n ta g e  o f  co rrec t r e sp o n se s  fo r  ea ch  d ay  during b oth  parts o f  train ing fo r  ea ch  m o u s e  
a v era g ed  o v e r  th e  g ro u p s. R ep ea ted  M ea su res  A N O V A  fo r  th e  first part r ev e a le d  s ig n if ic a n t  
e f f e c t  o f  a  tra in in g  d a y , g e n o ty p e  and  s ig n ific a n t in tera ctio n s o f  a d ie t w ith  g e n o ty p e  and  o f  a  
d a y  and  d ie t. A fter  e x c lu d in g  n o n -tra n sg en ic  a n im a ls  from  a n a ly s is , th e  e f fe c t  o f  d ie t rea ch ed  
a ls o  s ig n if ic a n c e . F or th e  re -testin g , rep ea ted  m ea su res  A N O V A  r e v e a le d  a h ig h ly  s ig n if ic a n t  
e f f e c t  o f  g e n o ty p e  and  a tra in in g  d ay . T h e  e f f e c t  o f  d ie t w a s  n o t s ig n ifica n t.
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diet and interactions between diet, genotype and day were not significant (all p> 0.05). 
Excluding non-transgenic animals from the analysis only confirmed significant main 
effect of day (F=3.7, p<0.001) whereas diet and interaction between day and diet 
remained not significant (all p>0.05).
Post-hoc Tukey's pair-wise comparisons confirmed that transgenic mice were 
significantly worse than non-transgenic mice irrespective of diet, indicating no effect of 
diet on memory impairment measured in the FCA task at this stage of experiment. It can 
be concluded that transgenic mice on ibuprofen diet were impaired in re-acquisition of the 
T-maze task. Also transgenic mice switched from control diet to ibuprofen diet, after the 
first part of testing, remained impaired in FCA task.
The analysis of the second part of testing suggests that transgenic mice on any diet 
showed impairment in FCA task as compared to non-transgenic animals and ibuprofen 
treatment had no effect on FCA performance.
In analysing both parts of exjperiment together, time as an additional factor was 
introduced. It was meant to show the differences between testing at 8 and 11 months of 
age. Repeated measures ANOVA (with day as a repeated factor and genotype, diet and 
time as between subject factors) revealed a highly significant main effect of day (F=13.8, 
p<0.001) and genotype (F= 76.6, p<0.001). The interaction between diet and genotype 
was significant (F=3.9, p=0.048) indicating that ibuprofen influenced Tg2576 mice 
performance in the T-maze during both stages of testing. Also interaction between diet, 
day and time was significant (F=2.1, p=0.036) indicating a different influence of 
ibuprofen on FCA acquisition of Tg2576 mice at two parts of testing. A main effect of 
diet and other interactions between diet, genotype, time and day were not significant (all 
p> 0.05). Excluding non-transgenic mice from the analysis (see above for explanation), 
confirmed the significant effect of day (F= 76.6, p<0.001) and diet (F= 76.6, p<0.001). 
Time and its interaction with either diet or genotype did not reach significance (all p> 
0.05).
Post-hoc Tukey's pair-wise comparisons confirmed that transgenic mice on either diet 
during both parts of testing were significantly different from non-transgenic mice 
regardless of diet. This result confirms the fundamental finding that an effect of genotype
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on performance of Tg2576 mice in the T-maze is very strong and that ibuprofen diet had 
only modest effect.
The analysis of both parts of testing suggests that ibuprofen given as prevention (before 
the onset of deficit) delays the development of impairment in Tg2576 transgenic mice in 
FCA task but does not reverse it.
The percent of mice reaching Learning Criterion (defined as 80% correct or better on at 
least 3 consecutive days during training) was affected by ibuprofen administration at the 
first part of testing (8 months old) as shown on Figure 3.6. This effect disappeared at the 
second part of testing (at the age of 11 months); a significantly smaller percentage of 
transgenic mice reached Learning Criterion comparing to non-transgenic littermates, 
indicating a significant effect of only genotype and no effect of diet (for analysis see 
Figure 3.6). Thus, the preventive, but not the treatment, effect of ibuprofen on learning of 
transgenic mice as measured by percentage of correct choices (Figure 3.5) was confirmed 
by analysis of Learning Criterion.
Electrophysiology in vivo
To determine whether the behavioural deficits in aged Tg2576 mice were associated with 
changes in synaptic function and whether ibuprofen affected this, I examined field 
potentials in the dentate gyrus in response to medial perforant pathway stimulation in 
Tg2576 mice in vivo. Mice from experiment A (see Figure 3.1), after finishing testing in 
the T-maze, were used. For analysis, changes in the field-excitatory postsynaptic potential 
(fEPSP) slope and pop spike (PS) amplitude were measured.
First, synaptic function was assessed by using a range of stimulus intensities to generate 
input-output (I/O) curves to study baseline responses before induction of LTP. I/O curves 
of the fEPSP slope and PS amplitude were created as a function of stimulus intensity (see 
Figure 3.7). Although the numbers of mice in the prevention group were quite low (n=4- 
6), analysis could still be performed. Repeated measures 3-factor ANOVA (diet x 
genotype, with stimulus intensity as the repeated-measure factor) revealed no significant 
effects of either genotype or diet for the size of the fEPSP slope or the PS amplitude at 
any intensity (all p > 0.05). An overall effect of stimulus intensity was significant for both 
the fEPSP slope and the PS amplitude (both p<0.001) indicating a normal physiological
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Reaching Learning C riterion -  results from experim ent C
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Figure 3.6. T h e  p e r c e n ta g e  o f  m ic e  in  ea ch  g ro u p  at tw o  tim e  p o in ts  that rea ch ed  lea rn in g  
cr iter ion , d e f in e d  a s  8 0 %  correct or b etter  o n  at le a s t 3 c o n se c u t iv e  d ays. Ib u p ro fen  had  
s ig n if ic a n t  e f f e c t  o n  tran sgen ic  T g 2 5 7 6  at th e  a g e  o f  8  m o n th s  (tra n sg en ic  m ic e  o n  ib u p ro fen  
w e r e  n o t d ifferen t from  n o n -tra n sg en ic  o n  an y  d ie t an d  w ere  s ig n if ic a n tly  d ifferen t from  
tra n sg en ic  o n  co n tro l d ie t). A fter  11 w e e k s  th is  e f f e c t  w a s  a b o lish e d  and  a ll tra n sg en ic  w ere  
s ig n if ic a n tly  w o r se  than all n o n -tra n sg en ic . Ib u p ro fen  had  n o  e ffe c t . T h e  p a ired  co m p a r iso n s  
b e tw e e n  g ro u p s  w e r e  p er fo rm ed  u s in g  F ish er 's  e x a c t  test, tw o -s id e d .
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I/O Curves for responses recorded in Dentate Gyrus in transgenic Tg2576 and
non-transgenic mice treated with ibuprofen/control diet
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Figure 3.7. I/O  c u r v e s  o f  th e  flEPSP s lo p e  and  p o p -sp ik e  a m p litu d e  as a fu n ctio n  o f  s t im u lu s  
in ten s ity  b e fo r e  in d u c t io n  o f  L T P  fo r  p reven tion  (A )  and  treatm ent (B )  g ro u p s ffo m  
E x p er im en t A . T h e  y -a x is  d e n o te s  th e  s lo p e  o f  th e  fE P S P  m easu red  in  m V  p er m s  o r  P S  
a m p litu d e  m ea su red  in  m V  and th e  x -a x is  in d ica tes  th e  lo w e s t  and  h ig h e s t in te n s it ie s  u se d  in  
m A . In th e  p r e v e n tio n  grou p , rep eated  m ea su res 3 -fa c to r  A N O V A  (d ie t x  g e n o ty p e , w ith  
st im u lu s  in ten s ity  a s  th e  rep ea ted -m ea su re  factor) rev ea led  n o  s ig n if ic a n t e f f e c ts  o f  e ither  
g e n o ty p e  or d ie t fo r  th e  s iz e  o f  the fE P S P  s lo p e  or the P S  am p litu d e  at an y  in te n s it ie s , 
a lth o u g h  an o v era ll e f f e c t  o f  s tim u lu s in ten sity  w a s  s ig n ifica n t fo r  b oth  g ro u p s (p <  0 0 0 1 )  (A ). 
F or th e  trea tm en t g ro u p , a n a ly s is  rev ea led  s ig n ifica n t in teraction  b e tw e e n  g e n o ty p e  an d  d ie t  
fo r  th e  s iz e  o f  th e  fE P S P  s lo p e  and  a  s ig n if ic a n t m ain  e f fe c t  o f  g e n o ty p e  and  s ig n if ic a n t  
g e n o ty p e  x  in te n s ity  in teraction  fo r  th e  P S  a m p litu d e  m ea su rem en ts (B ).
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reaction of increasing response to increasing stimulus intensity. Post-hoc comparisons 
between groups did not find any significant differences (Figure 3.7A).
In the treatment group (mice aged 12-14 months), the fEPSP slope analysis revealed a 
significant interaction between genotype and diet (F=5.5, p=0.025) indicating a 
relationship between these factors influencing physiological reaction of response 
(increasing response with increasing current). Analysis of the PS amplitude revealed a 
significant main effect of genotype (F=8.9, p=0.005) and significant interaction genotype 
x intensity (F=3.03, p=0.036) indicating that increasing stimulus intensity affects PS of 
the two genotypes differently. All the mice showed a significant increase in fEPSP slope 
and PS amplitude with increased stimulus intensities (both p< 0.001) Post-hoc 
comparisons between groups did not find any significant differences (Figure 3.7B).
Examination of the I/O curves from Tg2576 mice and littermate controls on 
ibuprofen/control diets indicated a significant enhancement of the baseline population 
spike in the dentate gyrus of transgenic mice. This effect was more evident in the older 
treatment group and did not depend on diet. Although younger mice also showed higher 
PS amplitudes than non-transgenic littermates, the effect did not reach significance (this 
might have been a consequence of the low numbers of mice in this group). Representative 
responses from transgenic and non-transgenic mice from the older group illustrating the 
difference in PS amplitude are shown on Figure 3.8.
Following the generation of input-output curves, 20-minutes of baseline responses were 
recorded (see methods for details) followed by theta-burst stimulation of the perforant 
pathway (see chapter 2.2). All data were normalized with respect to the mean fEPSP 
slope or mean PS amplitude during this 20-min period (Figure 3.9). Although care was 
taken to ensure the stability of the pre-tetanus baseline, analyses after the completion of 
the experiments indicated that responses were declining in most subjects prior to theta- 
burst stimulation. Ultimately, it was therefore impossible to conduct statistical analyses 
of the fEPSP after LTP. Most of the mice had to be excluded by the end of 20-minute 
baseline, as their fEPSP response had decreased below 90% of average (Figure 3.9)
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Representative baseline responses recorded in dentate gyrus in transgenic Tg2576 
and non-transgenic mice treated with ibuprofen/control diet
Non-transgenic mouse Transgenic mouse
30 pA 10 pA
Figure 3.8. Baseline responses recorded in dentate gyrus after stimulating middle perforant 
pathway from Tg2576 mice and littermate controls on both diets. Analysis indicated a significant 
enhancement o f the baseline population spike in the dentate gyrus o f transgenic mice. This effect 
was more evident in the older treatment group and did not depend on diet.
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LTP induction recorded in dentate gyrus of hippocampus in transgenic Tg2576 and
non-transgenic mice treated with ibuprofen/control diet
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Figure 3.9. L T P  in  th e  d en ta te  g y ru s  reco rd ed  fo r  6 0  m in u te s  after th e  in d u ctio n , o f  fE P S P  s lo p e  
(A )  and P S  a m p litu d e  (B )  in the T g 2 5 7 6  m ic e  o n  e ith er  ib u p ro fen  or  co n tro l d iet. T h e  y -a x is  
d e n o te s  th e  p ercen ta g e  o f  th e  b a se lin e  fE P S P  s lo p e  (A )  or  P S A  (B )  after in d u ctio n  o f  L T P  
( in d ica ted  b y  arrow ), and th e  x -a x is  d e n o te s  th e  tim e  o f  record in g . B urst stim u la tio n  in d u c e d  an  
im m e d ia te  in crea se  in  b o th  E P S P  s lo p e  and  P S A  fo r  a ll g ro u p s o f  m ic e . G raph  A  rep resen ts  
a v era g ed  data for a ll th e  m ic e  reg a rd le ss  o f  d ie t and  ty p e  o f  e x p er im en t (p rev en tio n  or  treatm en t 
g ro u p ) for  th e  m ea su rem en t o f  fE P S P  s lo p e . A lth o u g h  th e  L T P  se e m s  to  b e  greater in  n o n -  
tra n sg en ic  a s  co m p a red  to  tra n sg en ic , sta tis tica l a n a ly s is  w a s  n ot p erfo rm ed  d u e  to  s tea d y  d e c lin e  
o f  r eco rd in g s . G raph B  sh o w s  a v era g ed  data  fo r  P S  a m p litu d e  m ea su rem en ts  j u s t  fo r  a n im a ls  on  
co n tro l d ie t (d ata  fo r  m ic e  o n  ib u p ro fen  d ie t w e r e  s im ilar  and e x c lu d e d  to  s im p lify  th e  graph). 
D ata  are m e a n s  o f  ev ery  2  m in u tes . A lth o u g h  th e  b a se lin e  s e e m s  to  b e  m o re  stab le , but P S  
a m p litu d e  m ea su rem en ts  w ere  v e r y  u n sta b le  fo r  tran sgen ic  m ice .
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P-amyloid levels in transgenic Tg2576 mice treated longitudinally for 6 
months (ibuprofen) or 3 m onths (control) with ibuprofen
Ap40 in SDS and FA fraction
■  tg/control=>ibuprofen, n=20
■ tg/ibuprofen longitudinally, n=20
SDS40 FA40
AP42 in SDS and FA fraction
■  tg/control=>ibuprofen, n=20
■  tg/ibuprofen longitudinally, n=20
SDS42 FA42
Figure 3.10. T h e  le v e ls  o f  (3-am ylo id  4 0  and 4 2  in tra n sg en ic  T g 2 5 7 6  m ic e  treated  w ith  
eith er  ib u p ro fen  lo n g itu d in a lly  or con tro l => ib u p ro fen  c h o w s  w ere  n o t a ffe c te d  b y  d ie t  
(o n e -w a y  A N O V A  w ith  d ie t as a factor). T ra n sg en ic  m ic e  from  ex p er im en t C  w e r e  u se d  
fo r  P -a m y lo id  4 0  and 4 2  m ea su rem en ts and th u s th ere  w e r e  n o  tra n sg en ic  m ic e  o n  con tro l 
d ie t an d  th e  in f lu e n c e  o f  ib u p ro fen  o n  T g 2 5 7 6  m ic e  c o u ld  n o t h a v e  b een  a s s e s se d . T w o -  
step  ex tra c tio n  w ith  so d iu m  d o d e c y l su lfa te  (S D S )  and fo r m ic  a c id  (F A ) w a s  p erform ed . 
T h e  S D S  fra ctio n  rep resen ts  so lu b le  A p , w h ile  F A  rep resen ts  in so lu b le  A p , p o s s ib ly  from  
p la q u es  (K a w a ra b a y a sh i e t a l., 2 0 0 1 ) .
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P-amyloid brain levels
Ibuprofen treatment had no significant effect on Ap in the brains of the APP 
overexpressing mice. Figure 3.10 shows results obtained from Sandwich ELISA analysis 
of p-amyloid 40 and 42 in SDS and FA brain extracts obtained from mice from 
experimental group C. Non-transgenic mice (data not shown) had significantly lower 
levels of Ap protein, which is in agreement with previous data for Tg2576 mice 
(Kawabarayashi et al., 2001).
The design of the experiment was not ideal as all the mice at this point were on ibuprofen, 
although the duration of treatment was different (6 months or 3 months). To assess the 
influence of ibuprofen, transgenic mice on control diet would be required. Also a group of 
mice should have been killed after the first part of behavioural testing. None of the groups 
had significantly different levels of both SDS-soluble and insoluble (FA) Ap. Analysis 
comparing transgenic mice by 1-factor ANOVA (diet) revealed non-significant changes 
in SDS40, SDS42, FA40 and FA42 (all p-values>0.05).
Immunohistochemistry
Immunohistochemical procedures were performed on a sample of brains from transgenic 
and non-transgenic mice on ibuprofen and control/ibuprofen diet after the final testing 
from experimental group C. Coronal brain sections of brain halves in paraffin wax were 
double stained for Ap42, APP, and microglia and activated astrocytes. Comparable 
plaques with similar activated swollen astrocytes around them were detected in both 
ibuprofen and control/ibuprofen animals (Figure 3.11). As at this stage of experiment all 
the animals were on ibuprofen chow and there were no visible difference in the plaque 
burden and astrocytosis, detailed statistical analysis was not performed. This result agrees 
with ELISA data that revealed no significant differences in any fraction of Ap.
Ibuprofen levels in the plasma and brain tissue
Ibuprofen levels were measured in the brain tissue and the plasma (blood) from 22 
transgenic and non-transgenic mice from Experimental group C. At this stage of the 
experiment all the mice were on ibuprofen diet so no control was available. No significant 
differences could be observed in the ibuprofen level in either brain or blood of transgenic 
and non-transgenic animals (ANOVA with genotype as a factor, all p-values>0.05). The
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Double Im m unostaining for p-amyloid and astrocytes in Tg2576 
mice brain sections on Ibuprofen/Control diet.
m
B
Figure 3.11. R ep resen ta tiv e  e x a m p le s  o f  a  1 2 -m o n th -o ld  T g 2 5 7 6  m o u s e  brain  se c t io n  
th rou gh  the cereb ra l c o r te x  ( A ,B )  and  h ip p o c a m p u s  (C , D ). S e c tio n s  w ere  su b je c te d  to  
D A B  im m u n o h is to c h e m istr y  fo r  p -a m y lo id  (b ro w n  c o lo u r )  co u n tersta in ed  w ith  
V e c to r  S B  im m u n o h is to c h e m istr y  fo r  G F A P  (g r e y -b lu e  c o lo u r )  to  la b e l a c tiv a ted  
a stro cy te s  su rrou n d in g  p la q u es . T h is  d em o n stra tes  a p ro m in en t p -a m y lo id -p la q u e -  
a sso c ia te d  a strog lia l re sp o n se . S e c t io n s  A  an d  C  c o m e  from  m ic e  from  Ib u p rofen  
L o n g itu d in a lly  gro u p  w h ile  s e c t io n s  B  and D  c o m e  from  m ic e  from  
C on tro l= > Ib u p ro fen  d ie t. T h ere  w a s  n o  v is ib le  d if fe r e n c e  in  th e  n u m b er  o f  p la q u es  
and  n u m b er  o f  a s tro cy te s  arou n d  p la q u es .
average plasma concentration for all the mice was 13000±7000 nM and the average brain 
concentration was 600±400 nM. These numbers are similar to plasma and brain levels 
measured in Tg2576 mice in other studies (Ericksen et al., 2003). In humans, a single oral 
dose of 400 mg of ibuprofen induces a rise in plasma concentrations to 20-40 pg/ml 
(Cmax) within 1-2 hours; concentrations fall back to about 5pg/ml after 6 hours 
(Rainsford, 1999). Re-calculation of blood levels in mice indicated concentration of 
around 2.6 pg/ml, which is in similar range as for humans. Also the ratio of brain/plasma 
concentrations, 0.05, is similar to humans (Rainsford, 1999). Although kinetics of most 
drugs in human and mouse is completely different, this result confirms the presence of 
ibuprofen in the mouse brain. It is also important to note that plasma and brain samples 
were taken in the afternoon (when testing occurred) and dosing, through normal food 
consumption, would have taken place mostly at night, thus complicating any estimates of 
Cmax. Thus, the optimum dose for mice cannot easily be determined.
3.4. Discussion
In this study I have reported that ibuprofen delays the onset of behavioural impairment in 
Tg2576 mice on a spatial learning task in the T-maze, when it is administered early 
during the evolution of their disease phenotype. By contrast, if ibuprofen supplementation 
is started at a later point, when Ap levels start to build up, no significant effect on is 
observed. Straightforward associations were not fully established, as only performance in 
the T-maze was improved, while levels of P-amyloid in the brains were not affected and 
electrophysiological studies were not conclusive.
What effects did ibuprofen administration have on behavioural impairment in FCA in 
Tg2S76 mice?
The results clearly indicate that chronic administration of ibuprofen to young (2-4 month) 
Tg2576 mice reduced transgene induced impairment in learning and memory when tested 
at 8 months of age. These transgenic mice begin to show memory impairment at the age 
of 8 months as measured with the Forced Choice Alternation task in the T-maze 
(Chapman et al., 1999). When testing was performed later (after 10 months of age) the 
protective effect of ibuprofen was abolished. Because no other measurements indicated 
any mechanism of action, it is unclear how ibuprofen produced any effect on the onset of 
behavioural deficits.
Why did ibuprofen not reverse memory impairments in Tg2576 mice?
As twice confirmed with naive (experiment A) and pre-tested (experiment C) animals, 
ibuprofen at a approx. dose of 62.5mg/kg/day did not succeed in reversing memory 
deficits as tested in the FCA task in the T-maze. A few possible explanations for this 
situation are as follows:
• Ibuprofen is not capable of reversing learning and memory impairment in Tg2576 
mice given after the onset of pathology. The accumulation of A(3 is not reversible, so 
ibuprofen is only effective in younger mice when it can prevent the creation of harmful 
species of Ap (e.g. oligomers), but not remove them once formed. The same argument 
would hold if the initial effects are due to anti-inflammatory actions of ibuprofen that 
are insufficient to rescue behaviour in more advanced stages of pathology.
• The measured average plasma and brain concentrations were similar, although a bit on 
the lower side as compared to other studies (Ericksen et al., 2003). It is possible that 
this small difference will account for this effect and if the dose were a bit higher, 
ibuprofen would have reversed the deficit.
• The FCA task in the T-maze is too difficult for Tg2576 mice. Thus as a prevention the 
effect is just minor, and as a treatment the effect disappears. Confirming this finding 
with another test, such as the water maze or an object recognition task, would help to 
answer this question.
• Results from a study using a chronic model of neuroinflammation (Hauss- 
Wegrzyniak, 1999) showed that Flurbiprofen attenuated the neuroinflammatory 
reaction and reduced the inflammation-induced memory deficit as tested in spatial 
learning in Morris water maze. It is interesting that Flurbiprofen improved the 
performance of only young, but not old rats. This result supports the data from this 
project that NSAID therapies designed to influence the onset of AD should be initiated 
before age-associated inflammatory processes within the brain have a chance to 
develop pathology.
Why did ibuprofen have no effect on p-amyloid levels and plaque deposition in Tg2576 
mice?
As the main cause of learning impairment in Tg2576 is thought to be an over-production 
of human mutated APP and its further metabolic changes (Ashe, 2001), brain 
concentrations of SDS-soluble and insoluble (FA fraction, mainly contained in plaques) 
Ap and P-amyloid plaques were measured in experimental animals.
During these experiments I had no access to the brains after testing mice at the age of 8-9 
months, as Ap measurements at this stage were performed in Prof Steve Younkin’s and 
Prof Karen Hsiao-Ashe' laboratories. Unpublished data from their work did not show any 
significant differences in any measured fractions of Ap (Ap40 and 42 in SDS and FA 
fractions). This result suggests that either the preventive effect of ibuprofen on the 
learning and memory deficit is not due to reduction of APP-induced pathology or that the 
APP metabolic product responsible for memory impairment was not measured. This 
could support the hypothesis that some form of Ap (proto-fibrillar or oligomeric), that is 
transient and difficult to measure, might be associated with the onset of behavioural 
deficits in mice and humans. It is unlikely that deposited P-amyloid is playing a major 
role in the onset of the observed memory deficits, since plaques are infrequent at eight 
months of age (Hsiao et al., 1996).
This finding is different from that reported by Lim et al. (2000). These authors reported a 
decrease in total concentrations of both SDS-insoluble and soluble Ap in the cortex and 
the hippocampus in old Tg2576 mice after 4 month ibuprofen treatment. Two reasons can 
account for this difference. The measurements from my mice were performed using the 
entire cerebral hemisphere rather than sub regions of the brain (hippocampus and cortex) 
and the mice used by this group were older at the time of analysis (14 months of age).
The Ap ELISA and immunostaining results from Experiment C were uninformative, as 
all the mice were on ibuprofen and control mice brains were not available. The only 
confirmation comes that they still had plaques.
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Why were the electrophysiological data not conclusive?
The memory deficits in aged Tg2576 mice might reflect a decline in synaptic function 
and/or plasticity. To address this hypothesis, I recorded field potentials response in vivo 
from the dentate gyrus. The in vivo protocol was chosen because of the possibility that 
extracellular soluble Ap is important to behavioural and/or synaptic pathology, in which 
case in vitro preparations might underestimate the extent of the deficit. Unfortunately, the 
experiments were flawed in that I was not able to maintain stable baseline responses, 
making quantitative analysis of LTP impossible. The only significant result was the 
increase in PS amplitude as reported previously (Chapman et al., 1999). The population 
spike, measured at the same time as the fEPSP amplitude, is an indication of the 
excitability of the population of neurons that are synoptically activated by afferent 
stimulation. Larger population spikes indicate a greater percentage of the neuronal 
population reaching action potential threshold, and suggest enhanced excitability that may 
be related to decrease in resting membrane potential, decreased synaptic inhibition, and 
changes in the sensitivity of post-synaptic potassium channels, or any combination of 
these.
The physiological abnormalities detected in the dentate gyrus in vivo in Tg2576 mice 
baseline population spike are also consistent with the hypothesis that behavioural deficits 
might be caused by relatively subtle physiological abnormalities. This suggests that 
functional deficits, even in the absence of cell loss or plaque deposition, might contribute 
significantly to the cognitive deficits of AD.
3.5. Conclusions and future questions
This study supports the clinical and epidemiological data providing evidence that long­
term NSAID therapy has a clear effect on the incidence of AD (reviewed in chapter 1.5). 
It also, unfortunately, mirrors these data in failing to provide a suitable explanation for 
these effects.
Tg2576 mice show impairment in the FCA task in the T-maze and ibuprofen only 
postponed the development of the deficit. Re-testing them in the same test after 10 weeks 
abolished this positive effect. Ibuprofen, even as prevention, did not alter any Ap 
fractions (data from collaborative laboratories). This is an important reminder that we do
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not fully understand the relationship between observable pathology and memory 
impairment in mouse and human.
To provide the important and necessary data concerning the role of ibuprofen and other 
NSAIDs in AD development, future studies will need to focus on establishing a more in- 
depth understanding of all the mechanism involved in the action of this group of drugs. 
The simplest explanation for the action of NSAIDS is their ability to inhibit both COX-1 
and -2  and therefore, interleukin and prostaglandin formation. This reduces inflammation 
but also has other features. For example, prostaglandin H2 was shown to markedly 
accelerate the formation of dimers and higher oligomers of amyloid AfJ42 (Boutaud et al., 
2002). Another recognised target of NSAIDs action is PPARy (Landreth et al., 2001). 
NSAIDs have also been shown to target directly y-secretase (Weggen et al., 2001; Eriksen 
et al., 2003).
So although chronic use of NSAIDs is widely known to reduce the risk of AD, we still 
know little about the mechanisms involved. More research needs to be undertaken to 
clarify the mechanism underlying this action but also more questions need to be answered 
about the direct causes of dementia.
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Chapter 4 
Can an n-3 fatty acid enriched diet 
prevent AD-like impairment in 
transgenic Tg2576 mice?
4.1. Introduction 
Overview
Docosahexaenoic acid (DHA; 22:6-3), a major n-3 fatty acid of the brain, has been 
implicated in restoration and enhancement of memory-related functions. Alzheimer's 
disease impairs memory and transgenic mice, modelling this disease, show reduced 
learning ability. In this project we investigated the effect of dietary DHA on learning 
ability and pathology in Tg2576 Alzheimer's disease model mice.
PUFA and learning and memory in animal models
The fatty acid composition of brain lipids and their biological role has been extensively 
studied, as reviewed in chapter 1, and numerous animal studies have addressed the 
relationship between the diet-induced changes in PUFA content and learning performance 
in behavioural tests.
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In 1987 Yamamoto and co-workers performed one of the first studies with spontaneously 
hypertensive rats, which were fed diets enriched with either safflower oil (rich in n-6) or 
with perilla oil (rich in n-3). Diet modifications significantly affected the ratio of n-3/n-6 
of the rats’ brains and the rats on perilla oil were superior in learning ability in a 
brightness discrimination task.
Enslen (1991) and collaborators studied the effect of dietary restriction of n-3 using 
Sprague-Dawley rats. They reported lower exploratory activity in a novel environment in 
rats fed with safflower (n-6) oil comparing to those fed normal or soybean (n-3) diets. 
Furthermore, inferior performance in the brightness discrimination task of rats bred on n- 
6 enriched diet was reported to be restored by supplementing with ALA, an n-3 PUFA 
precursor (see Figure 1.6; Okaniwa et al., 1996). This suggested that learning impairment 
caused by n-3 deficiency could be a reversible process.
In 1997 Yoshida and co-workers compared two generations of rats fed safflower oil 
(enriched in n-6 fatty acids) with rats fed perilla oil (rich in n-3 fatty acids). They 
confirmed that the rats fed safflower oil showed inferior learning ability (as tested in the 
brightness discrimination test), but also showed a 30% decrease in synaptic vesicle 
density in the hippocampal CA1 region of tested rats. This effect was only observed 
following behavioural manipulations and therefore may be linked to the formation of 
memory.
Gamoh and co-workers investigated the effect of 10-week supplementation of DHA to 
young (Gamoh et al., 1999) and old (Gamoh et al., 2001) rats, which were kept on an n-3 
PUFA deficient diet for three generations. Rats were tested for working and reference 
learning performance in an eight-arm radial maze. In young rats, DHA significantly 
reduced the number of reference memory errors, without affecting the number of working 
memory errors. Further analysis revealed a negative correlation between reference 
memory errors and a DHA/AA ratio in rat brains. In old rats DHA affected both reference 
and working memory errors.
Although most of the studies support the hypothesis that long chain PUFAs have a 
positive influence on learning and memory, Wainwright et al. (1994,1999) did not find 
any relationship between brain fatty acid composition and performance in a working- 
memory task in the Morris water maze for either rats or for mice.
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In the mice studies, one of the first investigations was performed on specifically inbred 
senescence-accelerated mice (SAMP8). Umezawa (1995) and co-workers supplemented 
mice diets with either safflower oil or perilla oil. The proportions of n-3/n-6 in the brain 
reflected the n-3/n-6 balance of the diets and the group given perilla oil (n-3) showed 
much greater improvement in learning in the active avoidance task, higher ratio of correct 
responses in light and dark discrimination task and reduced exploratory behaviour in open 
field.
In 1998 Suzuki and collaborators studied the effect of 12-month feeding of a fish oil diet 
(rich in DHA) on maze-learning ability, fatty acid composition and synaptic membrane 
fluidity in mice. The results showed a positive influence of DHA on learning, on the ratio 
of DHA/AA in the brain and on the fluidity of the membranes.
More recently, the same authors (Lim & Suzuki, 2000a, 2000b, 2001, 2002a, 2002b) in 
multiple studies demonstrated that the intake of DHA ethyl ester improved the learning 
ability as measured by the maze-leaming test in old mice rather than in young mice. 
Additionally old mice, in general, had a poorer learning ability than young mice. They 
have also shown that old mice had a lower DHA level in brain phosphatidylcholine than 
young mice and suggested that these lower levels of DHA in brain phosphatidylcholine in 
old mice were associated with an inferior learning ability and perhaps influenced synaptic 
membrane fluidity.
All these studies performed in rodents suggest that DHA is an important component for 
maintaining and improving learning and memory functions in aged animals. However, the 
mechanism by which diet-induced changes can influence learning performance in training 
tests has not been established yet.
PUFA and Alzheimer models
The effect of n-3 PUFA has also been investigated in Alzheimer rodent models. 
Hashimoto (2002) and collaborators studied the effect of dietary DHA on avoidance 
learning ability in P-amyloid peptide infusion Alzheimer’s disease model rat. Pre­
administration of DHA had a beneficial effect on the decline in avoidance learning ability 
and this was associated with an increase in the cortico-hippocampal DHA/AA molar ratio 
and a decrease in neuronal apoptotic products. Additionally, DHA pre-supplementation
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increased cortico-hippocampal glutathione levels and glutathione reductase activity and 
suppressed the increase in lipid peroxide and reactive oxygen species levels in the rat 
brain.
PUFA and amyloid pathology
Although the influence of DHA and other PUFA on cognitive functions has been widely 
investigated, any direct interaction between them and Ap is still unknown. The product of 
the oxygenation of AA by cyclooxygenase (COX) activity, prostaglandin H2 (PGH2) 
markedly accelerates the formation of dimers and higher oligomers of Ap42 in studies in 
vitro (Boutand et al., 2002), providing a basis for linking dietary PUFA and amyloid 
cascade hypothesis.
Based on these different reports, my study aimed to determine whether there is a 
relationship between DHA level and learning and memory impairment in Tg2576 mouse 
Alzheimer model. The study examined the effect of dietary DHA on learning and 
memory impairment measured in Forced Choice Alternation task, levels of 40 and 42 P- 
amyloid, markers of amyloid pathology and on brain fatty acid composition.
4.2. Materials and Methods
Animals and diets
Four-month-old male Tg2576 mice and their non-transgenic littermates (25-40 g body 
weight) were studied. The mice were randomly divided into four groups: the transgenic 
DHA group (n = 22), the transgenic control group (n = 19), the non-transgenic DHA 
group (n=  16) and the non-transgenic control group (n = 15). Mice were group housed 
with littermates (with transgenic and non-transgenic housed together), and all testing was 
conducted during the light phase. Transgenic mice were compared to littermate controls 
to ensure that age and background strains were equivalent.
The DHA group was put on a special chow prepared by Special Diet Services (SDS, UK) 
by incorporating 5% of Martek Oil (derived from algae and obtained from Martek, US) 
into standard rodent chow. Martek oil is expected to contain up to 40% of pure DHA, as 
provided in the company leaflet. The DHA-enriched special diet produced by SDS 
contained an average of 4.5 mg of DHA in a gram of a chow, as measured by gas
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chromatography in collaboration with Prof J.Harwood. Assuming that a healthy male 
mouse eats around 5g of chow a day, the DHA dose for mice was estimated to be 22.5mg 
per day. That accounts for a dose of around 750mg/kg per day (average mouse weighs 
30g). Even if the estimation is too high, the range is similar to other projects, where rats 
were fed orally with an ethyl-ester derivative of DHA at a dose of 300mg/kg/day (Gamoh 
et al., 1999, 2001).
For the control chow, the added volume of Martek oil was substituted for the same 
volume of a mixture of palm oil, lard, olive oil and coconut oil in the proportions 
(3:3:3:1). The oils were chosen in order to substitute n-3 PUFA with more saturated or 
monounsaturated fats but not to increase the total n-6 PUFA content. DHA content and 
lipid analysis in a special chow was assessed on arrival and after two months upon arrival. 
There was no significant reduction in DHA level during the feeding and storage time. The 
chows were stored at 4 °C and fresh supplies were given to the mice every day. The fatty 
acid compositions of the diets at two different time points are given in Figure 4.1.
Experimental Procedures
The full experimental procedure consisted of a series of phases, which were conducted on 
all animals. These included:
• Feeding with special chows (DHA and control) and drinking water ad libitum from 
the age of 4 till 8-8.5 months. Mice were weighed every 2 weeks.
• Forced Choice Alternation task as described in Chapter 2.1.1. The experimental 
design is pictured in Figure 4.2. During testing, mice were put on water deprivation 
regime (20 hours of no water, 2 hours experiment with 25% sucrose reward and 2 hours 
of free water access after experiment). Mice were kept on the special chow diets till the 
end of testing (9-9.5 months).
• Brain dissections. Mice were killed after the behavioural experiments. The brains 
were dissected and the hemispheres separated along the midline. Half of the brain was 
frozen on dry ice for Ap ELISA analysis. The other hemisphere was either immersed in 
4% paraformaldehyde for immunostaining (20 brains) or frozen for fatty acid 
measurements.
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Fatty  Acid Composition of Diets
%weight (*) of Fatty Acids in Martek and Control oil diet
□ Control Oil
Martek Oil
FATTY ACIDS DHA diet, weight% 
mean ±sem
16:0 0.38 ±0.04
16:1 n-7 0.03 ±0.01
18:0 *(S) 0.03 ±0.01
18:2 n-6 0.53 ±0.06
18:3n-3 (ALA) 0.05 ±0.01
22:6n-3 (DHA) *(S) 0.43 ±0.05
CONTROL 
diet,weight% 
mean ±sem
0.44 ±0.03 
0.03 ±0.01
0.09 ±0.01
0.49 ±0.04
0.04 ±0.01
0.01 ± 0.01
Figure 4.1 F atty  a c id  c o m p o s it io n  o f  d ie t s  (M artek  o i l  and  co n tro l o i l )  at th e  t im e  o f  arrival 
to  th e  lab ora tory . M ajor  fa tty  a c id s  a b o v e  2%  o f  to ta l c o n ten t are sh o w n . M ea n ±  s e m  are  
ca lc u la te d  fro m  tr ip lica tes . D ie t s  w e r e  a n a ly s e d  at th e  t im e  o f  arrival an d  a fter 2  m o n th s  o f  
storage . 2 -fa c to r  A N O V A  a n a ly s is  w ith  d ie t  an d  t im e  a s fa c to r s  r e v e a le d  s ig n if ic a n t  
d if fe r e n c e  in  2 2 :6 n -3  (D H A )  and  18 :0  (S te a r ic  A c id )  le v e ls  b e tw e e n  M artek  an d  C o n tro l d ie t  
b ut n o  e f f e c t  o f  sto ra g e  t im e  and  n o  in tera ctio n  b e tw e e n  s to r a g e  t im e  and  a  ty p e  o f  d ie t. T h e  
co n tro l d ie t  a ls o  c o n ta in s  sm a ll a m o u n ts  o f  m e d iu m -c h a in  fa tty  a c id s  (1 0 - 1 4 C )  but, 
in d iv id u a lly , th ere  w e r e  le s s  th an  2 %  a n d  h a v e  n o t b e e n  in c lu d e d  in  th e  tab le .
( a)  %  w e ig h t  w a s  c a lc u la te d  as a  p e r c e n t o f  certa in  fa tty  a c id s  co n te n t (m g )  in  1 g  o f  d ry  d iet. 
* (S )  -  s ig n if ic a n t  d if fe r e n c e  in  th e  fa tty  a c id  co n ten t.
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• ELISA measurement using commercially available kit (Biosource) in SDS and FA 
brain extracts to assess the total amount of Ap 40 and 42 in brain tissue (details in 
Chapter 2.3);
• Immunostaining using Ap, APP, activated astrocytes and microglia recognising 
antibodies (as described in Chapter 2.4);
• Lipid extractions. Lipids were extracted from chopped and mixed whole half of the 
brain (hippocampus was not extracted separately) and fatty acid composition was 
determined by gas chromatography. Fatty acid profiles in the brain and in diets were 
measured in collaboration with the laboratory of Prof. J.Harwood.
Statistical analysis
All data are presented as the means ± SEM. The statistical significance of differences in 
the learning and perseveration measured over the training time between the groups was 
determined by repeated-measures 3-factor ANOVA, with genotype and diet as between- 
subject factors and training day as a within-subject factor. The statistical significance of 
differences in the value of Perseveration Count, Right/Left Preference, fatty acids and the 
Ap levels between the groups was determined by the 2-factor ANOVA, with genotype 
and diets as between-subject factors. Tukey's pair wise comparisons post hoc tests were 
used to determine differences between groups. The % mice reaching learning criterion 
was compared using pair wise Fisher’s test. Relationship between various factors was 
counted using Regression analysis and Pearson Correlation test. Differences were 
considered to be significant at P < 0.05.
4. 3. Results
Body weight, survival assessment and chow quality
There were no significant differences in body weight gain over the treatment period 
between the transgenic and non-transgenic groups whether on control or DHA-enriched 
diets. Final body weight for transgenics on DHA diet was 29.9 ± 0.5g, transgenics on 
control diet was 30.7 ± 0.7g, non-transgenics on DHA was 32.1 ± 0.8g and non- 
transgenics on control diet was 32.4 ± 0.9g.
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Experimental Design
DHA treatment
0 2 4 6 8 10 Age (months)
I
Onset o f memory loss in FCA 
and time o f testing
Figure 4.2 Experimental design. The box above the timeline represents the time when 
mice were kept on DHA/control chow. At the age o f 4-4.5 months they were switched 
from a standard chow and kept on special diets until the end o f experiments. The arrow 
underneath the timeline indicates the initiation o f memory loss and the start o f 
behavioral testing in the T-maze (FCA -  Forced Choice Alternation task). Numbers o f 
mice tested are: transgenic on DHA diet (tg/DHA) -16, transgenic on control chow 
(tg/control) -12, non-transgenic on DHA diet (nontg/DHA) -14 and non-transgenic on 
control chow (nontg/control) -13.
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Analysis was performed using repeated measures 3-factor ANOVA with week as a 
repeated measure and diet and genotype as between-subject factors and revealed no 
significant differences. The effects of week (F=0.98, p=0.961), diet (F=0.82, p=0.486) or 
genotype (F=0.23, p=0.87) were not significant. Also none of the interactions were 
significant.
During the time of chronic administration of either DHA or control diets (from 4 until 8- 
8.5 months of age) four mice died in the transgenic-DHA group, three in the transgenic- 
control group and one from non-transgenic-control group. These numbers are similar for 
groups on both types of diet, but show a trend (not significant, Fisher exact test, p=0.123) 
to a higher mortality rate for transgenic Tg2576 mice compared to non-transgenic 
littermates. This finding is consistent with other groups breeding Tg2576 mice (Karen 
Hsiao-Ashe's or Steve Younkin’s laboratories).
During the experiment, quality analysis on the specially prepared chows was performed. 
There was no significant difference between the constitution of the chow at the time of 
arrival, nor after two months of storage. Martek Oil had consistently significantly more of 
the n-3 polyunsaturated fatty acid (22:6) DHA and less of the saturated Oleic acid (18:0) 
compared to control diet. Detailed results of constitution of both Martek Oil and Control 
Oil enriched animal chows are presented in Figure 4.1.
Forced Choice Alternation task in the T-maze
During testing, 2 transgenic mice on DHA diet, 3 transgenic mice on control, 2 non- 
transgenic mice on DHA and 1 non-transgenic mouse on control were excluded because 
they failed to move. The criteria for exclusion are described in Chapter 2.1.1.
Figure 4.3 shows the effect of chronic administration of dietary DHA on episodic-like 
memory related learning ability in Tg2576 mice and their non-transgenic littermates. 
Forced Choice Alternation (FCA) task assesses spatial episodic like memory using the T- 
maze. Training lasts for 10 days and each mouse receives 6 trials a day. The percent 
correct value for each mouse was calculated daily. Repeated measures 3-factor ANOVA 
revealed highly significant effect of genotype, indicating that all the transgenic mice were 
impaired in FCA task. The time of training had a significant effect, confirming overall 
improvement during training of all the groups. Statistical analysis revealed no main effect 
of diet, indicating no influence of dietary DHA on performance in the T-maze. However
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when the interaction between genotype and diet was considered, a significant result was 
observed indicating a protecting effect of DHA-enriched diet but only for transgenic 
mice. No other interactions were significant. Post-hoc Tukey's pair-wise comparisons 
confirmed that transgenic mice on DHA-enriched diet were significantly better than 
transgenic mice on the control diet, indicating a protective effect of DHA against memory 
impairment measured in the FCA task. It is noticeable on the Figure 4.3 that the rate of 
improvement of the transgenics on DHA was comparable with all the non-transgenics, but 
that they started from a lower level. If the experiment had been extended, it is possible 
they would have reached similar level.
The percent of mice reaching Learning Criterion (defined as 80% correct or better on at 
least 3 consecutive days during training) was not affected by DHA administration as 
shown on Figure 4.4. Transgenic mice overall in a significantly smaller percent reached 
Learning Criterion comparing to non-transgenic littermates. It indicates significant effect 
of only genotype and no effect of a diet (analysis performed using exact Fisher test). 
Thus, although transgenics fed DHA were clearly able to improve during training 
(Fig.4.3), most of them did not attain the 80% threshold.
Figure 4.5 shows the effect of chronic administration of DHA on response strategies 
(perseveration) in Tg2576 mice and their non-transgenic littermates. The analysis was 
performed to distinguish various response strategies while being tested in the T-maze. 
Graph A shows the perseveration count for four groups of animals as the mean number of 
consecutive free choices made in the same direction averaged for each group and over 2 
days of training. Repeated-measures two-way ANOVA analysis was performed based on 
these scores and revealed a significant main effect of genotype and no effect of diet, time 
or any interaction. Similarly analysis performed on data from graph B revealed only a 
significant effect of genotype, indicating no effect of DHA on response strategies.
To evaluate if the conditions throughout the testing time were biased, the preference 
towards any of sides (Right or Left) was calculated with no significant effect of either 
right or left side (Figure 4.6).
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Learning in Tg2576 and Non-Transgenic littermates on DHA/Control
chow
• • nontg/con 
■*— tg/con 
-■— tg/dha 
- nontg/dha
day 1/2 day3/4 day 5/6 day 7/8 day9/10
Figure 4.3 C h ron ic  ad m in istra tion  o f  d ietary  D H A  in  T g 2 5 7 6  m ic e  p reserv es spatial 
e p is o d ic  - l ik e  m em o ry  a s a s s e s se d  u sin g  th e  T -m a ze . D ata  are m ean  ±  s .e .m . o f  the  
p ercen ta g e  o f  correct r e sp o n ses  a v era g ed  o v er  tw o  d a y s for  each  m o u se . R ep ea ted  
M ea su res A N O V A , rev ea led  h ig h ly  s ig n ifica n t e ffe c t  o f  a  g e n o ty p e  (F = 6 8 .6 , p <  0 0 1 ) ,  
and a s ig n ifica n t in teraction  o f  a d ie t w ith  g e n o ty p e  (F = 5 .3 , p =  0 .0 2 5 ) ,  but n o  
sig n ifica n t e ffe c t  o f  d ie t (F = 2 .1 , p = 0 .1 5 4 ) . T h e  e ffe c t  o f  tim e (d a y s  o f  train ing) w a s  
h ig h ly  s ig n ifica n t for  all su b jec ts  (F =  8 .9 1 , p < 0 0 0 1 ) .  In teractions o f  tim e  and d ie t  
(F = 2 .3 0 7 , p = 0 .0 7 2 ) , tim e b y  g e n o ty p e  b y  d ie t (F = 1 .8 2 0 , p = 0 .1 4 0 )  and tim e  b y  
g en o ty p e  (F = 2 .0 0 7 , p = 0 .1 0 8 )  w ere  n ot sig n ifica n t. P o st h o c  a n a ly s is  u s in g  T u k e y 's  
p a ir -w ise  co m p a r iso n s  rev ea led  that tra n sg en ic  m ic e  on  b oth  D H A  and con tro l d ie ts  
perform  s ig n ifica n tly  le s s  w e ll than e ith er  n o n -tra n sg en ic  grou p  (a ll p < 0 .0 0 1 ) , but that 
tran sgen ic  m ic e  o n  D H A  w ere  a lso  s ig n ific a n tly  better co m p a red  to  tran sgen ic  m ic e  on  
con tro l d ie t (p = 0 .0 4 9 ) . N u m b ers  o f  m ic e  are tg /D H A = 1 6 , tg /co n tro l= 1 2 , 
n o n tg /D H A = 1 4 , n o n tg /co n tro l= 1 3 .
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Reaching Learning Criterion
100 n
illO
1
Reached Learning 
Criterion
I
nontg/con tg/con nontg/dha tg/dha
Paired Comparisons Between Groups P value Stat.significance.
TG/CON -  TG/DHA 0.4010 NS
TG/CON -  NONTG/DHA 0.0011 S
TG/CON -  NONTG/CON <0.0001 s
TG/DHA -  NONTG/DHA 0.0106 s
TG/DHA -  NONTG/CON 0.0004 s
NONTG/CON -  NONTG/DHA 0.4815 NS
Figure 4.4. T h e p ercen ta g e  o f  m ic e  in  each  g rou p  that rea ch ed  learn in g  cr iter ion , 
d e fin e d  as 80 %  correct or b etter o n  at lea st 3 c o n se c u t iv e  tra in in g  d a y s . D H A  h a s n o  
s ig n ific a n t e f fe c t  on  e ith er  T ra n sg e n ic  T g 2 5 7 6  or  N o n -tra n sg en ic  m ic e . T h ere  is  a  
s ig n if ic a n t e f fe c t  o f  g e n o ty p e , m e a n in g  that s ig n if ic a n tly  fe w e r  m ic e  rea ch ed  lea rn in g  
criter ion  a m o n g  tra n sg en ic  than  n o n -tra n sg en ic  su b jects . T h e  p a ired  co m p a r iso n s  
b e tw e e n  g ro u p s w ere  p er fo rm ed  u s in g  F isher's e x a c t  t e s t  tw o -s id e d . N u m b ers  o f  
m ic e  are tg /D H A = 1 6 , tg /con troT = 12 , n o n tg /D H A = 1 4 , n o n tg /c o n tr o l= 1 3 .
I l l
Response Strategies - Perseveration Count
A
B
Figure 4.5 T ran sgen ic  T g 2 5 7 6  m ic e  tend  to  ad op t a p erseveration  stra tegy  s ig n if ic a n tly  
m o re  o ften  (a s  q u a n tified  b y  the P ersev era n ce  C ou n t [P C ]) than N o n -tra n sg en ic  
litterm ates, w h eth er  th ey  h a v e  b een  g iv e n  D H A -r ich  d ie t or con tro l d iet. P C  is  m easu red  
a s a m a x im u m  nu m b er o f  c o n se c u tiv e  free  c h o ic e s  m a d e  in  the sa m e  d irectio n  fo r  each  
an im al per day. D ata  are m ean  ±  s .e .m . o f  the P C  av era g ed  for tw o  d a y s  durin g  tra in in g  
(A )  or averaged  o v er  th e last f iv e  d a y s  (B )  for each  m o u se . A  rep eated  m ea su res  
A N O V A  p erform ed  on  data sh o w n  in graph A  rev ea led  a  s ig n ifica n t e f f e c t  o f  g e n o ty p e  
(F = 1 5 .0 6 2 6 , p = 0 .0 0 0 3 )  and n o  e ffe c t  o f  d ie t (F = 0 .0 9 1 9 , p = 0 .7 6 3 1 ) , w ith  n o  in teraction  o f  
th e se  factors (F = 0 .5 5 5 1 , p = 0 .4 5 9 7 ) . T im e  as a w ith in -su b jec ts  factor  w a s  n o t s ig n if ic a n t  
o n  its  o w n  (F = 4 .4 9 3 , p = 0 .0 1 6 2 ) , or in  an y  in teraction  w ith  d ie t and  g e n o ty p e . A n  
A N O V A  carried  ou t o n  th e  data  rep resen ted  in (B )  rev ea led  a s ig n ifica n t e ffe c t  o f  
g e n o ty p e  ( F = 1 6 .6 6 , p  <  .0 0 0 1 ) , and n o  s ig n ifica n t e ffe c t  o f  d ie t (  F = 0 .0 4 , p = 0 .8 5 2 )  and  
n o  in teraction  o f  th e se  factors ( F = 0 .3 , p = 0 .5 8 9 ) . N u m b ers o f  m ic e  are tg /D H A = 1 6 ,  
tg /co n tro l= 1 2 , n o n tg /D H A = 1 4 , n o n tg /co n tro l= 1 3 .
Perseverance Count During Training
*- • - nontg con
■ nonlgUha
2
1.5 ----------------------------------- i------------------------------------ ------------------------
djyS/6 d*y7/8 <Uy9/10
Last 5 Day Perseverance Count Mean
Nontg/con nontg/dha tg/con tg/dha
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Right/Left Preference
y / s >
nontg/con nontg/dha tg/con lg/dha
Figure 4.6., T h e  ratio o f  R ig h t/L e ft arm  en tries w a s co u n ted  o v er  a ll te s tin g  d a y s  
and a v era g ed  for g rou p s, data are m ea n s ±  s .e .m . A lth o u g h  there w a s  a  s lig h t  
ten d en cy  for tran sgen ic  m ic e  o n  D H A  d ie t to  turn tow ard s the right arm , there  
w ere  n ot s ta tis tica lly  s ig n ifica n t d if fe r e n c e s  a m o n g  any o f  the g rou p s (m ea su red  
b y  A N O V A  w ith  g e n o ty p e  and d ie t a s  factors). N u m b ers o f  m ic e  are  
tg /D H A = 1 6 , tg /c o n tr o l= 1 2 , n o n tg /D H A = 1 4 , n o n tg /co n tro l= 1 3 .
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fi-amyloid brain levels
Figure 4.7 shows results obtained from Sandwich ELISA analysis of Tg2576 mice of p- 
amyloid 40 and 42 in SDS and FA extracts. Non-transgenic mice (data in the table only) 
had significantly lower levels of Ap-amyloid as compared to Tg2576 (previously reported 
by Kawabarayashi, 2001). DHA did not affect any fraction of P-amyloid in either 
transgenic or non-transgenic mice. The non-significant results from analysis of p-amyloid 
42 in FA fraction are likely to be due both to the expected low levels (transgenic mice 
only 9.5 month old) and problems with sensitivity of Biosource kit on brain extracts 
(described in Chapter 2.3).
Fatty acid profiles of brain tissues
Fatty acid composition of brain tissue of the experimental animals is shown in Figure 4.8. 
No significant differences could be observed in the fatty acid composition of transgenic 
and non-transgenic animals. Chronic administration of Martek Oil resulted in a significant 
increase in the DHA level and a reduction in the AA level in the brain, with a 
concomitant increase in the DHA/AA molar ratio. The levels of fatty acids were affected 
similarly in transgenic and non-transgenic mice. Detailed statistical analysis is presented 
in the table in the Figure 4.8.
Immunohistochenustry
Coronal sections of half brains in paraffin wax were cut at 6 pm and double stained for 
AP42, APP, microglia and activated astrocytes. A small number of plaques were detected 
in both DHA and control-treated transgenic animals (Figure 4.9). The numbers of plaques 
were too low for meaningful statistical analysis. This outcome was expected as Tg2576 
mice at the age of 9.5 months show very few diffuse plaques (Hsiao et al., 1996). Also the 
planned analysis of activated astrocytes and microglia was not useful for the same reason.
Relationship between learning ability, fi-amyloid and fatty acids levels
The possible relationships between learning ability (expressed as an average of percent 
correct during the last 4 days of training), p-amyloid and fatty acid levels in the brain was 
examined.
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P-amyloid levels in transgenic Tg2576 and non-transgenic mice treated with
DHA/control diet
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■ TO/CON
■ TG/DHA
0 s
Number of mice
FA 40 IN TC257600 DHA/CONTROL DIET
160
140 ■
r ° •  TG/CONJB ioo ■ TG/DHA
I "I .  60
■ ■
40 ■
20
A
•  i  '  ■ .  |  ■ l  
■ 1 |  1  1 1  ■ l  ................................v
(1 $ 10 15 20
Number o f mice
SOS 42 IN TG2576 mi DHA/CONTROI. D IET FA 42 IN TG2576 on DHA/CONTROL DIET
351 151
30 ■ 20 ■
25
JS 20 
m
m a ■TG/CON 
■ TG/DHA
J  15 
00
■ B ■ TG/CON
■ TG/DHA
■ .
|  15 
10
5
■ ■ ■ 
"  ■ ■ ■ _  ■ 1
1  10
5
A
1 1 ■ ■
: ■  ■ ■
•  * ■
■
A wU
5 10 IS 20 
Number o f mice
» 5 10 15 20 
Number o f mice
SDS 40 SDS 42 FA 40 FA 42 Total Ab
GROUP
pmoles/g
brain
± SF.M
pmoles/g
brain
±  SF.M
pmoles/ 
g brain
± SF.M
pmoles/g
brain
+ SF.M
pmoles/g
brain
TG/DHA,
n-16
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11.9
11.9 + 
1.7
23.65 ± 
9.0 901 ± 1.1
104.45
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n=*15
44.84 ± 
6.5
1133 ± 
1.0
16.05 ± 
5.0 8.05 4 13
80.27
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H A .n-5
1.74 + 
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1.9
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0.5 4.78 4  1.4 14.42
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0 3
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Figure 4.7 P -a m y lo id  le v e ls  in tran sgen ic  T g 2 5 7 6  and n on -tran sgen ic  m ic e  are n o t a ffec ted  
b y  d iet. N o n  tran sgen ic  m ice  had s ig n if ic a n tly  lo w e r  le v e ls  o f  both  S D S -so lu b le  and in so lu b le  
(F A ) P -a m y lo id  m easu red  b y  tw o -w a y  A N O V A  (g e n o ty p e , d ie t) after ex c lu d in g  3 ou tliers  
(m o re  than 2 standard d ev ia tio n s). T h e  v a lu e s  are re sp e c t iv e ly  S D S 4 0  (F = 4 1 .2 2 , p < 0 .0 0 1 ) ,  
S D S 4 2  (F = 1 3 .3 2 , p = 0 .0 0 1 ) ,  F A 4 0  (F = 1 0 .5 6 , p = 0 .0 0 3 ) . F or F A 4 2  (F = 3 .3 0 , p = 0 .0 7 8 )  the  
d iffe r e n c e  w a s  n o t sta tis tica lly  s ig n ifica n t, p rob ab ly  d u e to  p ro b lem s w ith  E L IS A  accu racy  
( s e e  m eth o d s sec tio n  in  C hapter 2 .3 ) . T h e  test r ev ea led  n o  e ffe c t  o f  d iet in any o f  the fraction s.
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Fatty Acid (%) Composition of Tg2576 and Non-transgenic littermate brains
on DHA/ControI diet
FORMULA NONTG
DHA
NONTG
CON
TG/DHA TG/CON SIGNIFICAN
CE
n = 14 n = 9 n=  12 n = 8
16:0 16.91 17.06 16.76 16.81 NS
18:0 17.16 17.88 16.66 18.44 S, p=0.009
18:1, b 9 17.31 15.97 15.41 15.99 NS
18:1, a 7 3.37 3.47 3.22 3.63 S,p=0.019
18:2, b 6(LA) 0.67 0.51 0.78 0.40 S, p=0.001
00 u> » 0.12 0.13 0.43 0.13 NS
20:0 0.51 0.30 0.40 0.29 NS
20:1,b 9 2.34 2.18 1.92 1.74 NS
20:3,8 6 0.84* 0.53b 0.97* 0.48b S, p<0.001
20:4,8 6(AA) 4.23* 7.54b 4.13* 7.380 S, pO.001
22:4,8 6 1.22* 2.01b 1.08* 2.360 S, pO.OOl
22:6,8 3(DHA) 15.49* 11.94b 15.13* 12.850 S, pO.OOl
DHA/AA 
MOLAR RATIO 4.0* 1.70 4.0* 1.90 S, pcO.OOl
Figure 4.8. Fatty acid composition (major components) of brain lipids in different 
dietary groups. Amount of each fatty acid was calculated as a % in total fatty acids, 
using gas chromatography. 2-factorial (diet, genotype) ANOVA revealed no main effect 
of genotype but a significant effect of diet for some of the fatty acids. No interaction 
between genotype and diet was detected. Detailed statistical results are presented in the 
table. Groups that are different (p<0.05) are marked with a or b.
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Double Immunostaining for P-amyloid and astrocytes in Tg2576 
mice brain sections on DHA/Control diet.
'  - A :
* J 7 *
' 7 v .
►
V T v
V x > .
y v
\
F ig u r e  4 .9  A  rep resen ta tive  e x a m p le  o f  a  9 -m o n th -o ld  T g 2 5 7 6  m o u se  brain sec tio n  through  
th e  h ip p o ca m p u s. T h is  s e c t io n  w a s  tak en  from  th e m o u s e  on  D H A  diet. S e c tio n s  w ere  
su b jected  to  im m u n o h is to ch em istry  fo r  3 -a m y lo id  (b row n  co lo u r ) cou n tersta in ed  w ith  
im m u n o h is to ch em istry  fo r  G lia l fib rillary  a c id ic  protein  (G F A P ), (g rey -b lu e  co lo u r ) to  lab e l 
activ a ted  astrocy tes . T h e  m eth o d  rev ea led  a  p rom in en t p -a m y lo id -p la q u e -a s so c ia te d  
astrog lia l r e sp o n se  (in d ica ted  b y  an arrow ) in  m ic e  o n  b oth  d ie ts , and n o  d if fe r e n c e s  w ere  
d etected . T h e  m ea n  n u m b er o f  p la q u es  and a nu m b er o f  a stro cy tes around p la q u es  w ere  
cou n ted , bu t data  w ere  n ot su ita b le  fo r  sta tistica l a n a ly s is  d u e to  th e  sm all nu m b er o f  
p la q u es  (at th e  a g e  o f  9  m on th s, T g 2 5 7 6  m ic e  h a v e  o n ly  s in g le  p laq u es , in  a p relim in ary  
sta g e). In fact, it  h as b een  rep orted  that T g 2 5 7 6  m ic e  start sh o w in g  prom in en t p laq u e  
p a th o lo g y  at the a g e  o f  10 to  12 m o n th s  (H s ia o  e t al. 1 9 9 6 ).
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Regression analysis revealed a significant positive relationship between the molar ratio of 
DHA/AA in the brain and learning ability (r = 0.48; P < 0.05) and a significant negative 
relationship between the value of AA (as % of total fatty acids) in the brain and learning 
ability (r = 0.45; P < 0.05). Graphs and statistical analysis are presented in the Figure 
4.10. The % level of DHA in the brain did not correlate with the learning ability. Also, 
none of the fractions of p-amyloid showed any correlation with the learning ability.
A significant negative correlation was observed between the value of DHA (as % of total 
fatty acids) in the brain and brain FA fraction of p-amyloid 40 levels in Tg2576 mice (r = 
0.43, P < 0.05). Graphs and statistical analysis is presented in the Figure 4.11.
4.4. Discussion
The purpose of the above experiments was to explore whether administration of dietary 
DHA to transgenic mice, over-expressing human mutated APP, would alter their learning 
ability, proportions of fatty acids in their brains and levels of P-amyloid and APP 
pathology in their brains. Straightforward associations were not fully established, as only 
performance in the T-maze was improved, while levels of p-amyloid and P-amyloid 
induced pathology in the brains were not affected.
How did DHA supplementation affect episodic-like learning and APP-induced 
pathology in Tg2576 mice?
The results clearly indicate that chronic administration of dietary DHA to Tg2576 mice 
influenced transgene induced impairment in Forced Choice Alternation task in the T- 
maze. As only interaction of genotype x diet was significant, it cannot be concluded that 
learning in FCA task is enhanced, but only that some aspect of performance is improved.
These transgenic mice have been shown to start showing memory impairment at the age 
of 8 months as measured with Forced Choice Alternation task in the T-maze (Chapman et 
al., 1999). As the main cause of learning impairment in Tg2576 is thought to be an over­
production of human mutated APP and its further metabolic changes (Ashe, 2001), 
experimental animals were checked for changes in SDS-soluble and insoluble (FA 
fraction, mainly contained in plaques) P-amyloid and P-amyloid plaques.
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Relationship between behavioural results and fatty acids levels
CORRELATION OF MOLAR RATIO DHA/AA AND AVERAGED 
SCORE OF THE LAST 4DAYS IN THE TMAZE
y = 0.0266x+ 1.2611 
R2= 0.2
100
averaged score for the last 4 days in T maze
CORRELATION OF % VALUE OF AA IN TOTAL FATTY ACIDS 
AND AVERAGED SCORE OF THE LAST 4 DAYS IN THE T 
MAZE
y =- Q0456x + 8.6105 
R2 = 0.2058
10040
averaged score for the last 4 days in the T maze
Figure 4.10. Regression analysis between the behavioural results and fatty acids levels 
revealed a significant positive correlation between averaged learning score for the last 4 
days and the ratio o f DHA/AA in mice brains (p=0.048). Averaged learning score for the 
last 4 days showed also a negative correlation with AA amount (as % o f total fatty acids) 
(p=0.045). The correlation graphs were prepared using linear trend line function in Excel 
(Microsoft Office). Numbers o f mice are tg/DHA=7, tg/control=7, nontg/DHA=5, 
nontg/control=4.
119
Relationship between P-amyloid measurements and fatty acids 
level in the brains of Tg2576 mice and non-transgenic littermates.
Correlation of ^ -amyloid FA40 and % DHA in total fatty acids
160 
140 -
y — 67144x + 113.27 
R2= 0.183
-  100 -
20 -
DHA as % of total Fatty Acids
Figure 4.11. Regression analysis revealed a negative correlation between the 
level of ^-amyloid 40 in FA extract and the % DHA in total fatty acids in 
individual mice brains (p=0.047). The correlation graphs were prepared using 
linear trend line function in Excel (Microsoft Office). Numbers of mice are 
tg/DHA=8, tg/control=6, nontg/DHA=5, nontg/control=3.
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No changes were detected, suggesting either the preventive effect of DHA on learning 
and memory deficit is not due to reduction of APP-induced pathology or that the APP 
metabolic product responsible for memory impairment was not measured.
To support the latter hypothesis, most APP mice models that show increased levels of 13- 
amyloid and impairment in learning and memory, do not show a correlation between 
learning ability and total P-amyloid levels. More detailed analysis of metabolic APP 
products (e.g. measuring p-amyloid oligomers like dimers or tetramers) in Tg2576 brains 
is required to answer this question.
The positive influence of DHA and other n-3 PUFAs on learning and memory in various 
rodent models, which has been referred to previously (Yamamoto et al., 1987; Yoshida et 
al., 1997; Lim & Suzuki 2000, 2001,2002a, 2002b), has not been related to a reduction in 
APP pathology. Therefore, the preventive effect of DHA on learning and memory 
impairment in Tg2576 mice might be due to some other functions of DHA, like anti­
oxidant properties, increasing membrane fluidity or preventing neuronal damage.
Tg2576 mice on DHA-enriched diets were significantly different from transgenic 
littermates on control diet, but also significantly different from non-transgenic mice. That 
means that DHA improved but did not completely reverse memory deficit. Its effect was 
only minor. This could explain why the effect of DHA was not significant in the numbers 
of mice that reached the learning criterion in 10 days of training. Similarly DHA had no 
effect on Tg2576 perseveration.
There were no measurable differences between non-transgenic mice on either DHA or 
control diets. If non-transgenic mice were affected by DHA-enriched diet in the same way 
as Tg2576, this could suggest that learning improvement is not due to influencing APP 
pathology. However, non-transgenic mice reached 85% or better of correct responses. 
Ceiling effect in non-transgenic mice could mask general enhancement of performance by 
DHA in all mice. Therefore, to see if DHA feeding could result in an improvement, the 
task should be made more difficult. One of the ways to do this would be to introduce 
delays between sample and choice runs of each trial. More difficult tasks might have also 
helped determine whether DHA influenced APP-pathology or improved memory in a 
different mechanism.
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What effect did DHA administration have on fatty acid composition in mice brains?
In both transgenic and non-transgenic mice with pre-administered DHA, the increase in 
DHA content in the brain was accompanied by a significant increase in the DHA/AA 
molar ratio, which positively correlated with learning in FCA task. This finding agrees 
with the previous studies performed with infusion P-amyloid rat model where the cortico- 
hippocampal DHA/AA molar ratio correlated positively with acquisition of avoidance 
learning ability (Hashimoto et al., 2002) and was inversely related to memory errors in Y- 
maze tasks (Gamoh et al., 1999).
The DHA/AA ratio is recognised as an indicator of the antioxidative action of DHA 
(Gamoh et al., 1999). It would therefore appear that a decrease in the DHA/AA ratio 
might contribute to increased level of oxidation (lipid peroxide). Also lipid peroxide level 
is a recognised factor for neuronal damage. Therefore an increased DHA/AA ratio in the 
brain may play a protective role against oxidative neuronal damage and learning ability 
deficit in AD mouse model. The free radical hypothesis of AD suggests that increased 
production of lipid peroxides causes deterioration of a wide variety of cellular enzymes, 
ultimately exacerbating the neurodegenerative processes (Yatin et al., 1999). Chronic 
treatment with antioxidants (e.g. alpha-tocopherol) has been found to improve cognitive 
functions in aging (Yamada et al., 1999); a chronological process frequently associated 
with increased oxidative damage and neurodegenerative diseases including AD.
Another plausible reason relates to the anti-inflammatory nature of n-3 as opposed to n-6 
PUFAs. This has been documented in a wide variety of tissues and is thought to be 
relevant to arthritis (Curtis et al., 2001) and cardiovascular disease (Calder et al., 2003). 
Decreased ratios of n-6/n-3 acids would be expected to lower inflammatory response. 
Aggravated inflammatory response is a part of Alzheimer pathology, and therefore raised 
DHA should help to alleviate this activation and might explain the preventive effect seen 
in transgenic mice on DHA-enriched diet.
4.5. Conclusions and future questions
The results of this study suggest that dietary DHA ameliorates the deterioration of 
learning ability as tested in FCA task in the T-maze in an AD mouse model. The fact that 
DHA supplementation improves memory in Tg2576 transgenic mice might help to
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understand how learning is impaired in AD patients and may allow a better insight into 
AD pathology.
This study supports the clinical and epidemiological data suggesting that a high-PUFA 
diet reduces the risk of developing AD. The application of this knowledge to the 
treatment and prevention of AD is a major focus of current research. The data has suggest 
that diet rich in n-3 PUFA can reduce the risk of developing the disease and therefore that 
drugs which modulate PUFA levels could be considered as potential therapy for AD.
To provide the important and necessary data concerning the role of n-3 PUFA in AD, 
future studies need to focus on establishing a more in-depth understanding of the function 
of brain PUFAs and their possible interactions with APP.
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Chapter 5 
Can high cholesterol diet trigger 
amyloid cascade-induced pathology in 
transgenic GP56 rats?
5.1. Introduction 
Overview
Recent data suggests that high plasma cholesterol is coincident with susceptibility to 
Alzheimer’s disease. However, no direct evidence has been reported linking cholesterol 
metabolism and the pathogenesis of AD. The AD model transgenic rats (GP56) 
overexpress human mutated APP but show no detectable AD-related pathology 
(described in chapter 1). These animals were used to test the hypothesis that p-amyloid 
pathology can be modulated by diet-induced hypercholesterolemia. The project 
investigated the effect of dietary administration of cholesterol-enriched diet on learning 
ability, synaptic physiology and Ap pathology in these rats.
Cholesterol in learning and memory studies in animals
While the hypothesis that high cholesterol levels could affect learning and memory can be 
easily tested, only a few animal studies have been undertaken to clarify this relationship.
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In 1985 Kessler and co-workers investigated the effects of learning on the constitution of 
brain membranes. Rats were trained in a T-maze, and after reaching certain criteria, were 
sacrificed. Biochemical analysis revealed a marked learning-induced decrease in the level 
of cholesterol in the hippocampal and cortical regions and increase in the membrane lipid 
fluidity. In another study, Miller et al. (1994) treated DBA mice with cholesterol pellets 
for 11 days. This study showed that short treatment with cholesterol enhanced learning 
performance in DBA mice in the Morris water maze. O’Brien’s group investigated the 
effect of blocking cholesterol synthesis on conditioned eye blink response in rabbits. 
Chronic inhibition of cholesterol synthesis in just-weaned rats impaired acquisition of the 
classically conditioned eye blink response (O’Brien et al., 2000). While these studies 
showed interesting results, other groups have not investigated this subject further and no 
final conclusion can be drawn from the limited results so far available.
Cholesterol in AD animal models
As described in Chapter 1.6.3, brain cholesterol homeostasis is thought to be largely 
independent of peripheral fluctuations in cholesterol content (Edmond et al., 1991). 
Therefore dietary cholesterol should have no effect on brain cholesterol concentrations 
and should not affect cerebral processing of APP. However, this has not proved to be the 
case.
Sparks and co-workers provided the first evidence that increased dietary cholesterol 
affected amyloid production. They demonstrated that a high cholesterol diet for 4 weeks 
caused increased p-amyloid immunoreactivity in rabbit hippocampal neurons (Sparks et 
al., 1994). However, other groups could not reproduce these results. Subsequent work by 
Sparks et al. (2003) revealed that traces of copper in the animal drinking water (from the 
tap) were essential to induce P-amyloid plaques and learning deficit in the rabbits on a 
high-cholesterol diet.
Experiments on transgenic mouse models have provided conflicting evidence on the role 
of cholesterol in APP processing and the production of Ap. Feeding APP transgenic mice 
a 5% cholesterol diet for 8 weeks resulted in a significant reduction in brain levels of APP 
derivatives, Ap40, and Ap42 (Howland et al., 1998). Conversely, another study using the 
double mutant PS/APP transgenic mouse revealed opposite effects following similar
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treatment. This second study found that a high cholesterol diet resulted in increased Ap 
production and deposition of amyloid plaques (Refolo et al., 2000).
In response to epidemiological data indicating the ability of statins to reduce the risk of 
AD (Jick et al., 2000; Wolozin et al., 2000), more detailed studies on animals were 
initiated to investigate their role in more detail. High doses of statins were found to 
reduce both intracellular and extracellular levels of Ap40 and AP42 peptides in primary 
cultures of hippocampal neurons, in brain tissue and in cerebrospinal fluid of guinea pigs 
(Fassbender et al., 2001). Studies on PS/APP transgenic mice using statins have shown 
that they can significantly reduce the levels of Ap40 and AP42 (Petanceska et al., 2002). 
Another study by Refolo (2001) and colleagues used a different cholesterol synthesis 
inhibitor (BM15.766) and found reduced plaque formation in the PS/APP transgenic 
mice. This is an important finding as it suggests that plaque formation can actually be 
inhibited by reducing cholesterol levels and that the previously observed effects are not 
drug-specific or due to the side effects of statin use.
A recently published study by Park et al. (2003) investigated the effect of lovastatin on 13- 
amyloid pathology in Tg2576 mice. This statin was found to reduce plasma and brain 
cholesterol levels in both female and male mice, but to enhance the amounts of p-amyloid 
in females only. Although there is evidence that gender differences may play a role in AD 
development (Molero et al., 2001), this hypothesis requires further research and might be 
applicable only to this animal model.
Cholesterol, APP processing and amyloid plaque pathology
As reviewed in chapter 1, brain cholesterol metabolism is not well understood. It is 
known that cholesterol accumulates in senile plaques and tangles of AD patients and in 
mutant APP transgenic mice (Mori et al., 2001). Recently, a study in PS/APP double 
transgenic mice showed that Ap, ApoE, and cholesterol co-localize in the core of fibrillar 
plaques (Bums et al., 2003). This could indicate a role for both cholesterol and ApoE in 
plaque deposition. Removal of either of them prevents plaque deposition (Pitas et al., 
1987; Refolo et al., 2001). Furthermore, extracellular cholesterol does not bind to soluble 
Ap, but associates strongly with aggregated Ap (Avdulov et al., 1997) and is therefore an
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ideal candidate as the “seed” required for deposition of aggregated Ap. Binding of 
cholesterol to aggregated Ap may also prevent clearance of Ap to the periphery.
Synaptic plasticity and cholesterol
Many factors (age, stress, diet, environment and drugs) can affect neuronal plasticity, 
including long-term potentiation (LTP). Koudinov et al. (1998, 2001) investigated 
extensively the relationship of neuronal cholesterol redistribution and synthesis with 
synaptic plasticity and neurodegeneration. Extracellular recording of field-evoked 
postsynaptic potentials (fEPSP) showed enhanced paired pulse facilitation (PPF) and 
impaired LTP in the CA1 region of adult rat hippocampal slices subjected to induced 
cholesterol efflux. This study suggested that cholesterol is essential for normal synaptic 
plasticity.
The results of electrophysiological studies performed in transgenic mice overproducing 
and accumulating Ap are not very consistent. Chapman et al. (1999) found normal 
synaptic transmission and impairment in LTP in vitro and in vivo in both CA1 and dentate 
gyrus of the hippocampus of Tg2576 mice. Larson (1999) and co-workers found altered 
synaptic function in PDAPP mice in advance of amyloid plaque formation and normal 
long-term synaptic plasticity. Furthermore, Giacchino (2000) and his group found normal 
baseline synaptic function in PDAPP mice and deficits in CA1 LTP maintenance in both 
young and aged animals. This variation in results might be due to the differences in 
procedures (e.g. preparation of brain slices in the presence of kynurenate, a broad- 
spectrum glutamate-receptor antagonist), exposure to learning and memory testing in the 
past, or differences in transgenic mouse strains.
Results of studies in rats are no clearer. Stephan (2001) and co-workers injected 
aggregated Ap into the dorsal dentate gyrus of rats in vivo, tested them on several 
different learning tasks and assessed synaptic transmission and plasticity in vivo. Rats 
were tested after 7-16 weeks after injection and were found to be impaired specifically in 
working memory type tasks; synaptic transmission and long-term potentiation were also 
severely impaired. Although these findings suggest that aggregated amyloid induces 
cognitive deficits similar to those observed in AD, the effect of injection and the time 
scale make it difficult to draw a final conclusion. But as more interest is currently focused 
on less aggregated forms of Ap (reviewed in chapter 1.3.2), Walsh et al. (2002) injected
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intracerebroventricularly soluble oligomers and found that they inhibited the late phase of 
LTP in the rat hippocampus in vivo. These experiments attribute an inhibition of 
hippocampal LTP in vivo specifically to oligomers, not monomers or fibrils of Ap.
GP56 transgenic rats overexpressing the mutated (Swedish) human APP have not been 
tested for synaptic physiology impairments. Although they have not shown any 
impairment on behavioural learning and memory tasks in the T-maze or water maze 
(Marshall, 2002), it is still possible that they manifest deficits in neuronal plasticity.
Although studies employing animal models of AD are inconsistent, they suggest 
generally that cholesterol modulates APP processing and consequently alters Ap 
production and senile plaque deposition. To further explore the interaction between 
cholesterol and AD, the effects of a high cholesterol (5%) diet on APP pathology, 
behaviour and synaptic plasticity in GP56 transgenic rat were studied. I chose to study the 
GP56 rats, rather than Tg2576 mice, because of the likelihood of a floor effect on spatial 
learning in the mice (which are severely impaired at 8  months of age) and because of the 
intriguing possibility that increasing cholesterol might reveal deficits in animals that 
otherwise failed to express a behavioural or physiological phenotype.
5.2. Materials and Methods
Animals and diets
Fifteen-month-old Sprague-Dawley transgenic homozygous GP56 rats and non-transgenic 
littermate controls were studied. Animals of both sexes weighing 300-500g (females) and 
500-800g (males) were used in the study. The rats were randomly divided into four 
groups: the transgenic cholesterol group (n = 1 2 ), the transgenic control group (n =8 ), the 
non-transgenic cholesterol group (n =6 ) and the non-transgenic control group (n = 5). 
Rats were group housed with littermates (transgenic and non-transgenic housed together), 
and all testing was conducted during the light phase. Transgenic rats were compared to 
littermate controls to ensure that age and background strains were equivalent.
The cholesterol group was put on a special chow prepared by Special Diet Services (SDS, 
UK) by incorporating 5% of pure cholesterol into standard rodent chow. Analysis of the 
quality of the diet and exact amount of cholesterol was provided by SDS (UK). From 
previous data at Cardiff we know that a healthy male rat (500-800g) eats around 50g (10-
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16g/100g weight) of chow a day and a healthy female rat (300-500g) eats around 30g of 
chow a day. From these figures, the cholesterol dose for rats was estimated to be on 
average 1.5-2.5 g per day. That accounts for a dose of around 4g/kg per day. The range is 
similar to other studies, where mice were put on 5% enriched cholesterol diet (Refolo et 
al., 2000). For the control chow, nothing was added into standard rodent chow, which 
contains traces of cholesterol (analysis provided by SDS, UK).
Experimental Procedures
The full experimental procedure consisted of a series of phases, which were conducted on 
all animals. These included:
• Feeding with special cholesterol-enriched or control chow and drinking water ad 
libitum for 9 weeks. Rats were weighed every week;
• Water Maze training to measure spatial learning as described in chapter 2.1.2. Rats 
were kept on special diets until the end of testing;
• Electrophysiology in vivo measured in dentate gyrus for induction of LTP (details in 
chapter 2.2). Rats were killed after electrophysiological experiments, brains removed, cut 
into two halves for Ap measurements and immunostaining;
• ELISA measurement using commercially available kit (Biosource) in formic acid- 
treated (FA) brain extracts to quantify the total amount of p -amyloid 40 and 42 in brain 
tissue (details in chapter 2.3);
• Immunostaining using p-amyloid, APP, activated astrocytes and microglia 
recognising antibodies (as described in chapter 2.4)
Statistical analysis
All data are expressed as means ± SEM. The statistical significance of differences in the 
learning parameters in the water maze over the training time and the values of 
electrophysiological analysis measured over time were calculated by repeated-measures 
3-factor ANOVA, with genotype and diet as between-subject factors and time as the 
within subjects factor. The statistical significance of differences in P-amyloid levels 
between the groups was determined by 2-factor ANOVA, with genotype and diet as
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between-subject factors. Tukey's pair wise comparisons post hoc tests were carried out to 
determine the source of a significant main effect or interaction. Correlations were counted 
using regression analysis and Pearson Correlation test. Differences were considered to be 
significant at p < 0.05.
5.3. Results
Body weight and animal survival assessment
To examine the effects of dietary cholesterol on GP56 rats, animals were placed on either 
a high-cholesterol diet or a basic diet containing traces of cholesterol for 9 weeks. There 
was a significant difference in body weight gain over the treatment period between 
animals on control or cholesterol-enriched diets regardless of genotype. Repeated 
measures over the feeding time 3-factor ANOVA, with diet and genotype as between 
subject factors, revealed a significant effect of diet (F(i;27)= 6  08, p=0 .0 2 ) and no effect of 
genotype or no interaction. Final body weight for transgenic rats on cholesterol diet was 
106.7 ±1.4% original weights, transgenic rats on control diet 99.9±2.7%, non-transgenics 
on cholesterol diet 106±2.4% and non-transgenics on control diet 102±2.0%. During the 
time of chronic administration of either cholesterol-enriched or control (from 15 till 18- 
18.5 months of age) none of the rats died.
Reference Memory in the Water Maze
Figure 5.1  shows the effect of chronic administration of cholesterol on spatial reference 
learning ability in GP56 rats and their non-transgenic littermates fed with cholesterol- 
enriched or control chow. Nearly all animals swam well in the pool and learned to use the 
platform as a mean of escape from the water (two transgenic rats (one on each diet) were 
excluded due to problems with swimming). During spatial training, all animals spent 
progressively less time at or near the sidewalls and showed a gradual decrease in the 
latency to escape from the water. A repeated measure ANOVA revealed significant main 
effect of genotype, indicating that the transgene causes performance impairments (longer 
latency period to find hidden platform). There was also a main effect of a training day, 
confirming an overall improvement during training, and diet, indicating an influence of 
the treatment on rats' performance in the water maze. There were no significant
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Escape Latency in the Reference W ater maze in transgenic GP56 and
non-transgenic rats fed with cholesterol or control diet
. .A . .  Nontg/Chol 
. . .  A .. .  N'ontg eon
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groups
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Figure 5.1 Im paired  spatia l learn in g  in  G P 5 6  rats and n on -tra n sg en ic  litterm ates o n  e ith er  
con tro l or ch o le s tero l d iet. O n  the graph A , th e  tim e  to  reach  the p la tform  is  p lo tted  aga in st  
tra in ing  d ay  and  d em on stra tes  th e  la te n c y  (m ea n  and standard error) to  e sc a p e  o n to  the  
h id d en  p latform . R ep ea ted  m ea su re  A N O V A  fo r  e sc a p e  la ten cy  data ( s e c )  r e v e a le d  a  
s ig n ifica n t m ain  e f f e c t  o f  g e n o ty p e  (F (128)= 5 .3 3 , p = 0 .0 2 9 ) ,  s ig n ifica n t e f fe c t  o f  d ie t  
( f (, 28)=10 .08 , p =  0 .0 0 4 )  bu t n o  in teraction  o f  th is fa c to rs (F (U4)= 0 .0 3 , p = 0 .8 7 4 ) .  T h e  
p erform an ce  o f  each  grou p  im p ro v ed  sim ila r ly  a cro ss  th e  d a y s  (o v era ll d a y  e f fe c t  
F (^ 2 ,)= 13 .14 , p < 0 0 0 1 ) ,  but n either o f  th e  factors sh o w e d  a s ig n ifica n t in teraction  w ith  
tra in in g  day. A lth o u g h  in teraction  o f  g e n o ty p e  and  d ie t w a s  n o t s ig n ifica n t, p o s t  h o c  
T u k ey  s  s  pair w is e  co m p a r iso n s  rev e a le d  a  s ig n ific a n t d if fe r e n c e  b e tw e e n  n o n -tra n sg en ic  
rats o n  con tro l d ie t and tran sgen ic  o n  c h o le s te r o l (p = 0 .0 2 ) . G raph B  d em on stra tes  co lu m n  
chart o f  e sca p e  la ten cy  a v era g ed  o v e r  a ll tr ia ls  and o v er  a ll tra in in g  d ays. N u m b ers  o f  rats 
are tg /c h o l= l  1, tg /c o n = 7 , n o n tg /c h o l= 6 , n o n tg /c o n = 5 .
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interactions between any of these factors indicating that the diet did not affect transgenic 
rats in a different way than non-transgenic, and there was not particular interaction of 
high cholesterol and APP that could affect learning in the water maze. Although 
interactions failed to be significant, post hoc comparisons revealed that transgenic rats on 
cholesterol diet were significantly worse than non-transgenic rats on control diet.
Figure 5.2 illustrates statistical analysis of swim speed, path-length and the percent of 
time spent in the target quadrant during the training trials in which the platform was 
present. These revealed no effect of genotype, diet or their interaction. Swim speeds were 
similar for all groups, and rats did not exhibit floating behaviour. The deficits observed in 
the acquisition of this task could not therefore be explained by aberrant motor behaviour.
Figure 5.3 illustrates the analysis of the influence of genotype and diet on the probe trials 
(no escape platform present), performed after every three days of training (protocol 
described in chapter 2.1.2). The graphs represent the percent of time spent in all quadrants 
of the maze. Four groups of rats performed similarly, and 2-factor ANOVA did not reveal 
any significant effects of either transgene or diet on percent time spent in the target 
quadrant (all p-values>0.05).
Taken together, these data indicate that high cholesterol diet and overexpression of 
mutated APP were each capable of producing minor acquisition deficits in the water maze 
independently. Importantly, neither of these factors had an effect on probe trial 
performance, which was relatively poor even in control animals, compared to published 
literature. This is likely to be a strain effect, as hooded rats (Lister or Long-Evans) are 
more commonly used to test reference memory in the water maze, and Sprague-Dawley 
are known to perform poorly (D'Hooge & De Deyn, 2001).
Electrophysiology in vivo
After behavioural testing, electrophysiological analysis was undertaken to verify whether 
the reference water maze impairment correlated with a deficit in synaptic transmission 
and plasticity measured in the dentate gyrus. For analysis, changes in the field-excitatory 
postsynaptic potential (fEPSP) slope and pop spike amplitude (PSA) were measured.
Basal synaptic function was assessed by using a range of stimulus intensities to generate 
input-output (I/O) curves and to determine the appropriate stimulus intensity for baseline
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Swim Speed and % time in a target quadrant during water maze training in
transgenic GP56 and non-transgenic rats fed with cholesterol or control diet
A
■ nontg/cho
■ nontg/con
■ tg/chol
■ tg/con
nontg/chol nontg/con tg/chol
B
nontg/chol 
o- •. nontg/con 
-■— tg/chol 
-•— "tg/con
Training day
Figure 5.2 T h ere w ere  n o  s ig n if ic a n t e f f e c t s  o f  g e n o ty p e  or d ie t o n  sw im  sp eed , %  t im e  in  
a target quadrant or path len g th . G raph  A  sh o w s  sw im  sp eed  a v era g ed  o v er  a ll tr ia ls and  
tra in ing  d a y s  w h ile  graph  B  rep resen ts  in crea s in g  %  t im e  sp en t in  target quadrant d u rin g  
the tra in ing  d ays. R ep ea ted  m ea su res  2 -fa c to r  A N O V A  for  sw im  sp e e d  data  re v e a le d  n o  
e f fe c t  o f  g en o ty p e , n o  e ffe c t  o f  d ie t and  n o  in teraction  o f  th e se  factors (a ll p -v a lu e s  >  
0 .0 5 ) .  S ta tistica l a n a ly s is  o f  p a th -len g th  (a v era g ed  o v er  tria ls and tra in in g  d a y s )  sh o w e d  
a lso  n o  e ffe c t  o f  g e n o ty p e , n o  e ffe c t  o f  d ie t and  n o  in teraction  (a ll p -v a lu e s  >  0 .0 5 ) .  3 -  
factor  A N O V A  p erfo rm ed  o n  %  tim e  sp en t in a target quadrant data  rev e a le d  a lso  n o  e f fe c t  
o f  g e n o ty p e , n o  e ffe c t  o f  d ie t and  n o  in teraction  (a ll p  v a lu e s  >  0 .0 5 ) .  O v era ll, th e  tra in in g  
d ay  n u m b er  w a s  s ig n if ic a n t fo r  %  t im e  sp en t in  a target quadrant (F (g lg)= 8 .5 3 , p < . 0 0 0 1 )  
but d id  n o t sh o w  a n y  in tera ctio n s  (a ll p -v a lu e s  > 0 .0 5 ) .
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%  time spent in each quadran t during probe trials in reference w ater maze in 
transgenic GP56 and non-transgenic rats on cholesterol or control diets
■TARGET 
□ OPPOSITE 
BRIGHT
nontg/chol nontg/con tg/chol tg/con
B
nontg/chol nontg/con
Figure 5.3 B ar graph A  d em o n stra te s  th e  tim e  sp en t in  ea ch  o f  th e  fou r quadrants o f  th e  
w ater  m a z e  (target, o p p o s ite , righ t and  le ft)  o n  th e  third p rob e. R ats w ere  su b jec ted  to  th ree  
p ro b e  tria ls w h ich  fo l lo w e d  e v e r y  th ree  d a y s  o f  train ing. 2 -fa c to r  A N O V A  (g e n o ty p e  and  
d ie t) rev ea led  n o  s ig n ific a n t e f f e c t  o f  an y  o f  th e se  fa cto rs d u ring  an y  o f  th e  p r o b e s  (a ll p -  
v a lu e s >  0 .0 5 ) .  T o  a n a ly se  i f  rats im p r o v e d  du rin g  tra in in g  and  sp en d  m o re  t im e  in  target 
quadrant durin g  th e  3 rd p ro b e  co m p a red  to  the 1st o n e , n o rm a lised  ratio w a s  ca lcu la ted . 2 -  
w a y  A N O V A  (g e n o ty p e  and  d ie t)  r e v e a le d  n o  s ig n ific a n t e f f e c t  or  in teraction  o f  an y  o f  
th e se  factors o n  th is  ratio  (a ll p -v a lu e s>  0 .0 5 ) .  T h ere  w ere  n o  sta tistica l d if fe r e n c e s  
b e tw e e n  rats d u rin g  p ro b e  trials.
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responses before induction of LTP. There were no statistical differences in fEPSP slope 
measurements (all p-values > 0.05), as calculated by repeated measure 3-factor ANOVA 
(diet x genotype, with stimulus intensity as the repeated-measure factor). All the rats 
showed a significant increase in EPSP slope with increased stimulus intensities (Figure 
5.4A).
Analysis of input-output curves for the PSA measurements showed a significant overall 
effect of stimulus intensity, indicating that PSA changed as the stimulus intensity 
increased. There was no main effect of either diet or genotype (all p-values > 0.05). 
Though there was a significant interaction of “genotype x diet” and “stimulus intensity x 
genotype x diet” (Figure 5.4B) which could suggest synergistic effect of transgene and 
cholesterol on synaptically driven neuronal excitability in GP56 rats. Post hoc Tukey's 
pair wise comparisons revealed no significant differences between tested groups.
The paired pulse study was performed at intensities just above PS threshold and with 
inter-pulse-intervals of 30-300ms. It showed the typical relationship of facilitation of the 
fEPSP, maximal at inter-pulse intervals of 30-50ms and inhibition with longer stimulus 
interval (Figure 5.5A). All groups behaved similarly in this study. No significant 
differences between groups were found at any inter-stimulus interval for slope EPSP 
measurements.
Analysis of PSA in the paired-pulse study revealed no change of spike at short inter­
stimulus intervals (30-50ms) and its facilitation at longer intervals in all four groups of 
rats. (Figure 5.5B). This outline of first no-change at short inter-stimulus intervals 
followed by facilitation at longer intervals reflects inhibition and disinhibition processes 
characteristic for postsynaptic events (Joy et al., 1993). Statistical analysis of PSA values 
revealed significant effect of inter-pulse interval and significant interaction of “inter-pulse 
interval x genotype x diet”. Although short-term presynaptic plasticity and network 
excitability in the dentate gyrus seem to be impaired at middle length inter-pulse intervals 
(50-150ms) and seem to depend on both transgene and cholesterol, being the most 
impaired for transgenic rats on cholesterol diet, but no significant differences between 
groups were established (Tukey's pair wise comparisons post hoc tests).
After collecting the paired pulse data, a 20-minute baseline was recorded followed by 
tetanic stimulation of the perforant path (see chapter 2.2). All data were normalized with
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I/O Curves for responses recorded in Dentate Gyrus in transgenic GP56 and
non-transgenic rats fed with cholesterol or control diets
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“tg/con 
nontg/chol 
' nontg/con
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Figure 5 .4  I/O cu r v e s  o f  the fE P S P  s lo p e  (A )  and  P S  a m p litu d e  (B )  a s  a fu n c tio n  o f  
stim u lu s in ten sity  b e fo r e  in d u ctio n  o f  L TP. T h e  y -a x is  d e n o te s  th e  s lo p e  o f  the fE P S P  
m easu red  in  m V  per m s  (A ) , or P S  a m p litu d e  m easu red  in  m V  (B )  and th e  x -a x is  in d ic a te s  
the lo w e s t  and  h ig h es t in ten s it ie s  u se d  in m A . R ep ea ted  m ea su re  3 -fa c to r  A N O V A  (d ie t  x  
g e n o ty p e , w ith  stim u lu s in ten sity  a s th e  rep ea ted -m ea su re  factor) rev ea led  n o  s ig n if ic a n t  
e f fe c ts  o f  eith er g e n o ty p e  or d ie t for  th e  s iz e  o f  th e  fE P S P  s lo p e  at all in ten sit ie s , a lth o u g h  an  
o v era ll e f fe c t  o f  stim u lu s in ten sity  w a s  s ig n if ic a n t (F (616)= 1 3 .6 9 ,  p < 0 0 0 1 )  (A ).
For the P S A  m ea su rem en ts , rep ea ted  m ea su res  3 -fa c to r  A N O V A  (d ie t x  g e n o ty p e , w ith  
stim u lu s in ten sity  th e  rep ea ted -m ea su re  factor) r e v e a le d  n o  s ig n ifica n t m a in  e f f e c t  o f  e ither  
g e n o ty p e  or d ie t, but s ig n ifica n t in tera c tio n  b e tw e e n  th em  (F (| >22)= 5 .43 , p = 0 .0 2 9 ) .  T h e  o v era ll 
e f fe c t  o f  s tim u lu s in ten sity  w a s  a ls o  s ig n ifica n t (F (617)= 1 6 .1 7 , p O .O O l) , and in teraction  
g e n o ty p e  x  d ie t x  stim u lu s in ten sity  rea ch ed  a lso  s ig n ifica n t d if fe r e n c e  (F (617)= 3 .0 4 ,  
p = 0 .0 3 3 ) .  P o st h o c  T u k e y  s ' s  pa ir  w is e  co m p a r iso n s  re v e a le d  n o  d if fe r e n c e s  b e tw e e n  te s te d  
g ro u p s (B ).
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Paired Pulse Curves for responses recorded in DG of hippocampus in
transgenic GP56 and non-transgenic rats fed with cholesterol or control diets
105
A * tg/chol 
~*“ tg/con 
nontg/chol 
—-  nontg/con
100
100 150
inter-pulse interval (ms)
200 250 300
B 600
—-  tg/chol 
—-  tg/con 
■— nontg/chol 
nontg/con
500
r  400
cu 300
200
100
100 150 200
inter-pulse interval (ms)
250 300
F ig u r e  5 .5  PP fa c ilita tio n  c u r v e s(v a lu e s  o f  th e  re la tive  am p litu d e  in  the se c o n d  p o ten tia l w ith  
resp ect to  th e first p oten tia l (P 2 /P 1  x 1 0 0 )) o f  the E P S P  s lo p e  (A ) and P S  am p litu d e  (B )  a s a  
fu n ctio n  o f  in ter-stim u lu s in terva l b e fo r e  in d u ctio n  o f  L T P . T h e  y -a x is  d e n o te s  th e  P 2 /P 1  x 
100  ratios o f  s lo p e  o f  the fE P S P  (A ), or  P S  a m p litu d e  (B )  an d  th e x -a x is  in d ica tes  th e  ra n g e  o f  
in ter-p u lse  in terva ls in m s. R ep ea ted  3 -fa c to r  A N O V A  (d ie t x  g e n o ty p e , w ith  in ter -p u lse  
in terval a s the w ith in  su b ject fa c to r ) rev ea led  n o  s ig n ifica n t e f f e c t s  o f  e ither g e n o ty p e  or d ie t  
for  th e s iz e  o f  th e fE P S P  s lo p e  at a ll t im e  in terva ls, a lth o u g h  an ov era ll e f fe c t  o f  in ter-p u lse  
in terval w a s  s ig n ifica n t (F (616)= 4 8 .2 7 ,  p <  0 0 0 1 )  (A ).
F or the P S A  m ea su rem en ts , rep ea ted  3 -fa c to r  A N O V A  (d ie t  x  g en o ty p e , w ith  in ter -p u lse  
in terval as th e  w ith in  su b ject factor) r ev ea led  n o  s ig n ifica n t m a in  e f fe c t  o f  e ith er  g e n o ty p e  or  
d iet. T h e  o v era ll e f fe c t  o f  p u lse  in terva l (F (6 20)= 8 .2 6 , p <  0 0 0 1 )  and in teraction  g e n o ty p e  x  d ie t  
x  in ter -p u lse  in terva l (F (620)= 3 .4 5 , p = 0 .0 1 6 7 )  reach ed  s ig n if ic a n c e  (B ).
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respect to the mean fEPSP slope or mean PSA during this 20-min period (Figure 5.6). 60 
minutes following tetanic stimulation, all four groups of rats showed significant and 
similar potentiation of fEPSP slope (p< 0.0001) and PSA (p<0.0001). Statistical analysis 
revealed no effects of either diet or genotype. Thus, neither cholesterol nor APP affected 
the long-term potentiation in the dentate gyrus.
p-amyloid brain levels
The mean brain concentrations of Ap40 and Ap42 from all animals participating in the 
behavioural study are shown in Figure 5.7. Formic-acid extracted total amounts of Ap40 
levels were significantly increased in transgenic GP56 rats comparing to their non- 
transgenic littermates. Cholesterol had no effect on either transgenic or non-transgenic 
animals, and there were no interaction between these factors. There were detectable levels 
of Ap42 in the transgenic rats, but the values were not significantly different between 
transgenic and non-transgenic animals nor did the treatment also have an effect.
Immunokistochemistry
Immunohistochemical procedures were performed on a sample of brains from transgenic 
and non-transgenic rats on either cholesterol or control diet. Immunostaining with an anti- 
Ap antibody revealed no signs of P-amyloid deposition (Figure 5.8), which agrees with 
ELISA data that revealed no significant increase in AP42 in GP56 rats on either diet. 
Because a common feature of Alzheimer pathology is inflammation (Akiyama et al., 
2000), GFAP and OX-42 immunostaining was used to detect signs of astrocytosis and 
activation of macrophages and microglia. There was a GFAP- and OX-42- 
immunopositive reaction present in all the rats but there were no obvious differences 
between any of the groups. Therefore, the conclusion is that neither genotype nor 
cholesterol was able to induce significant p-amyloid pathology in GP56 rats.
Relationship between learning ability, synaptic physiology and P-amyloid levels
Although rats showed slightly impaired performance in the water maze and most of them 
exhibited normal dentate LTP, it is possible that some of the rats that displayed less LTP 
showed a bigger impairment in the behavioural task or had higher levels of P -amyloid.
However, inspection of the data revealed no significant correlation between the mean 
escape latency averaged over the 9 spatial training trials and the amount of LTP 1 h post-
138
LTP induction recorded in dentate gyrus of hippocampus in transgenic GP56
and non-transgenic rats fed with cholesterol or control diets
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F ig u r e  5 .6  L T P  in th e  d en ta te  g y ru s  reco rd ed  for  6 0  m in u tes  after the in d u ctio n , o f  fE P S P  
s lo p e  (A )  and P S A  (B )  in  th e  G P 5 6  rats on  e ith er  c h o le s te r o l or con tro l d iet. T e ta n ic  
s tim u la tio n  in d u ced  an im m ed ia te  in crea se  in  b o th  E P S P  s lo p e  and P S  a m p litu d e  fo r  all 
g ro u p s o f  rats. D ata  are m ea n s tak en  ev e r y  2 m in u te s  w ith  S E M  v a lu e s  in c lu d ed  fo r  ev ery  
2 nd m ean  resp on se . T h e  y -a x is  d e n o te s  th e  p ercen ta g e  o f  th e  b a se lin e  fE P S P  s lo p e  (A )  or  
P S A  (B )  after in d u ctio n  o f  L T P  ( in d ic a te d  b y  arrow ), and  the x -a x is  d e n o te s  th e  t im e  o f  
record ing . N e ith er  ad m in istra tion  o f  c h o le s te r o l an d /n or p resen ce  o f  th e  A P P  tra n sg en e  
had  a s ig n ifica n t e f fe c t  o n  in d u c t io n  and m a in ten a n ce  o f  L T P  in  rats. O v era ll e f f e c t  o f  
tetan u s w a s  s ig n ifica n t fo r  b o th  fE P S P  s lo p e  (F(714)= 2 5 .0 8 , p < .0 0 0 1 )  and  fo r  P S  a m p litu d e  
v a lu e s  (F (714)= 1 1 .72 , p < 0 0 0 1 ) .
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p-amyloid levels in transgenic GP56 and non-transgenic rats fed
with cholesterol or control diets
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F ig u r e  5 .7  (3-am yloid  4 0  and  4 2  le v e ls  in  F A  extract in tra n sg en ic  G P 5 6  and  n o n -  
tra n sg en ic  rats are n o t a ffe c te d  b y  d iet. 2 -fa c to r  A N O V A  (g e n o ty p e , d ie t)  sh o w e d  that 
n o n -tra n sg en ic  rats h ad  s ig n if ic a n tly  lo w e r  le v e ls  o f  AJ340 in F A  ex tract (F A 4 0 ) ,  bu t 
g e n o ty p e  had  n o  e ffe c t  on  A (342 in  F A  extract (F A 4 2 ) . A n a ly s is  sh o w e d  s ig n if ic a n t m a in  
e f fe c t  o f  g e n o ty p e  for  F A 4 0  (F (1;J0)= 2 3 .1 7 ,  p < 0 0 0 1 ) ,  and  n o  o th er  fa c to rs  (d ie t, 
in tera ctio n s or g e n o ty p e  and d ie t fo r  F A 4 2 )  w e r e  s ig n if ic a n t (a ll p -v a lu e s  > 0 .0 5 ) .
P-Am yloid 42 - FA extract
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Immunostaining for p-amyloid and astrocytes in GP56 ra t brain 
sections from rats on cholesterol or control diets.
m m
F ig u r e  5 .8  R ep resen ta tiv e  e x a m p le s  o f  1 9 -m o n th -o ld  G P 5 6  rat brain  s e c t io n s  su b je c te d  to  
im m u n o h is to ch em istry  fo r  P -a m y lo id  to  la b e l p o s s ib le  a m y lo id  p a th o lo g y  and  fo r  G F A P  (A , B )  
to  la b e l a c tiv a ted  a strcy tes  (1 0 - 2 0 x ) .  N o  p -a m y lo id  p a th o lo g y  w a s  n o tic e d  in  tr a n sg e n ic  rats on  
e ith er  c h o le s te r o l or  con tro l d iet. A c tiv a t io n  o f  a s tro cy te s  (in d ica ted  w ith  an  arrow ) w a s  
id en tica l a m o n g  all tra n sg en ic  an d  n o n -tr a n sg e n ic  rats r eg a rd le ss  o f  th e  d ie t an d  is  ty p ica l for  
th is  a g e  o f  an im a ls . T h e se  se c t io n s  are ta k en  fr o m  th e  h ip p o c a m p u s  o f  G P 5 6  tra n sg en ic  rats on  
h ig h -c h o le s te r o l (A )  and con tro l d ie ts  (B ) .
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tetanus measured as an average of the last 10 minutes (p-values> 0.05). Nor was there a 
significant correlation between the mean escape latency averaged over the 9 spatial 
training trials and the concentration of p-amyloid 40 and 42 (all p-values> 0.05) in the rat 
brain.
5.4. Discussion
The purpose of these experiments was to explore whether increases in dietary cholesterol 
in transgenic rats over-expressing human mutated APP would induce amyloid pathology 
in their brains, thus causing disruptions in learning ability, synaptic plasticity and levels 
of p-amyloid in the brain. This association was not really established, as only 
performance in the water maze was slightly impaired, while synaptic plasticity was 
normal, levels of p-amyloid were low and no P-amyloid pathology was detected in brain 
sections.
Why did the high cholesterol diet fa il to induce AD-like pathology in GP56 rats?
Results of previous studies on the biological relationship between cholesterol and AD are 
controversial (see section 5.1) and re-examination of this question in transgenic GP56 rats 
on high cholesterol diet did not clarify this issue any further. There are a few possible 
explanations why cholesterol did not induce significant p-amyloid pathology in these rats:
• The amount of cholesterol provided in the diet was too low and/or the administration 
period was too short. To imitate conditions for humans, rats might have needed to eat this 
diet for most of their life.
• Rats were too old (18-month old). Looking at previous studies, when mice were 
younger - 5 weeks (Refolo et al., 2000), cholesterol succeeded in inducing p -amyloid 
pathology. Conversely it had an opposite action in older mice - 210-408 days old 
(Howland et al., 1998). As investigated in human studies, higher levels of cholesterol 
correlate with risk of developing AD but only in midlife (Kivipelto et al., 2001). By 
comparison, during the progression of the disease in older individuals, the levels of 
cholesterol seem to be lower than in healthy people (Mason et al., 1992). This could be a 
possible explanation of the difference.
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• The transgene does not have a big enough effect in GP56 rats, when compared to 
similar transgenic mice models, like Tg2576. The difference might be due to an insertion 
place of the transgene, strain sensitivity to human APP or different immunological 
responses. Thus cholesterol could be a trigger factor in inducing AD-like pathology in 
transgenic mice highly overexpressing APP, but not in GP56 rats.
• Rats might have a (as yet unknown) mechanism (microglia? astrocytes?) that prevents 
them from accumulating p-amyloid. Although the expression of APP is only 3 times 
smaller than Tg2576 mice, the levels of produced Ap are 100 times less! To support this 
hypothesis, no successful AD transgenic rat model showing p-amyloid pathology has 
been generated up to now.
• There was a lack of significant co-factor helping cholesterol to induce APP-associated 
pathology. Normal rabbits on high cholesterol diet show high levels of amyloid and even 
plaques, but only if there is also copper in their drinking water (Sparks et al., 2003).
What effect did cholesterol feeding have on spatial learning in water maze on GP56 
rats?
As previously described by Marshall (2002) heterozygous GP56 rats show no impairment 
in either episodic-like memory in the T-maze or in spatial learning in the water maze. 
Homozygous GP56 rats, not previously assessed for behaviour impairments, were used 
for this project. The results of this study demonstrate a subtle behavioural impairment in 
escape latency during acquisition with significant effect of only diet and genotype, while 
no deficit on probe trials was detected. There could be a number of reasons for this 
observation:
• The protocol used for this study included giving a probe trial to rats after every 3 days 
of training (averaging 3 probes altogether). It is possible that the choice of this protocol 
was a mistake. Rats could have been over-probed and learned that every third day was a 
trial with no escape platform. Consequently they did not search for the platform. 
Following a standard protocol, with 1 probe trial at the end of testing, may have given a 
more accurate result.
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• Deficits detected during the acquisition could be due to the effects of either 
cholesterol or genetic modifications on other processes, not directly involved with the 
learning mechanism. Performance in complex learning tasks, such as the water maze, can 
be disrupted in a number of different ways which are independent of the learning process 
per se, such as by effects on sensory-motor or motivational processes necessary for 
normal task performance (reviewed in D'Hooge & De Deyn, 2001)
• The uncommon pattern of deficit in water maze, meaning impairment in escape 
latency during training and poor probe performance could be also caused by the rat strain 
characteristics. There are reported differences in water-maze learning ability between 
different strains of rats and mice (reviewed in D'Hooge & De Deyn, 2001).
• All rats on high-cholesterol diet gained more weight than the controls on normal diet, 
which could make it more difficult for them to swim. This is a less likely explanation, 
since there was no statistical difference in the swim speed among all groups.
What can be concluded from  deficits in synaptic plasticity?
The analysis of electrophysiological recordings in dentate gyrus showed slight changes of 
population spike, but not EPSP slope measurements. Although measurements of fEPSP 
slope are a standard way of evaluating synaptic plasticity in experiments in vitro, 
recordings in vivo are more susceptible to be masked by the dipole of the overlaying 
population spike. Therefore, calculating the EPSP from these potentials could be 
inappropriate because it varies strongly with the amplitude of the population spike.
Input-output recordings for PSA revealed a significant interaction of “genotype x diet” 
and “stimulus intensity x genotype x diet”. Although transgenic rats on cholesterol diet 
seemed to have the smallest population spikes and the difference was the most visible at 
higher intensities, post hoc comparisons revealed no differences between rat groups. 
These results could suggest a synergistic effect of transgene and diet limiting synaptically 
driven neuronal excitability in GP56 rats. There were no significant differences in the 
stimulus intensity needed to obtain threshold in both transgenic and non-transgenic rats 
on either diet.
Similarly in the paired-pulse paradigm, differences were observed in PSA, but not in 
fEPSP slope. Analysis revealed significant interaction of “inter-pulse interval x genotype
144
x diet”. Short-term facilitation of PSA characterises presynaptic function. Although it 
seems to be impaired at middle length inter-pulse intervals (50-150ms) and seems to 
depend on equally cholesterol diet and the transgene (being the most impaired for 
transgenic rats on cholesterol diet), post hoc comparisons between tested groups revealed 
no differences. Long-term synaptic plasticity was not impaired in any group of the rats.
These data suggest that dysregulation of cholesterol homeostasis combined with mutant 
APP over-expression could impair both basic neurotransmission and presynaptic 
functioning, but this effect was very minor. Perhaps higher doses of either APP or 
cholesterol, or a longer administration period of cholesterol, could amplify this effect.
Why did cholesterol treatment not alter amyloid pathology in GP56 rats?
Although cholesterol seems to have no effect on Ap levels in this model, subtle 
disturbances in spatial learning and short-term synaptic plasticity were detected. As 
described in chapter 2.3, ELISA techniques have many limitations and, as levels of 
amyloid were low anyway (all values were at the bottom of the standard curve), it is 
possible that the differences could not be detected. To answer this problem, the Ap levels 
could be measured using a more sensitive technique such as mass spectroscopy.
Transgenic mice carrying the same transgene (Tg2576) overexpressing the same mutated 
human APP show similar types of disturbance in synaptic plasticity and behaviour, but 
the features are more prominent (reviewed in chapter 1.7). The processes underlying these 
impairments are not fully understood, but are based on the same underlying genetic 
manipulation; high over-expression of APP. GP56 rats do not show this level of 
impairment, regardless of having high levels of APP. As cholesterol feeding in transgenic 
GP56 rats induced slightly more evident behavioural and physiological deficits (some 
factors were significant), we might conclude that high dietary cholesterol played some 
kind of role in inducing Ap pathology, or induced some other processes that led to 
observed effects.
Other studies using mice transgenic models also provided conflicting evidence. Refolo et 
al. (2000) demonstrated that cholesterol feeding resulted in a significant increase in the 
accumulation of Ap in PS/APP mice, but an earlier study using APP gene-targeted mice 
showed, in contrast, that a similar high-cholesterol diet resulted in a significant reduction 
in Ap peptides (Howland et al., 1998). These conflicting experimental outcomes may be
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attributed to the differences between the genetic models. Refolo et al. (2000) used 
standard transgenic mice over-expressing many copies of both APP and PS1 genes, while 
Howland et al. (1998) used a genetically-engineered (knock-in) mouse model in which 
the mouse APP gene was partly replaced with a human mutated gene. GP56 rats are 
transgenics overexpressing human mutated APP. Also the age of animals might be 
important. Younger animals (5 weeks old mice fed for 9 weeks, [Refolo et al., 2000]) 
could be more susceptible to the effects of high cholesterol diet, because at this age 13- 
amyloid pathology is starting to develop. Older mice (30-50 weeks old fed for 8 weeks on 
a diet, [Howland et al., 1998]) could be more resistant, as they already have established 
pathology. Finally the difference in the background strain of the mice used in the two 
studies could make them more or less sensitive to cholesterol diet causing alterations in 
APP processing and/or Ap deposition.
Given the difference apparent between two mouse models, it is perhaps not surprising that 
we failed to see any effect of cholesterol on GP56 rats, since using a different species than 
mice would involve even more differences in metabolism and physiology.
5.5. Conclusions and future questions
This study does not really support the clinical and epidemiological data suggesting that a 
high-cholesterol diet raises the risk of developing AD. GP56 transgenic rats failed to 
exhibit any Ap pathology and showed only some disturbances in spatial learning and 
neurotransmission.. If we assume that the noticed changes could precede development of 
Ap pathology, the results of this study support the role of cholesterol as an inducing factor 
of these changes. This finding suggests that diet could be crucial in modifying the risk of 
developing various diseases, including Alzheimer’s disease.
To provide the important and necessary data concerning the role of cholesterol in AD, 
studies will need to focus on establishing a more in-depth understanding of brain 
cholesterol metabolism. It is plausible that specific subcellular fractions, e.g., synaptic 
membranes or caveolae-like microdomains from specific brain regions have altered levels 
of cholesterol in AD, and this could provide the basis for cholesterol mediated Ap 
pathology. The simplest explanation for the sensitivity of APP processing to cholesterol, 
though, is chemical; the transmembrane proteins that process APP might simply require a 
high cholesterol environment to function. A somewhat more biological hypothesis is that
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regulation of APP processing can respond to changes in cholesterol membrane dynamics. 
For instance, synaptic plasticity may need alterations in cholesterol, other lipids and 
membrane proteins, possibly including those that may control APP processing. The 
association of APP and Ap with uptake of cholesterol also raises the possibility that APP 
or Ap contributes to cholesterol trafficking. However, although cholesterol clearly 
influences APP metabolism, data has yet to surface suggesting that APP influences 
cholesterol metabolism.
Although research from genetics, epidemiology, cell biology and studies in animals 
suggest that cholesterol plays a central role in the biology of APP and Ap, these results 
were not fully confirmed in this project. More research needs to be under-taken to clarify 
the functional significance underlying the connection between cholesterol and Ap.
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Chapter 6 
General Discussion
6.1. Overview
Forgetfulness was, in the past, accepted as a normal consequence of ageing; however this 
assumption is now known to be untrue. This realisation has facilitated the expanding 
understanding of dementia (Mattson et al., 2000). Life expectancy is increasing 
constantly, and the elderly proportion of the population is growing rapidly in relation to 
the young. Dementia, however, is growing even more rapidly, since incidence increases 
exponentially after the age of 65.
Significant progress has been made during the last two decades in understanding many 
aspects of AD, including its neuropathology, the mechanisms of its biochemical and 
cellular abnormalities and genetic causes and risk factors. Also, more environmental and 
pharmacological risk factors influencing developing AD have been identified. In parallel, 
several kinds of non-transgenic and transgenic animal models for AD have been 
developed. In this PhD project, I aimed to use transgenic animal models of AD to answer 
questions regarding the influence of dietary (cholesterol and DHA) and pharmacological 
manipulations (ibuprofen) on AD-like pathology in two such animal models.
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6.2. Why transgenic animals are imperfect, but indispensable, models of Alzheimer 
disease.
A new phase of AD research commenced when the first transgenic mouse model showing 
deposits of human Ap protein in brain, was reported (Games et al., 1995). There are 
significant numbers of researchers who doubt the utility of rodent models of AD (or any 
human disorders), but an equally large number who recognise the value of developing 
these models. In either case, their widespread use demands that we find the best way to 
apply what we can learn from them to the development of both novel therapeutic 
strategies and an understanding of the disease.
Those who question the applicability of rodent AD models claim that:
• They develop neither neurofibrillary tangles (NFTs) nor neuronal loss, which are 
essential hallmarks of AD (see chapter 1.7).
• The amyloid peptides generated in APP Tg2576 transgenic mice are physically and 
chemically distinct from those characteristics of AD (Kalback et al., 2002). Transgenic 
mouse Ap peptides lack the N-terminal degradations, post-translational modifications and 
cross-linkages abundant in the stable Ap peptide deposits observed in AD
• The Ap peptides that create the amyloid plaque cores in transgenic mice, in contrast to 
AD, are soluble in Tris-SDS-EDTA solutions, revealing both monomeric and SDS-stable 
oligomeric species of Ap (Kalback et al., 2002).
• The transgenic mouse levels of carboxy-terminal APP fragments are nearly 10-fold 
greater than those of human brains, and this condition may contribute to the unique 
pathology observed in these animals (Kalback et al., 2002).
• APP transgenic mice show weak inflammatory responses as compared to AD patients 
(Schwab et al., 2004). In both elderly transgenic mice (APP23 mice) and AD, similar 
staining for Ap has been observed and amyloid deposits were ApoE-positive and 
surrounded by activated astrocytes. However, mice had only weakly activated microglia, 
which are gathered around the periphery of the deposits. In contrast, AD lesions had 
strongly activated microglia, which were associated with the plaque core. Also
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immunostaining for complement proteins was weak in transgenic mice but very strong in 
AD deposits.
• The genetic mouse background influences the transgene-induced pathology in mice 
very strongly. It can change mortality rates and has a significant effect on the results of 
behavioural tests and makes the testing incoherent (Carlson et al., 1997).
In spite of all these problems, transgenic rodent models have invaluable advantages:
• Transgenic animal models overexpressing APP with mutations linked to familial AD 
show Ap deposits that closely resemble the amyloidosis observed in AD (see chapter 1.7). 
Therefore, they are useful for assessing the effects of drugs that inhibit Ap synthesis, 
fibril formation, and deposition in the brain.
• Analysing anatomy and physiology of transgenic animals overexpressing various AD- 
1 inked genes (APP, PS or Tau) allows better understanding of the impact of certain types 
of AD pathology on specific brain systems (e.g. temporal lobe versus frontal lobe 
systems) and the physiological processes, which are responsible for the formation of AD 
neuropathology and dementia. For example in Tg2576 mice, Shie and co-workers (2003) 
demonstrated intraneuronal Ap deposition in the somas of hippocampal CAl/subiculum 
neurons far in advance of the occurrence of extracellular Ap plaques. Similar to 
extracellular Ap deposits, these deposits increased exponentially with age. This finding 
supports the role of the transgenic mice as a promising model for the study of in vivo 
mechanisms of intraneuronal Ap deposition and seeding relevant to AD, and for testing 
measures to prevent or ameliorate intraneuronal Ap deposition.
• Transgenic models provide an opportunity to evaluate potential therapies on specific 
aspects/features of AD and cognition. Also the impact of potential risk factors on 
hippocampal Ap on neuronal functions, behavioural changes, and amyloid plaque 
formation can be assessed and investigated in cellular and biochemical details.
Although many controversial theories have been raised about the validity of rodent 
animal models, and it is true that results from testing them cannot be directly linked to 
humans, we should not underestimate how much scientist have already learned from 
them. Moreover, at the moment there is no better alternative. Even the “humble” fruit fly 
might contribute to the understanding of Alzheimer's disease (Greeve et al, 2004). Thus,
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for example, signalling from the Notch receptor is essential for proper cell-fate 
determinations and tissue patterning and requires a presenilin-dependent transmembrane- 
cleaving activity that is closely related or identical to the y-secretase proteolysis of APP 
involved in AD. A compound inhibiting y-secretase in transgenic mice induces 
developmental defects in Drosophila remarkably similar to those caused by genetic 
reduction of Notch. These results show that genetics and developmental biology can 
provide new understanding of the function of proteins like Notch receptor and its function 
in humans (Micchelli et al, 2003).
Consequently, differences in disease progression and biochemistry must be considered 
when using transgenic animals to evaluate drugs or therapeutic interventions intended to 
reduce the Ap burden in Alzheimer's disease. Nevertheless, these animals are widely used 
for developing and assessing the validity of novel drugs and interventions and also 
considering the function of suspected risk factors. So, while accepting that that direct 
transfer of results from mouse to human is not possible, we can learn much from 
experiments in transgenic models of AD.
6.3. Can we treat AD or only prevent?
A number of drugs are now available to minimise and delay the cognitive and behavioural 
symptoms of AD, but none of them are disease modifying. In general, however, scientists 
concentrate more on developing treatments, whereas prevention is relatively neglected. 
One possible reason for this is that there is no consistent method for an early diagnosis 
available.
Normally, the degenerative process has already progressed to an advanced stage with 
massive loss of cell mass before diagnosis can be made. In view of the limited capacity of 
the central nervous system tissue to repair, early intervention in the degenerative 
processes to spare as much tissue as possible will be crucial to obtain success. The 
transition from normal cognitive performance to the AD phenotype is probably gradual 
and takes years.
The interesting cases are patients with so-called mild cognitive impairment. As various 
studies have shown, these patients are at a very high risk of developing AD (Jack et al., 
2000). Thus patients with mild cognitive impairment are an important group to test
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potential preventive therapies. A number of ongoing clinical trials are recruiting such 
individuals to test whether certain drugs are effective in reducing the rate at which they 
progress to Alzheimer's disease.
Moreover, a variety of medications have been associated with significant reductions in the 
risk of developing AD, such as an anti-inflammatory therapy, antioxidant 
supplementation or statins. Early diagnosis may then help to increase the possibilities for 
developing and using these therapies.
For the studies reported in this PhD thesis, I investigated the role of the NSAID 
ibuprofen, as a potential agent for prevention or treatment in transgenic mice models. 
Ibuprofen and other NSAIDs have been implicated in many epidemiological studies in 
reducing the risk of developing AD (see chapter 1.5). As transgenic mice modelling this 
disease show age-related reduction in learning ability and concomitant increase in Ap 
pathology, I investigated the effect of dietary administration of ibuprofen on learning 
ability, synaptic physiology and pathology in Tg2576 Alzheimer's disease model mice at 
different stages of the development of pathology.
The results from the study indicated that ibuprofen delays the onset of behavioural 
impairment in Tg2576 mice as tested in the FCA task in the T-maze, when it is 
administered early during the evolution of their disease phenotype. By contrast, if 
ibuprofen supplementation is started at a later point, when Ap levels start to build up, no 
significant effect on learning and memory is observed. Only performance in the T-maze 
was improved, while levels of Ap in the brains were not affected and electrophysiological 
studies were not conclusive. This study supports the clinical and epidemiological data 
providing evidence that long-term NSAID therapy has a dramatic effect on the incidence 
of AD in contrast to little effect as a symptomatic treatment.
6.4. Is modern lifestyle linked to developing Alzheimer’s disease?
Researchers have identified a number of factors that may predispose to developing 
Alzheimer's disease. Some of them, like genes, are very hard to change, but more and 
more evidence is accumulating around lifestyle factors like unhealthy diet, diabetes, high 
cholesterol and blood pressure. Studies have shown correlations between high blood 
pressure, obesity, atherosclerosis, high cholesterol, high levels of homocysteine and the
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subsequent development of AD years later. As the first neurodegenerative events in AD 
may start developing 20 or 30 years before the first symptoms appear, it seems that 
keeping healthy in younger life is vital to ensure healthy ageing.
High blood cholesterol as a risk factor fo r  developing AD
High blood cholesterol can narrow the arteries and raise the risk of heart disease but may 
also induce neurodegeneration in the brain in AD. Several lines of evidence support the 
theory that an elevated blood cholesterol level is related to the development of 
Alzheimer's disease. In experimental models, animals fed high fat and high-cholesterol 
diets exhibited impaired learning and memory performance compared with animals on 
control diets and also demonstrated more Ap deposition in the brain, greater loss of 
neurons, and other Alzheimer's disease-related neuropathology (Puglielli et al., 2003; 
Refolo et al., 2000). One study of 444 Finnish men found that an elevated blood 
cholesterol level in midlife was associated with 3 times the risk of developing Alzheimer's 
disease in late life (Notkola et al., 1998).
Additionally two studies of patients who had been prescribed statins found a significantly 
lower risk of Alzheimer's disease compared with similar patients who were not prescribed 
these medications (Jick et al., 2000; Wolozin et al., 2000). Statins, which reduce the 
levels of plasma cholesterol by inhibiting the enzyme HMG-CoA reductase, have been 
shown to reduce the risk of Alzheimer s disease by up to 70% (Austen et al., 2002).
Based on these data, the purpose of the project with GP56 transgenic rats was to explore 
whether increases in dietary cholesterol in transgenic rats over-expressing human mutated 
APP would induce Ap pathology in their brains, thus causing disruptions in learning 
ability, synaptic plasticity and levels of Ap in the brain. Homozygous GP56 rats were 
used and the results of this study demonstrated no important behavioural deficit. Although 
both the presence of the mutant transgene and the high cholestertol diets affected rat 
performance, these effects appeared to act independently and did not interact. There was 
no effect on Ap levels in this model.
The relation between dietary cholesterol and development of APP driven pathology in 
GP56 rats was not established. There are a few possible explanations why cholesterol did 
not induce significant Ap pathology in these rats: 1) the amount of cholesterol provided in
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the diet was too low, 2) the administration period was too short or 3) the rats were too old. 
GP56 transgenic rats failed to exhibit any Ap pathology and showed only slight 
disturbances in learning and memory and neurotransmission. If we assume that the 
observed changes could precede development of Ap pathology, the results of this study 
support the role of cholesterol as an inducing factor of these changes, a topic that clearly 
requires further investigation using more sensitive experimental methodology.
DHA supplementation as a factor reducing AD risk
Saturated fatty acids are known to be bad for the heart, but as recent research is pointing 
out, they may also be bad for the brain. Studying more than 800 people over the age of 
65, Morris et al (2003) found that the subjects with the highest intake of saturated fats 
were at over twice the risk of AD as those with the lowest intake of such fats. High intake 
of unsaturated, unhydrogenated fats (like PUFA) seemed to offer a slight protection 
against developing AD (Morris et al., 2003). Another study by the same authors 
established that older people who eat fish at least once per week reduce their chances of 
getting the illness four years later by 60 percent (Morris et al., 2003). These authors also 
examined the risk of disease according to intake of the n-3 fatty acids (see chapter 1.6). 
Higher total intake of the n-3 fatty acids was significantly associated with a lower risk for 
AD. DHA (one of the n-3 fatty acids) provided the strongest association, EPA was not 
associated, and ALA was associated with lower risk only among persons with the ApoE 
e4 allele.
I investigated the effect of dietary DHA on learning ability and pathology in Tg2576 
Alzheimer's disease model mice. The results indicated that chronic administration of 
dietary DHA to these mice slightly reduced transgene induced impairment in learning and 
memory as measured with the forced choice alternation task in the T-maze. These 
transgenic mice start showing memory impairment at the age of 8 months (Chapman, 
1999). Tested at this age, animals on DHA-enriched diet performed significantly better 
than transgenic littermates on control diet, but also significantly worse than non- 
transgenic mice. This implies that DHA improved, but did not completely reverse the 
memory deficit and indicated that its effect was only modest. Also both in transgenic and 
non-transgenic mice that received DHA supplementation, the increase in DHA content in 
the brain was accompanied by a significant increase in the DHA/AA molar ratio, which
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positively correlated with learning in the FCA task. No changes were detected in Ap 
levels or plaque pathology, suggesting either the preventive effect of DHA on learning 
and memory deficits is not due to reduction of APP-induced pathology or that the APP 
metabolic product responsible for memory impairment was not measured. This study 
supports the clinical and epidemiological data suggesting that a high-PUFA (especially 
DHA) diet during the lifetime reduces the risk of developing AD.
6.5. Future plans and experiments
There are a number of points raised by these results that would merit further investigation.
For the ibuprofen and DHA studies, although the effects of NSAIDs and n-3 fatty acids 
are known to reduce the risk of AD, there is still little known about the mechanisms 
underlying their action. More research needs to be undertaken to clarify the mechanism 
underlying the action of both NSAIDs and n-3 fatty acids but also more questions need to 
be answered about the direct causes of dementia.
DHA supplementation was only tested in a prevention paradigm and it would be valuable 
to determine the effect of DHA on transgenic Tg2576 mice after 8 months of age.
Although both ibuprofen and DHA has a preventive effect on the development of memory 
impairment in the FCA task in the T-maze, it would also be important to confirm this 
finding using another behavioural task, like water maze.
Additionally more detailed biochemical analysis of Ap and its subspecies, such as 
oligomers, should be performed. Also measuring markers of oxidative stress and 
inflammation in Tg2576 mice brains might provide more insight into action of both 
NSAIDs and n-3 fatty acids.
And finally comparing various doses and/or treatment periods, especially for cholesterol 
might help to induce pathology in GP56 rats.
This thesis has demonstrated that animal models are a valuable but limited tool in 
investigating pathology of Alzheimer’s disease.
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